{
  "letters": 751603,
  "pages": 201,
  "meta": {
    "end_of_period": {
      "year": 2022,
      "month": 12
    },
    "company_name": "Terns Pharmaceuticals, Inc.",
    "major_industry": "Healthcare",
    "mentions_recent_mergers_and_acquisitions": {
      "value": true,
      "elements": [
        {
          "type": "merger_acquisition",
          "page": 27,
          "title": "Clinical Development for NASH",
          "data": [
            {
              "key": "FDA IND application clearance date",
              "value": "April 2022"
            },
            {
              "key": "Trial name",
              "value": "DUET"
            },
            {
              "key": "Primary endpoint",
              "value": "Relative change from baseline in MRI-PDFF at Week 12 for TERN-501 monotherapy vs placebo"
            },
            {
              "key": "Patient enrollment completion date",
              "value": "February 2023"
            },
            {
              "key": "Total patients enrolled",
              "value": "160"
            },
            {
              "key": "Expected results announcement date",
              "value": "Q3 2023"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 37,
          "title": "THR-β Agonist Assignment Agreement and TERN-101 License Agreement",
          "data": [
            {
              "key": "Vintagence Agreement Date",
              "value": "June 2019"
            },
            {
              "key": "Vintagence Agreement Description",
              "value": "Assignment of worldwide intellectual property rights and know-how related to THR-β agonists, including a Chinese patent application and any related patents/applications. The agreement grants rights to license the assigned IP to affiliates, with obligations for regulatory activities and commercialization efforts."
            },
            {
              "key": "Vintagence Payment Terms",
              "value": "Upfront payment of CNY 5 million ($0.7 million) and additional milestone payments up to CNY 205 million (approximately $32 million) based on specified developmental, clinical and regulatory events."
            },
            {
              "key": "Vintagence Termination and Control Provisions",
              "value": "Termination rights on a country-by-country basis, with provisions for re-assignment of IP if payments or prosecution responsibilities are not met. Includes first rights to enforce the assigned patents and know-how."
            },
            {
              "key": "TERN-101 License Agreement Date",
              "value": "February 2018"
            },
            {
              "key": "TERN-101 License Agreement Description",
              "value": "Exclusive, worldwide, royalty-bearing license from Eli Lilly for intellectual property including patents and know-how related to LY2562175 for development, manufacture, and commercialization of TERN-101 Products. Agreement includes sublicensing rights and provisions for co-promotion negotiations in select regions (China, Hong Kong, Macau, Taiwan)."
            },
            {
              "key": "TERN-101 Obligations",
              "value": "Mandatory commercially reasonable efforts to develop, manufacture, obtain regulatory approvals and commercialize TERN-101 Products, with additional support provided by Eli Lilly for transfer of licensed materials."
            }
          ],
          "currency": "CNY"
        },
        {
          "type": "merger_acquisition",
          "page": 176,
          "title": "Anti-Takeover Effects of Provisions of Delaware Law and Corporate Governance Documents",
          "data": [
            {
              "key": "General Description",
              "value": "The document outlines various provisions in Delaware law and the company's amended and restated certificate of incorporation and bylaws that are designed to deter or complicate hostile takeover attempts, including tender offers, proxy contests, or other transactions aiming to change control."
            },
            {
              "key": "Delaware Anti-Takeover Statute",
              "value": "The company is subject to Section 203 of the Delaware General Corporation Law, which prohibits interested stockholders from engaging in a business combination for three years unless approved or an exception applies. 'Interested stockholders' are generally those holding 15% or more of the voting stock."
            },
            {
              "key": "Undesignated Preferred Stock",
              "value": "The ability to authorize undesignated preferred stock allows the board to issue preferred stock with special voting rights or preferences that can impede a change in control."
            },
            {
              "key": "Special Stockholder Meetings",
              "value": "The certificate of incorporation states that only the board of directors can call special stockholder meetings, not the stockholders or any other parties."
            },
            {
              "key": "Advance Notification Requirements",
              "value": "The bylaws require advance notice for stockholder proposals and director nominations, except those made by or at the direction of the board or its committee."
            },
            {
              "key": "Elimination of Stockholder Action by Written Consent",
              "value": "The certificate of incorporation eliminates the right of stockholders to take action by written consent, ensuring that decisions must be made in a formal meeting."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 187,
          "title": "Contract Clauses: Indemnification, Definitions & Change in Control",
          "data": [
            {
              "key": "No Duty to Mitigate",
              "value": "Amounts owed under the Agreement shall not be offset by any claims; the Company’s payment obligations remain unaffected by counterclaims or other defenses."
            },
            {
              "key": "Indemnification",
              "value": "The Agreement provides that you will receive defense and indemnification by the Company and Parent in accordance with any Indemnification Agreement, and as governed by applicable law."
            },
            {
              "key": "Cause",
              "value": "Defined to include criminal acts involving fraud, dishonesty, material contract violations, or gross insubordination that harm the Company’s business, subject to a cure period for certain actions."
            },
            {
              "key": "Change in Control",
              "value": "Defined as an Acquisition (as per Parent’s 2021 Incentive Award Plan) that may trigger deferred compensation only if the event qualifies under Code Section 409A requirements."
            },
            {
              "key": "Disability",
              "value": "Describes conditions where inability to perform essential functions (taking reasonable accommodations into account) qualifies as a long-term impairment, with disputes resolved by a mutually selected physician."
            },
            {
              "key": "Equity Awards",
              "value": "Encompasses all options to purchase Parent common stock and other stock-based awards granted by Parent."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_leadership_changes": {
      "value": true,
      "elements": [
        {
          "type": "leadership_change",
          "page": 55,
          "title": "Corporate Information",
          "data": [
            {
              "key": "Incorporation Date",
              "value": "December 9, 2016"
            },
            {
              "key": "De-registration Date",
              "value": "December 29, 2020"
            },
            {
              "key": "Previous Jurisdiction",
              "value": "Cayman Islands"
            },
            {
              "key": "Current Jurisdiction",
              "value": "Delaware"
            },
            {
              "key": "Principal Executive Offices",
              "value": "1065 East Hillsdale Boulevard, Suite 100, Foster City, California 94404"
            },
            {
              "key": "Telephone Number",
              "value": "(650) 525-5535"
            },
            {
              "key": "Website",
              "value": "www.ternspharma.com"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 102,
          "title": "CEO Health and Leadership Succession Risk",
          "data": [
            {
              "key": "CEO Name",
              "value": "Mr. Sundaram"
            },
            {
              "key": "Diagnosis",
              "value": "Cancer"
            },
            {
              "key": "Diagnosis Year",
              "value": "2021"
            },
            {
              "key": "Treatment",
              "value": "Traditional and investigational treatments, including chemotherapy"
            },
            {
              "key": "Leadership Continuation Plan",
              "value": "CEO intends to continue in his role during treatment while working with the board; however, contingency plans are in place for his replacement if his condition prevents him from performing his duties"
            },
            {
              "key": "Risk Impact",
              "value": "Potential leadership change may lead to business disruption and increased stock price volatility"
            },
            {
              "key": "Succession Process",
              "value": "In the event of CEO incapacity, the company will identify, recruit, hire, and integrate a new chief executive officer; interim management may also be implemented"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 172,
          "title": "SIGNATURES",
          "data": [
            {
              "key": "Senthil Sundaram",
              "value": "Chief Executive Officer and Director (Principal Executive Officer), Date: March 27, 2023"
            },
            {
              "key": "Mark Vignola, Ph.D.",
              "value": "Chief Financial Officer (Principal Financial and Accounting Officer), Date: March 27, 2023"
            },
            {
              "key": "David Fellows",
              "value": "Chairman of the Board of Directors, Date: March 27, 2023"
            },
            {
              "key": "Carl Gordon, Ph.D., C.F.A.",
              "value": "Director, Date: March 27, 2023"
            },
            {
              "key": "Jeffrey Kindler, Esq.",
              "value": "Director, Date: March 27, 2023"
            },
            {
              "key": "Hongbo Lu, Ph.D.",
              "value": "Director, Date: March 27, 2023"
            },
            {
              "key": "Jill Quigley, Esq.",
              "value": "Director, Date: March 27, 2023"
            },
            {
              "key": "Ann Taylor, M.D.",
              "value": "Director, Date: March 27, 2023"
            },
            {
              "key": "Radhika Tripuraneni, M.D., M.P.H.",
              "value": "Director, Date: March 27, 2023"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 177,
          "title": "Classified Board; Election and Removal of Directors; Filling Vacancies",
          "data": [
            {
              "key": "Board Structure",
              "value": "The board of directors is divided into three classes with nearly equal numbers, each serving staggered three‐year terms."
            },
            {
              "key": "Director Election",
              "value": "Only one class of directors is elected each year by the stockholders, and because there is no cumulative voting, stockholders holding a majority of common stock can elect all directors."
            },
            {
              "key": "Director Removal",
              "value": "Directors may only be removed for cause with a vote of at least 66 2/3% of the voting power."
            },
            {
              "key": "Vacancy Filling",
              "value": "Any board vacancy, including that resulting from an increase in board size, is to be filled by a board resolution unless the board determines that stockholders should fill the vacancy."
            },
            {
              "key": "Choice of Forum",
              "value": "The document designates the Court of Chancery of the State of Delaware as the exclusive forum for certain legal actions, with specific exceptions, and outlines procedures if the forum is challenged."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 178,
          "title": "Amendment of Charter Provisions and Corporate Governance Details",
          "data": [
            {
              "key": "Amendment Detail",
              "value": "Any amendment to the charter provisions (except the provision allowing the board to issue undesignated preferred stock) requires approval by stockholders holding at least 66 2/3% of the voting power."
            },
            {
              "key": "Potential Effects",
              "value": "These provisions may discourage hostile takeovers, inhibit temporary market price fluctuations, and potentially prevent changes in management."
            },
            {
              "key": "Nasdaq Listing",
              "value": "Common stock is listed on the Nasdaq Global Select Market under the trading symbol 'TERN'."
            },
            {
              "key": "Transfer Agent",
              "value": "Computershare, Inc. – 250 Royall Street, Canton, Massachusetts 02021."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_layoffs": {
      "value": true,
      "elements": [
        {
          "type": "layoff",
          "page": 19,
          "title": "Clinical validation of THR-β agonism",
          "data": [
            {
              "key": "NASH clinical studies",
              "value": "Data from other NASH clinical studies validate the potential of THR-β agonism as a NASH treatment."
            },
            {
              "key": "Madrigal Pharmaceuticals",
              "value": "Announced positive Phase 3 top-line results for resmetirom."
            },
            {
              "key": "Phase 3 results",
              "value": "Resmetirom achieved significant improvements on two histological endpoints."
            },
            {
              "key": "Histological endpoints",
              "value": "(1) NASH resolution with a two-point or greater NAS reduction without worsening of fibrosis; (2) fibrosis improvement by at least one stage without worsening of NAS."
            },
            {
              "key": "Phase 2 clinical trial results",
              "value": "Resmetirom showed significant reductions in liver fat and lipid levels."
            },
            {
              "key": "SHBG",
              "value": "Resmetirom increases in SHBG correlated with reductions in MRI-PDFF and NAS."
            },
            {
              "key": "FDA guidance",
              "value": "Histological responses may be suitable for accelerated approval under current draft guidance."
            },
            {
              "key": "Key aspects of THR-β regulation",
              "value": "Energy metabolism, fatty acid and lipid synthesis, liver fat removal through fatty acid oxidation."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "layoff",
          "page": 54,
          "title": "Employees and Human Capital Management",
          "data": [
            {
              "key": "Total Employees",
              "value": "46"
            },
            {
              "key": "Employment Type",
              "value": "Full-time"
            },
            {
              "key": "Employee Education",
              "value": "13 hold doctorate degrees (Ph.D., M.D. or Pharm.D.)"
            },
            {
              "key": "Collective Bargaining Agreement",
              "value": "None"
            },
            {
              "key": "Relationship with Employees",
              "value": "Good"
            },
            {
              "key": "Key Objectives",
              "value": "attracting, developing and retaining a diverse and talented workforce; providing opportunities for learning, development, career growth and movement; evaluating compensation and benefits; investing in health; obtaining feedback; enhancing culture; communicating with the board."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "layoff",
          "page": 188,
          "title": "Involuntary Termination and Good Reason Definitions",
          "data": [
            {
              "key": "Involuntary Termination",
              "value": "Means experiencing a Separation resulting from: (A) Termination Without Cause; (B) voluntary resignation for Good Reason; (C) termination due to Disability effective within 30 days after notice; or (D) death."
            },
            {
              "key": "Good Reason",
              "value": "Defined as, without your consent, an assignment of duties leading to a material diminution of function, a reduction of over 10% in annual base salary (except under a company-wide salary reduction program), or a relocation of your primary business office more than 30 miles from its current location. Notice and cure period requirements also apply."
            },
            {
              "key": "Separation",
              "value": "Refers to a separation from service as defined under the regulations of Section 409A of the Code."
            },
            {
              "key": "Termination Without Cause",
              "value": "A Separation resulting from the Company's decision to terminate employment without cause, provided the individual remains willing and able to continue performing services."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "layoff",
          "page": 190,
          "title": "Exhibit A Release",
          "data": [
            {
              "key": "Context",
              "value": "General release in connection with termination of employment, wherein the releasor waives all claims against Parent, Company and affiliated entities."
            },
            {
              "key": "Parties Involved",
              "value": "Terns, Inc. (or its successor) and Terns Pharmaceuticals, Inc. (Parent)"
            },
            {
              "key": "Reference Agreement",
              "value": "Letter agreement with Company dated September __ 2022"
            },
            {
              "key": "Claims Waived",
              "value": "All claims stemming from employment and its termination, including any claims under various federal and state employment laws (e.g., Title VII, ADA, ADEA, FLSA, ERISA, etc.)"
            },
            {
              "key": "Governing Law",
              "value": "California law, including waiver of rights under Section 1542 of the California Civil Code"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "layoff",
          "page": 191,
          "title": "Employee Termination Release and Confidentiality Provisions",
          "data": [
            {
              "key": "Attorney Consultation",
              "value": "Employee advised to consult an attorney before executing the Release."
            },
            {
              "key": "Non-Waivable Legal Rights",
              "value": "Employee retains rights under workers’ compensation, unemployment benefits, state indemnity provisions, and the ability to file charges or complaints with various government agencies including the SEC."
            },
            {
              "key": "Indemnification and Insurance",
              "value": "Employee will continue to be indemnified and covered by directors’ and officers’ liability insurance as provided in corporate documents and agreements."
            },
            {
              "key": "Benefits Contingency",
              "value": "Company benefits will only be provided upon execution of the Release; otherwise, accrued wages and unused vacation pay are to be provided regardless."
            },
            {
              "key": "Return of Company Property",
              "value": "Employee has returned or is required to return all company documents and property held during employment."
            },
            {
              "key": "Confidentiality Obligation",
              "value": "The terms of the Release and related benefits must be kept confidential, with disclosures limited to legal or immediate family counsel, or as required by law."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "layoff",
          "page": 192,
          "title": "Условия соглашения о выходном пособии и освобождении от ответственности",
          "data": [
            {
              "key": "Общие положения",
              "value": "Положение 7 устанавливает, что данный Release не будет трактоваться как признание вины или правонарушения ни со стороны Компании, ни со стороны сотрудника."
            },
            {
              "key": "Ограничение высказываний после увольнения",
              "value": "Положение 8 обязывает сотрудника после увольнения не делать недоброкачественных замечаний или заявлений о Компании, её сотрудниках, руководителях, подрядчиках, продукции, услугах и т.д."
            },
            {
              "key": "Сотрудничество в расследованиях",
              "value": "Положение 9 требует от сотрудника оказания разумного сотрудничества с Компанией в любых внутренних расследованиях, административных, регуляторных или судебных процедурах, а также предоставления запрашиваемых документов и возможности давать показания без вызова по повестке."
            },
            {
              "key": "Арбитраж и отказ от судебного разбирательства",
              "value": "Положение 10 предусматривает обязательное арбитражное разбирательство для претензий, вытекающих из соглашения или трудовых отношений, и отказ от права на суд присяжных."
            },
            {
              "key": "Период обдумывания и дата вступления в силу",
              "value": "Положение 11 указывает, что сотруднику предоставлено не менее 21 календарного дня на обдумывание исполнения Release, устанавливается срок истечения предложения и дата вступления в силу после подписания, с правом отзыва согласия."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "layoff",
          "page": 194,
          "title": "Employee’s Acceptance of Release",
          "data": [
            {
              "key": "Employee Statement",
              "value": "EMPLOYEE’S ACCEPTANCE OF RELEASE BEFORE SIGNING MY NAME TO THE RELEASE, I STATE THE FOLLOWING: I HAVE READ THE RELEASE, I UNDERSTAND IT AND I KNOW THAT I AM GIVING UP IMPORTANT RIGHTS. I HAVE OBTAINED SUFFICIENT INFORMATION TO INTELLIGENTLY EXERCISE MY OWN JUDGMENT. I HAVE BEEN ADVISED THAT I SHOULD CONSULT WITH AN ATTORNEY BEFORE SIGNING IT, AND I HAVE SIGNED THE RELEASE KNOWINGLY AND VOLUNTARILY. EFFECTIVE UPON EXECUTION BY EMPLOYEE AND THE COMPANY."
            },
            {
              "key": "Date Delivered",
              "value": "___________, ______"
            },
            {
              "key": "Execution Date",
              "value": "___________ day of ___________, ______"
            },
            {
              "key": "Signatures",
              "value": "Employee Signature; Employee Printed Name; Agreed and Accepted: Terns, Inc. by authorized signatory. Reference: [Signature Page to General Release Agreement] US-DOCS\\135311303.1"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_executive_compensation": {
      "value": true,
      "elements": [
        {
          "type": "executive_compensation",
          "page": 10,
          "title": "TERN-101 Overview and Clinical Trials",
          "data": [
            {
              "key": "Product Candidate",
              "value": "TERN-101"
            },
            {
              "key": "Disease Target",
              "value": "Non-Alcoholic Steatohepatitis (NASH)"
            },
            {
              "key": "Clinical Trial Status",
              "value": "Phase 2a LIFT Study"
            },
            {
              "key": "Fast Track Designation",
              "value": "Granted October 2019"
            },
            {
              "key": "GIPR Modulators Development",
              "value": "TERN-800 series"
            },
            {
              "key": "Key Drug Candidates",
              "value": "TERN-701, TERN-601"
            },
            {
              "key": "Collaborative Partner",
              "value": "Hansoh"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 22,
          "title": "Mean % Change from Baseline to Day 15",
          "data": [
            {
              "key": "Parameter",
              "value": "Sex Hormone Binding Globulin (%)"
            },
            {
              "key": "Placebo (N=8)",
              "value": "-6%"
            },
            {
              "key": "Img (N=6)",
              "value": "17%"
            },
            {
              "key": "3 mg (N=6)",
              "value": "57%*"
            },
            {
              "key": "6 mg (N=6)",
              "value": "135%*"
            },
            {
              "key": "10 mg (N=6)",
              "value": "165%*"
            },
            {
              "key": "Parameter",
              "value": "Low Density Lipoprotein — cholesterol (%)"
            },
            {
              "key": "Placebo (N=8)",
              "value": "-4%"
            },
            {
              "key": "Img (N=6)",
              "value": "-16%"
            },
            {
              "key": "3 mg (N=6)",
              "value": "-17%"
            },
            {
              "key": "6 mg (N=6)",
              "value": "-19%"
            },
            {
              "key": "10 mg (N=6)",
              "value": "-20%*"
            },
            {
              "key": "Parameter",
              "value": "Triglycerides (%)"
            },
            {
              "key": "Placebo (N=8)",
              "value": "-13%"
            },
            {
              "key": "Img (N=6)",
              "value": "-18%"
            },
            {
              "key": "3 mg (N=6)",
              "value": "-21%"
            },
            {
              "key": "6 mg (N=6)",
              "value": "-20%"
            },
            {
              "key": "10 mg (N=6)",
              "value": "-36%*"
            },
            {
              "key": "Parameter",
              "value": "Apolipoprotein-B (%)"
            },
            {
              "key": "Placebo (N=8)",
              "value": "5%"
            },
            {
              "key": "Img (N=6)",
              "value": "-14%"
            },
            {
              "key": "3 mg (N=6)",
              "value": "-18%*"
            },
            {
              "key": "6 mg (N=6)",
              "value": "-23%*"
            },
            {
              "key": "10 mg (N=6)",
              "value": "-27%*"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 23,
          "title": "LIFT Clinical Trial Design",
          "data": [
            {
              "key": "group",
              "value": "5 mg TERN-101 QD"
            },
            {
              "key": "n",
              "value": "24"
            },
            {
              "key": "duration_weeks",
              "value": "12"
            },
            {
              "key": "group",
              "value": "10 mg TERN-101 QD"
            },
            {
              "key": "n",
              "value": "24"
            },
            {
              "key": "duration_weeks",
              "value": "12"
            },
            {
              "key": "group",
              "value": "15 mg TERN-101 QD"
            },
            {
              "key": "n",
              "value": "24"
            },
            {
              "key": "duration_weeks",
              "value": "12"
            },
            {
              "key": "group",
              "value": "Placebo QD"
            },
            {
              "key": "n",
              "value": "24"
            },
            {
              "key": "duration_weeks",
              "value": "12"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 23,
          "title": "Patient incidence AEs by category, n (%)",
          "data": [
            {
              "key": "category",
              "value": "Any AE, all CTCAE grades"
            },
            {
              "key": "placebo",
              "value": "10 (38.5%)"
            },
            {
              "key": "5mg",
              "value": "13 (52.0%)"
            },
            {
              "key": "10mg",
              "value": "14 (53.8%)"
            },
            {
              "key": "15mg",
              "value": "15 (65.2%)"
            },
            {
              "key": "category",
              "value": "CTCAE Grade 3 or higher AEs"
            },
            {
              "key": "placebo",
              "value": "1 (3.8%)"
            },
            {
              "key": "5mg",
              "value": "0"
            },
            {
              "key": "10mg",
              "value": "0"
            },
            {
              "key": "15mg",
              "value": "1 (4.3%)"
            },
            {
              "key": "category",
              "value": "Serious AE"
            },
            {
              "key": "placebo",
              "value": "1 (3.8%)"
            },
            {
              "key": "5mg",
              "value": "0"
            },
            {
              "key": "10mg",
              "value": "0"
            },
            {
              "key": "15mg",
              "value": "1 (4.3%)"
            },
            {
              "key": "category",
              "value": "AE leading to death"
            },
            {
              "key": "placebo",
              "value": "0"
            },
            {
              "key": "5mg",
              "value": "0"
            },
            {
              "key": "10mg",
              "value": "0"
            },
            {
              "key": "15mg",
              "value": "0"
            },
            {
              "key": "category",
              "value": "AE leading to study or drug discontinuation"
            },
            {
              "key": "placebo",
              "value": "0"
            },
            {
              "key": "5mg",
              "value": "0"
            },
            {
              "key": "10mg",
              "value": "0"
            },
            {
              "key": "15mg",
              "value": "0"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 23,
          "title": "Patient incidence of any pruritus AE",
          "data": [
            {
              "key": "Pruritus, all CTCAE grades",
              "value": "5mg: 4 (16.0%)"
            },
            {
              "key": "10mg",
              "value": "3 (11.5%)"
            },
            {
              "key": "15mg",
              "value": "4 (17.4%)"
            },
            {
              "key": "Grade 1",
              "value": "5mg: 4 (16.0%)"
            },
            {
              "key": "10mg",
              "value": "1 (3.8%)"
            },
            {
              "key": "15mg",
              "value": "3 (13.0%)"
            },
            {
              "key": "Grade 2",
              "value": "5mg: 0"
            },
            {
              "key": "10mg",
              "value": "2 (7.7%)"
            },
            {
              "key": "15mg",
              "value": "1 (4.3%)"
            },
            {
              "key": "Grade 3",
              "value": "5mg: 0"
            },
            {
              "key": "10mg",
              "value": "0"
            },
            {
              "key": "15mg",
              "value": "0"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 148,
          "title": "Stock-Based Compensation & Net Loss Per Share Disclosure",
          "data": [
            {
              "key": "Compensation Topic",
              "value": "Stock-Based Compensation"
            },
            {
              "key": "Expense Measurement",
              "value": "Measured at grant date based on fair value using the Black-Scholes option-pricing model and recognized on a straight-line basis over the vesting period"
            },
            {
              "key": "Expected Term Estimation",
              "value": "Uses the simplified method estimating the midpoint between vesting date and contractual term due to limited historical data"
            },
            {
              "key": "Net Loss Per Share Calculation",
              "value": "Computed using the two-class method which allocates net income (loss) between common stock and participating securities; in loss periods, basic and diluted net loss per share are identical"
            },
            {
              "key": "Employee Stock Purchase Plan (ESPP)",
              "value": "Stock grants based on rights under the ESPP, valued at grant-date fair value"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 148,
          "title": "Stock-Based Compensation Summary",
          "data": [
            {
              "key": "Options to purchase common stock (2022)",
              "value": "4823928"
            },
            {
              "key": "Options to purchase common stock (2021)",
              "value": "3577485"
            },
            {
              "key": "Invested restricted stock units (2022)",
              "value": "128280"
            },
            {
              "key": "Invested restricted stock units (2021)",
              "value": "0"
            },
            {
              "key": "Shares issuable under employee stock purchase plan (2022)",
              "value": "25326"
            },
            {
              "key": "Shares issuable under employee stock purchase plan (2021)",
              "value": "6717"
            },
            {
              "key": "Total (2022)",
              "value": "4977534"
            },
            {
              "key": "Total (2021)",
              "value": "3584202"
            },
            {
              "key": "Summary",
              "value": "The summary shows a 39% increase in total stock-based compensation from 2021 to 2022, mainly driven by an increase in stock purchase options, addition of restricted stock units, and growth in ESPP shares."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 157,
          "title": "Notes to Consolidated Financial Statements – Equity Compensation Plans",
          "data": [
            {
              "key": "Company",
              "value": "TERNS PHARMACEUTICALS, INC."
            },
            {
              "key": "Document Section",
              "value": "Notes to Consolidated Financial Statements – Equity Compensation"
            },
            {
              "key": "2021 Incentive Award Plan",
              "value": "Approved by the board in January 2021. Permits granting incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance bonus awards, performance stock unit awards, and other stock awards to employees, directors, officers, and consultants."
            },
            {
              "key": "Authorized Shares under 2021 Plan",
              "value": "2,400,007 shares authorized in February 2021; cumulative annual increases from 2022 to 2031 based on the lesser of 5% of shares outstanding or a board-determined number. Additional increase of 2,686,158 shares effective January 1, 2023."
            },
            {
              "key": "Available Shares for Future Grants (2021 Plan)",
              "value": "1,107,362 shares as of December 31, 2022"
            },
            {
              "key": "2021 Employee Stock Purchase Plan (ESPP)",
              "value": "Approved in January 2021. Initially reserved 240,000 shares in February 2021; cumulative annual increases from 2022 to 2031 based on the lesser of 1% of shares outstanding or a board-determined number. As of December 31, 2022, 323,920 shares available. Shares purchased at 85% of fair market value with a one-year look-back feature."
            },
            {
              "key": "Unrecognized Stock-Based Compensation Expense (ESPP)",
              "value": "$0.2 million, to be recognized over approximately 1.53 years as of December 31, 2022"
            },
            {
              "key": "ESPP Shares Purchased in 2022",
              "value": "168,772 shares"
            },
            {
              "key": "2022 Employment Inducement Award Plan",
              "value": "Approved by the compensation committee in September 2022. Authorized 1,400,000 shares for issuance to newly hired employees and officers. As of December 31, 2022, 1,310,000 shares available for future grants."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 158,
          "title": "Notes to Consolidated Financial Statements – Stock Options and Pre-Funded Warrants",
          "data": [
            {
              "key": "Pre-Funded Warrants",
              "value": "In August 2022, TERNS PHARMACEUTICALS, INC. sold pre-funded warrants to purchase 14,630,000 shares of common stock at a price of $2.4199 per warrant, with a $0.0001 per share exercise price. No pre-funded warrants had been exercised as of December 31, 2022."
            },
            {
              "key": "Stock Options Summary Overview",
              "value": "The document provides a detailed table of stock option activity for 2020, 2021, and 2022, including numbers for outstanding, granted, exercised, and forfeited options, along with weighted average exercise prices, remaining contractual terms, and intrinsic values."
            },
            {
              "key": "Intrinsic Value of Stock Options",
              "value": "As of December 31, 2022, the total intrinsic value of outstanding options was $11.72 million, with approximately $3.66 million intrinsic value for options exercisable on that date."
            },
            {
              "key": "Unrecognized Stock-Based Compensation Expense",
              "value": "The unrecognized compensation expense related to unvested stock options amounted to $21.2 million as of December 31, 2022 and $28.6 million as of December 31, 2021, with an estimated recognition period of 2.19 years as of December 31, 2022."
            },
            {
              "key": "Total Fair Value of Vested Options",
              "value": "The total fair value of options vested during the years ended December 31, 2022 and 2021 was $10.9 million and $7.8 million, respectively."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 159,
          "title": "TERNS PHARMACEUTICALS, INC. - Restricted Stock and Stock-Based Compensation Expense",
          "data": [
            {
              "key": "RSU Vesting Period",
              "value": "Generally four years"
            },
            {
              "key": "RSU Issuance Net of Tax Withholdings",
              "value": "Shares issued on vesting date are net of minimum statutory tax withholdings paid in cash"
            },
            {
              "key": "Stock-Based Compensation Recognition",
              "value": "Expense recognized over the requisite service period equal to the vesting period"
            },
            {
              "key": "Invested Restricted Common Stock Movement Summary",
              "value": "From December 31, 2020 to December 31, 2022: Beginning balance 83,334 shares @ $1.96, vesting of 71,429 shares and forfeitures, grants of 147,750 shares @ $3.99, additional forfeitures of 19,470 shares, ending balance 128,280 shares @ weighted average fair value $4.09"
            },
            {
              "key": "Unrecognized Stock-Based Compensation Expense (2022)",
              "value": "$0.4 million estimated to be recognized over 3.46 years"
            },
            {
              "key": "Restricted Stock Vested (2021)",
              "value": "Total fair value of $0.1 million vested during year ended December 31, 2021"
            },
            {
              "key": "Stock Option Plans Metrics",
              "value": "Expected term 6.03 years, volatility 76.60%, risk-free interest rate 1.12%-2.29%, underlying common stock fair value $11.83, weighted average grant-date fair value per share $7.82"
            },
            {
              "key": "Employee Stock Purchase Plans Metrics",
              "value": "Expected term 0.75 years, volatility 60.82%-70.08%, risk-free interest rate 0.179%-2.55%, underlying common stock fair value $6.53"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 168,
          "title": "Item 11. Executive Compensation",
          "data": [
            {
              "key": "Description",
              "value": "The information required by this item will be set forth in our definitive Proxy Statement, which will be filed with the SEC in connection with the 2023 annual meeting of stockholders."
            },
            {
              "key": "Reference",
              "value": "Incorporated by reference from the Proxy Statement"
            },
            {
              "key": "Filing Deadline",
              "value": "Not later than 120 days after the end of the fiscal year ended December 31, 2022"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 169,
          "title": "Exhibit Index and Item 15 - Financial Statements, Schedules and Exhibits",
          "data": [
            {
              "key": "Item Description",
              "value": "PART IV Item 15. Exhibits, Financial Statement Schedules. (a)(1) Financial Statements: Referenced under Part II, Item 8. (a)(2) Financial Statement Schedules: Omitted, as information is included in Item 8. (a)(3) Exhibits: Listed in the Exhibit Index and filed or incorporated by reference."
            },
            {
              "key": "Form 10-K Summary",
              "value": "None. Incorporated by Reference."
            },
            {
              "key": "Exhibit Index Title",
              "value": "Exhibit Index"
            },
            {
              "key": "Exhibit Index Summary",
              "value": "This table presents a list of exhibits from various corporate filings and documents. It includes corporate governance documents (Certificate of Incorporation, Bylaws), securities-related documents, and various equity incentive plans and agreements. The exhibits span from January 2021 to August 2022, with filings primarily under forms S-1, S-1/A, 8-K, and S-8, suggesting relevance to corporate restructuring and executive compensation strategies."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 170,
          "title": "Exhibit Index",
          "data": [
            {
              "key": "Exhibit 10.4(d)#",
              "value": "Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2021 Incentive Award Plan; Form: S-1/A; Date: 2/1/2021; Reference: 10.5(d)"
            },
            {
              "key": "Exhibit 10.5#",
              "value": "2021 Employee Stock Purchase Plan; Form: S-8; Date: 2/12/2021; Reference: 99.3"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 179,
          "title": "Exhibit 10.7 TERNS, INC. Employment Agreement Amendment",
          "data": [
            {
              "key": "Effective Date",
              "value": "November 8, 2022"
            },
            {
              "key": "Employee Name",
              "value": "Senthil Sundaram"
            },
            {
              "key": "Position",
              "value": "Chief Executive Officer (CEO)"
            },
            {
              "key": "Additional Role",
              "value": "CEO of Parent entity, Terns Pharmaceuticals, Inc."
            },
            {
              "key": "Board Membership",
              "value": "Serves as a member of the Board; subject to re-election at term end"
            },
            {
              "key": "Base Salary",
              "value": "US$561,400 per year"
            },
            {
              "key": "Employment Terms",
              "value": "Revised employment agreement superseding the Prior Agreement dated July 24, 2020"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 180,
          "title": "Compensation, Bonus, Benefits and Termination Clauses",
          "data": [
            {
              "key": "Annual Bonus",
              "value": "Eligible for an annual target cash bonus equal to 50% of the Base Salary, with the actual bonus based on performance objectives communicated within 45 days of the new calendar year and paid within 2.5 months of the performance period end."
            },
            {
              "key": "Signing Bonus",
              "value": "Reference to Signing Bonus is made, though details are not specified."
            },
            {
              "key": "Equity Awards",
              "value": "Eligible to be granted equity awards at the discretion of the Board."
            },
            {
              "key": "Employee Benefits",
              "value": "Continues to receive employee benefits, bonus plan participation and perquisites similar to senior executives."
            },
            {
              "key": "Expense Reimbursement",
              "value": "Business expenses will be reimbursed in accordance with the Company's policies; attorney fees up to $1,500 related to negotiation of the Agreement will also be paid, treated as taxable compensation."
            },
            {
              "key": "Termination Payments",
              "value": "In case of any termination, including involuntary termination, salary through termination date is guaranteed. For involuntary termination, there is a severance package that includes salary continuation for 12 months."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 181,
          "title": "Prorated Bonus, Health Coverage and Accelerated Vesting Provisions",
          "data": [
            {
              "key": "Prorated Bonus",
              "value": "The Company will pay a lump sum payment equal to the Target Bonus for the year of Involuntary Termination, pro-rated on a daily basis for the days worked."
            },
            {
              "key": "Continued Health Coverage/COBRA",
              "value": "Provides for continued health insurance coverage for up to 36 months post-termination, including provisions for COBRA continuation or taxable installment payments if COBRA is unavailable."
            },
            {
              "key": "Accelerated Vesting and Option Exercise Period",
              "value": "Equity Awards vesting accelerates and options remain exercisable under specified conditions such as termination due to death, disability or in proximity to a Change in Control."
            },
            {
              "key": "Equity Awards in Change in Control",
              "value": "Outstanding equity awards accelerate and vest 100% if the Involuntary Termination occurs within specified period around a Change in Control, with performance criteria assumed met for non-vested awards."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 182,
          "title": "Modified Severance and Termination Provisions",
          "data": [
            {
              "key": "Severance Increase",
              "value": "18 months of Base Salary as a lump-sum payment and 150% of target Annual Bonus in lieu of a prorated bonus for the year of termination."
            },
            {
              "key": "Change in Control Definition",
              "value": "A legally binding definitive agreement for a corporate transaction (including a merger agreement, but not a term sheet) that constitutes a Change in Control."
            },
            {
              "key": "Release Requirement",
              "value": "Receipt of severance is conditioned on executing a release of claims within 60 days following Involuntary Termination."
            },
            {
              "key": "Payroll and Vesting Provisions",
              "value": "Installment or cash payments commence after the Release Period. Accelerated vesting of equity awards will occur on termination, with unvested awards accelerating if cancelled upon Change in Control."
            },
            {
              "key": "CIC Policy Reference",
              "value": "Benefits provided under any adopted change in control policy (CIC Policy), subject to its terms and conditions, without duplication of payments."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 183,
          "title": "Employment Relationship; Board Service and Tax Matters",
          "data": [
            {
              "key": "Employment Nature",
              "value": "At will – Employment with the Company is for no specific period and may be terminated at any time by either party with or without cause or notice."
            },
            {
              "key": "Job Duties, Title, Compensation, and Benefits",
              "value": "May change from time to time; however, the at-will nature of employment can only be modified in an express written agreement."
            },
            {
              "key": "Board Seat Obligation",
              "value": "If the CEO position is terminated by either party, the individual must promptly resign from the Company’s board and from Parent’s subsidiaries’ boards."
            },
            {
              "key": "Non-Disparagement",
              "value": "Both the Company (including its executive officers and board members) and the executive agree not to make negative or disparaging statements about each other, subject to legal disclosure requirements."
            },
            {
              "key": "Tax Withholding",
              "value": "All forms of compensation are subject to reductions for applicable withholding, payroll taxes, and other legal deductions."
            },
            {
              "key": "Section 409A – Salary Continuation Payments",
              "value": "Salary continuation payments under Section 6 are designated as separate payments. For specified employees under Section 409A at Separation, benefits commence on the first business day after either a six‐month period or the date of death, with prior installments paid as a lump sum."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 184,
          "title": "Deferred Compensation, Severance and Parachute Payment Provisions",
          "data": [
            {
              "key": "Section 9.2.3",
              "value": "Expense reimbursement and in-kind benefit provisions under Section 409A including limitations on the calendar year impact, timing, and non-liquidation of benefits."
            },
            {
              "key": "Section 9.2.4",
              "value": "Nonqualified deferred compensation payable in relation to employment-related actions, with payments commencing in a later taxable year as required by Section 409A."
            },
            {
              "key": "Section 9.2.5",
              "value": "Treatment of each payment installment under severance provisions as separate payments for Section 409A, including division of installments based on compensation limits and separation from service conditions."
            },
            {
              "key": "Section 9.3.1",
              "value": "Parachute payments (280G Payments) subject to Section 280G and potential Excise Tax (Section 4999), with the Reduced Amount determined to maximize after-tax economic benefit and methods for payment reduction."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 185,
          "title": "Tax Adjustment and Payment Modification Provisions (Section 9.3)",
          "data": [
            {
              "key": "Reduction Method Modification",
              "value": "If the Reduction Method or Pro Rata Reduction Method would result in any portion of the Payment being subject to Section 409A, they shall be modified to avoid the taxation."
            },
            {
              "key": "Priority 1",
              "value": "Modification shall preserve the greatest economic benefit for the individual on an after-tax basis."
            },
            {
              "key": "Priority 2",
              "value": "Payments contingent on future events (e.g., termination without cause) are reduced or eliminated before non-contingent Payments."
            },
            {
              "key": "Priority 3",
              "value": "Deferred compensation payments are reduced pro rata with payments that are not deferred."
            },
            {
              "key": "Accounting Firm Engagement",
              "value": "An accounting or valuation firm engaged by the Company will perform the required calculations, with provisions if conflicts arise."
            },
            {
              "key": "Excise Tax Adjustment",
              "value": "If later determined that some portion of the Payment is subject to the Excise Tax, the individual must return a sufficient amount to avoid any remaining Payment being subject to such tax."
            },
            {
              "key": "Tax Advice",
              "value": "Individuals are encouraged to obtain their own tax advice regarding compensation."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 195,
          "title": "Consent of Independent Registered Public Accounting Firm",
          "data": [
            {
              "key": "Plan References",
              "value": "2021 Incentive Award Plan, 2021 Employee Stock Purchase Plan, 2022 Employment Inducement Award Plan"
            },
            {
              "key": "Registration Statements",
              "value": "Form S-8 Nos. 333-263340, 333-253085, 333-268277; Form S-3 Nos. 333-263370, 333-269508"
            },
            {
              "key": "Company",
              "value": "Terns Pharmaceuticals, Inc."
            },
            {
              "key": "Report Date",
              "value": "March 27, 2023"
            },
            {
              "key": "Financial Statement Period",
              "value": "Year ended December 31, 2022"
            },
            {
              "key": "Auditor",
              "value": "Ernst & Young LLP"
            },
            {
              "key": "Location",
              "value": "San Jose, California"
            },
            {
              "key": "Exhibit",
              "value": "Exhibit 23.1"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_rnd_investment_numbers": {
      "value": true,
      "elements": [
        {
          "type": "rnd_investment",
          "page": 5,
          "title": "PART I Item 1. Business. Company Overview",
          "data": [
            {
              "key": "Company Stage",
              "value": "Clinical-stage biopharmaceutical company"
            },
            {
              "key": "Product Pipeline",
              "value": "TERN-701, TERN-501, TERN-601, and TERN-800 series"
            },
            {
              "key": "Therapeutic Areas",
              "value": "Oncology (CML), Non-alcoholic steatohepatitis (NASH), and Obesity/Metabolic diseases"
            },
            {
              "key": "Clinical Trials",
              "value": "TERN-701 Phase 1 trial expected H2 2023 (with potential interim readouts in 2024), TERN-501 in Phase 2a with top-line data expected Q3 2023, and planned first-in-human trial for TERN-601 in H2 2023"
            },
            {
              "key": "Development and Licensing",
              "value": "TERN-701 was internally discovered; retains worldwide rights outside greater China; in-licensed to Hansoh Pharmaceuticals (HS-10382) for development in greater China"
            },
            {
              "key": "Financial Outlook",
              "value": "Existing cash and cash equivalents are expected to fund operating expenses and capital expenditure requirements into 2026"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 6,
          "title": "Clinical Development and Pipeline Update",
          "data": [
            {
              "key": "Program TERN-501",
              "value": "A THR-β agonist with high metabolic stability, enhanced liver distribution and greater selectivity. Positive top-line Phase 1 trial results in healthy volunteers with mildly elevated LDL cholesterol; well-tolerated with no serious adverse events or significant safety signals."
            },
            {
              "key": "Pharmacodynamic Marker",
              "value": "Significant, dose-dependent increases in sex hormone binding globulin (SHBG) observed, associated with reductions in MRI-PDFF and improvements in NAFLD Activity Score."
            },
            {
              "key": "Clinical Trial Phases",
              "value": "Completed Phase 1 (SAD and MAD cohorts) with Phase 2a DUET clinical trial initiated in NASH patients (monotherapy and combination with TERN-101); top-line data expected in Q3 2023; planned initiation of Phase 2b/3 program in 2024."
            },
            {
              "key": "Co-administration Strategy",
              "value": "Preliminary pharmacokinetic results support co-administration of TERN-501 with TERN-101 in NASH patients without dose adjustment."
            },
            {
              "key": "Additional R&D Pipeline",
              "value": "Development of oral small-molecule GLP-1R agonists for obesity, lead candidate TERN-601 is undergoing IND-enabling activities with a first-in-human trial expected in the second half of 2023 and top-line data in 2024. Plans include evaluation of SAD and MAD trials, assessing body weight and glycemic control."
            },
            {
              "key": "Context on Orphan Indication",
              "value": "Overview of CML as an orphan indication, including current SOC using active-site TKIs, unmet medical needs due to resistant cases and mutations, with market estimates provided."
            },
            {
              "key": "Future Outlook",
              "value": "Ongoing efforts include drug supply manufacturing, chronic toxicology studies, and nomination of second-generation compounds."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 7,
          "title": "Obesity Trends and Drug Development Pipeline",
          "data": [
            {
              "key": "Obesity Definition",
              "value": "BMI of 30 or greater; represents a leading cause of cardiometabolic diseases and mortality."
            },
            {
              "key": "Epidemiology",
              "value": "Declared a global epidemic by WHO; one third of U.S. adults 20+ are obese."
            },
            {
              "key": "Health Impact",
              "value": "Increases risks of hypertension, dyslipidemia, type 2 diabetes, heart disease, stroke, gallbladder disease, arthritis, sleep apnea and certain cancers."
            },
            {
              "key": "Economic Impact",
              "value": "Associated with an estimated $260 billion in annual US healthcare expenditures."
            },
            {
              "key": "Therapeutic Approach",
              "value": "GLP-1 receptor agonists address insulin resistance and are emerging therapies for weight loss."
            },
            {
              "key": "Market Forecast",
              "value": "Worldwide sales for GLP-1 therapeutics forecasted to exceed $16 billion in 2021 and grow to over $30 billion by 2026."
            },
            {
              "key": "Pipeline Programs Overview",
              "value": "Multiple drug candidates advancing through clinical and preclinical stages; programs include TERN-701 (Oncology), TERN-501 +/- FXR for NASH, TERN-601 (Oral GLP-1R Agonist for Obesity), and TERN-800 Series (GIPR Modulators for Obesity)."
            },
            {
              "key": "Pipeline Table Details",
              "value": "Table titled 'Drug Development Pipeline Status' provided details on program names, categories, mechanisms, indications, development stages, and status updates."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "rnd_investment",
          "page": 25,
          "title": "NASH Combination Therapy Programs",
          "data": [
            {
              "key": "Therapies",
              "value": "Combination therapies targeting multiple mechanistic pathways for NASH patients."
            },
            {
              "key": "Phase 2a Trial",
              "value": "IND application cleared for Phase 2a DUET clinical trial of TERN-501 in combination with TERN-101."
            },
            {
              "key": "Mechanisms of Action",
              "value": "TERN-501 acts as a THR-β agonist and TERN-101 as a liver-distributed FXR agonist."
            },
            {
              "key": "Clinical Outcomes",
              "value": "Expected improvements in steatosis, inflammation, and fibrosis in NASH patients."
            },
            {
              "key": "Preclinical Data",
              "value": "Combination of TERN-501 and TERN-101 shows robust efficacy in reducing steatosis and improving fibrosis in NASH."
            },
            {
              "key": "Gene Expression",
              "value": "Expression of over 800 distinct genes activated by combination treatment."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 26,
          "title": "Medical/Biochemical Parameters Analysis",
          "data": [
            {
              "key": "Combination of TERN-101 + TERN-501",
              "value": "demonstrates improvements in liver histology and serum biomarkers in an in vivo NASH mouse model"
            },
            {
              "key": "Steatosis (Healthy)",
              "value": "0"
            },
            {
              "key": "Steatosis (NASH)",
              "value": "2"
            },
            {
              "key": "Steatosis (TERN-101)",
              "value": "1"
            },
            {
              "key": "Steatosis (TERN-501)",
              "value": "0"
            },
            {
              "key": "Steatosis (TERN-101+501)",
              "value": "0.2"
            },
            {
              "key": "Inflammation (Healthy)",
              "value": "0"
            },
            {
              "key": "Inflammation (NASH)",
              "value": "2"
            },
            {
              "key": "Inflammation (TERN-101)",
              "value": "2"
            },
            {
              "key": "Inflammation (TERN-501)",
              "value": "2"
            },
            {
              "key": "Inflammation (TERN-101+501)",
              "value": "2"
            },
            {
              "key": "Fibrosis (Healthy)",
              "value": "0"
            },
            {
              "key": "Fibrosis (NASH)",
              "value": "4"
            },
            {
              "key": "Fibrosis (TERN-101)",
              "value": "4"
            },
            {
              "key": "Fibrosis (TERN-501)",
              "value": "4"
            },
            {
              "key": "Fibrosis (TERN-101+501)",
              "value": "4"
            },
            {
              "key": "Serum TG (Healthy)",
              "value": "0.7 mmol/L"
            },
            {
              "key": "Serum TG (NASH)",
              "value": "1.0 mmol/L"
            },
            {
              "key": "Serum TG (TERN-101)",
              "value": "0.95 mmol/L"
            },
            {
              "key": "Serum TG (TERN-501)",
              "value": "0.7 mmol/L"
            },
            {
              "key": "Serum TG (TERN-101+501)",
              "value": "0.6 mmol/L"
            },
            {
              "key": "Serum TC (Healthy)",
              "value": "2.5 mmol/L"
            },
            {
              "key": "Serum TC (NASH)",
              "value": "4.0 mmol/L"
            },
            {
              "key": "Serum TC (TERN-101)",
              "value": "2.5 mmol/L"
            },
            {
              "key": "Serum TC (TERN-501)",
              "value": "2.0 mmol/L"
            },
            {
              "key": "Serum TC (TERN-101+501)",
              "value": "1.5 mmol/L"
            },
            {
              "key": "ALT (Healthy)",
              "value": "20U/L"
            },
            {
              "key": "ALT (NASH)",
              "value": "150U/L"
            },
            {
              "key": "ALT (TERN-101)",
              "value": "120U/L"
            },
            {
              "key": "ALT (TERN-501)",
              "value": "90U/L"
            },
            {
              "key": "ALT (TERN-101+501)",
              "value": "90U/L"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 29,
          "title": "Clinical validation of GLP-1 receptor agonists",
          "data": [
            {
              "key": "Overview",
              "value": "The section discusses clinical validation and trial outcomes for GLP-1 receptor agonists, focusing on weight loss effects and metabolic improvements."
            },
            {
              "key": "Semaglutide Findings",
              "value": "A recently approved once-weekly injection of semaglutide demonstrated an average 15% weight loss at 68 weeks along with improvements in blood pressure, cholesterol, and blood sugar."
            },
            {
              "key": "Other Candidates & Trial Data",
              "value": "Results from other agents like danuglipron, lotiglipron, and LY-3502970 are mentioned, with weight loss percentages ranging from ~3% to 7.1% over various durations."
            },
            {
              "key": "Drug Discovery Approach",
              "value": "The use of a proprietary three-dimensional quantitative structure activity relationship (3D QSAR) model to design novel GLP-1 receptor agonist candidates is highlighted."
            },
            {
              "key": "Development Landscape & Challenges",
              "value": "Discussion covers injectable versus oral formulations, potential advantages of non-peptidic small molecules, and challenges such as adverse effects and dosing requirements."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 30,
          "title": "Development of GLP-1R and GIPR Agonists",
          "data": [
            {
              "key": "Approach",
              "value": "Structure-based drug discovery using proprietary 3D QSAR model for GLP-1 receptor"
            },
            {
              "key": "Screening Effort",
              "value": "Over 20,000 molecular permutations screened to identify small-molecule scaffolds"
            },
            {
              "key": "Lead Molecule",
              "value": "TERN-601, a potent GLP-1R agonist biased towards cAMP generation"
            },
            {
              "key": "Target Product Profile",
              "value": "Non-peptide, orally administered once-daily dosing; applicable to obesity, NASH, and other indications"
            },
            {
              "key": "Clinical Development Plan",
              "value": "IND-enabling activities for TERN-601 with planned Phase 1 trials (SAD and MAD) in healthy volunteers; first-in-human trial targeted for the second half of 2023 with top-line data anticipated in 2024"
            },
            {
              "key": "Additional Program",
              "value": "Ongoing development of structurally distinct second-generation small molecule GLP-1R agonists and initiation of a GIPR modulator program (TERN-800 series) for obesity treatment"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 36,
          "title": "Licensing and Other Intellectual Property-Related Agreements TERN-701 Exclusive Option and License Agreement with Hansoh",
          "data": [
            {
              "key": "Agreement Overview",
              "value": "In July 2020, the company and its subsidiaries (CaspianTern LLC and Terns, Inc.) entered into an exclusive option and license agreement with Hansoh, granting Hansoh the exclusive option to obtain a sub-licensable, royalty-bearing license under certain patent and intellectual property rights related to TERN-701."
            },
            {
              "key": "Licensed Technology",
              "value": "Covers patents claiming the composition of TERN-701, a small-molecule allosteric inhibitor of the BCR-ABL fusion gene, and methods of using the same for therapeutic products targeting oncology indications."
            },
            {
              "key": "Geographical Scope",
              "value": "Mainland China, Taiwan, Hong Kong, and Macau (also referred to as the Hansoh Territory)."
            },
            {
              "key": "Financial Terms",
              "value": "An upfront refundable payment of $1 million (which becomes non-refundable upon option exercise in November 2021), potential milestone payments up to an aggregate of $67.0 million upon achieving specified clinical, regulatory, and sales milestones, and mid-single digit royalty percentages on net sales."
            },
            {
              "key": "Additional Provisions",
              "value": "Includes a manufacturing and technology transfer agreement with Hansoh for technical assistance, rights retention by the company outside the field of oncology and Hansoh Territory, and detailed termination provisions involving material breach, insolvency, and change of control."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "rnd_investment",
          "page": 39,
          "title": "IND Submission and Clinical Trial Protocol Requirements",
          "data": [
            {
              "key": "IND Submission",
              "value": "Design of a clinical protocol and submission to the FDA of an investigational new drug application (IND) that must become effective before human clinical trials may begin."
            },
            {
              "key": "IRB/Ethics Approval",
              "value": "Approval by an independent institutional review board (IRB) or ethics committee at each clinical site before starting each trial."
            },
            {
              "key": "Clinical Trials",
              "value": "Adequate and well-controlled human clinical trials conducted in accordance with good clinical practice (GCP) requirements to establish the proposed drug’s safety and efficacy."
            },
            {
              "key": "NDA Submission & Review",
              "value": "Submission of a new drug application (NDA) after completion of pivotal trials, with FDA determination to file within 60 days and subsequent review to permit commercial marketing."
            },
            {
              "key": "Manufacturing & Compliance Inspections",
              "value": "FDA inspection of manufacturing facilities to assess compliance with current Good Manufacturing Practice (cGMP) requirements and clinical investigation sites for GCP compliance."
            },
            {
              "key": "IND Activation",
              "value": "An IND automatically becomes effective 30 days after receipt by the FDA unless safety concerns prompt a clinical hold."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 40,
          "title": "Clinical Trial Protocols and Regulatory Requirements",
          "data": [
            {
              "key": "ClinicalTrialOverview",
              "value": "Describes the administration of investigational products to human subjects under GCP with informed consent, detailing the requirements for clinical protocols, IND submissions, IRB review, and ongoing monitoring."
            },
            {
              "key": "TrialPhases",
              "value": "Outlines the sequential phases of clinical trials (Phase 1, Phase 2, Phase 3, and Phase 4), including objectives for safety, dosing, efficacy and risk/benefit evaluation."
            },
            {
              "key": "RegulatoryCompliance",
              "value": "Highlights regulatory requirements such as separate IND submissions, IRB oversight at each site, and the possibility of trial suspension by regulatory authorities or the sponsor when safety risks are identified."
            },
            {
              "key": "DiversityActionPlan",
              "value": "Mentions the December 2022 FDORA mandate requiring sponsors to develop and submit a diversity action plan for pivotal studies to encourage enrollment of diverse patient populations."
            },
            {
              "key": "FDAInteractions",
              "value": "Describes scheduled meetings between sponsors and the FDA at various stages (pre-IND, post-Phase 2, pre-NDA) for discussing data, guidance, and development plans."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 125,
          "title": "Clinical Development and Capital Raising Update",
          "data": [
            {
              "key": "Clinical Program TERN-501",
              "value": "Second clinical stage program; THR-β agonist with high metabolic stability, enhanced liver distribution, and greater selectivity compared to other THR-β agonists."
            },
            {
              "key": "Phase 1 Trial Outcomes for TERN-501",
              "value": "Positive top-line data from SAD, MAD, and DDI cohorts; generally well-tolerated with mild to moderate AEs; predictable, linear, and dose-proportional pharmacokinetic profile."
            },
            {
              "key": "Pharmacodynamic Marker",
              "value": "Significant, dose-dependent increases in SHBG observed over 14 days, linked to markers of efficacy in NASH."
            },
            {
              "key": "Phase 2a DUET Clinical Trial",
              "value": "Initiated in July 2022 in NASH patients with both monotherapy and combination arms of TERN-501 and TERN-101; enrollment completed in February 2023; top-line data expected in Q3 2023."
            },
            {
              "key": "Clinical Program TERN-601",
              "value": "Lead GLP-1R agonist candidate for obesity; IND-enabling activities underway; first-in-human trial expected in the second half of 2023 with top-line data anticipated in 2024; trial to assess changes in body weight and HbA1c over 28 days."
            },
            {
              "key": "Capital Raising Events",
              "value": "IPO in February 2021: 8,625,000 shares at $17.00 ($133.0M); August 2022: 12,250,000 shares at $2.42 plus pre-funded warrants for 14,630,000 shares at $2.4199 ($60.7M); December 2022: 11,902,500 shares at $7.25 ($80.8M)."
            },
            {
              "key": "Resource Allocation",
              "value": "Substantial resources devoted to R&D, including clinical trials, preclinical studies, manufacturing, and organizational development."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "rnd_investment",
          "page": 128,
          "title": "Research and Development and General Administration Expense Analysis",
          "data": [
            {
              "key": "Consultant and External Fees",
              "value": "Costs associated with consultants for chemistry, manufacturing and controls development, regulatory, statistics and other services; expenses related to regulatory activities including filing fees paid to regulatory agencies; and facility costs including rent, depreciation and maintenance expenses."
            },
            {
              "key": "In-Process R&D Expense",
              "value": "Potential in-process research and development expense incurred when acquiring or in-licensing assets. Technology acquisitions are expensed or capitalized based on achieving technological feasibility as assessed by management."
            },
            {
              "key": "Internal R&D Costs",
              "value": "Employee and personnel-related costs and expenses, including salaries, benefits and stock-based compensation for personnel engaged in research and development functions. Internal resources are used to oversee research, discovery, preclinical development, process development, manufacturing and clinical development activities."
            },
            {
              "key": "Direct R&D Expenses",
              "value": "Direct research and development expenses include external costs such as fees paid to outside consultants, CROs, and CMOs for preclinical development, manufacturing and clinical development activities, as well as fees under license agreements."
            },
            {
              "key": "Year-over-Year Increase in R&D Expenses",
              "value": "For the year ended December 31, 2022, there was a $4.6 million increase in personnel-related expenses due to higher headcount and a $3.6 million increase in clinical and pre-clinical program expenses compared to the same period in 2021."
            },
            {
              "key": "General and Administrative Expenses",
              "value": "Costs include personnel-related expenses (salaries, benefits, stock-based compensation) for executive, finance, accounting, business development, legal, HR and administrative functions; facility costs; depreciation; and other expenses such as consulting and professional fees. An increase of $2.4 million in personnel costs and $0.6 million in other expenses was observed."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "rnd_investment",
          "page": 133,
          "title": "Research & Development Expenses and Loans Payable Accounting Policies",
          "data": [
            {
              "key": "Loans Payable",
              "value": "Loans are recorded at fair value on the date of issuance. Gains and losses from changes in fair value are recognized in the statement of operations each period while outstanding, with issuance costs expensed when incurred. The fair value is determined using a probability weighted expected return model."
            },
            {
              "key": "Research and Development Expenses",
              "value": "R&D costs are expensed as incurred and include costs to discover, research, and develop drug candidates. This includes personnel expenses, stock-based compensation, facility-related and depreciation expenses, third-party license fees, external consulting, and costs related to clinical trials and nonclinical studies. Prepayments for future R&D activities are recorded as prepaid expenses and expensed upon delivery of goods or performance of services. Costs for obtaining technology licenses are charged immediately if technological feasibility is not reached."
            },
            {
              "key": "Accrual Estimates",
              "value": "Accruals are recorded for estimated ongoing R&D costs based on progress in studies or clinical trials, invoices, and contracted costs, with significant judgments and estimates applied. Historical accrual estimates have been materially consistent with actual costs."
            },
            {
              "key": "Emerging Growth Company Status",
              "value": "The company has elected to use the extended transition period under the JOBS Act, delaying the adoption of new or revised accounting standards applicable to non‐emerging public companies. This status also exempts the company from providing an auditor attestation of internal control over financial reporting under Sarbanes-Oxley Act Section 404(b)."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 164,
          "title": "TERNS PHARMACEUTICALS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - License and Assignment Agreements",
          "data": [
            {
              "key": "Lilly VAP-1 2018 License Agreement",
              "value": "In March 2018, the Company entered into an exclusive, royalty-bearing license agreement with Eli Lilly. Under this agreement, Lilly granted the Company rights to develop, manufacture, and commercialize covered products, including sublicensing rights. The Company paid a non-refundable, non-creditable upfront payment of $4.0 million (recorded as R&D expense for 2018) and may pay up to $74.0 million for the first product and $30.0 million for a second indication. Tiered royalties are also payable based on net sales."
            },
            {
              "key": "Vintagence 2019 Assignment Agreement",
              "value": "In June 2019, the Company entered into an assignment agreement with Vintagence Biotechnology Ltd., acquiring worldwide rights to its technology with a sublicensing provision. A non-refundable, non-creditable upfront payment of $0.7 million was recorded as R&D expense for 2019. Additionally, the Company may pay up to CNY 205.0 million in development milestones. As of December 31, 2022, total payments to Vintagence amounted to $4.4 million, including a $1.5 million milestone for the IND filing and a $2.2 million milestone for the Phase 2a DUET trial, with $2.2 million recognized as R&D expense in 2022."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_new_product_launches": {
      "value": true,
      "elements": [
        {
          "type": "product_launch",
          "page": 8,
          "title": "Pipeline Candidate for Oncology: TERN-701",
          "data": [
            {
              "key": "Product Name",
              "value": "TERN-701"
            },
            {
              "key": "Indication",
              "value": "Chronic Myeloid Leukemia (CML); orphan indication"
            },
            {
              "key": "Mechanism of Action",
              "value": "Oral, potent, allosteric BCR-ABL TKI targeting the ABL myristoyl pocket"
            },
            {
              "key": "Context",
              "value": "Allosteric TKIs bind to the myristoyl pocket and aim to overcome limitations of active-site TKIs such as off-target activity and resistance mutations"
            },
            {
              "key": "Comparative Data",
              "value": "Asciminib, the only approved allosteric TKI, showed superior efficacy versus bosutinib in a Phase 3 trial (37.6% vs 15.8% MMR) and lower discontinuation rates (31.2% vs 60.5%)"
            },
            {
              "key": "Clinical Development Status",
              "value": "Phase 1 trial expected to start in the second half of 2023 with potential interim top-line readouts in 2024; update from an ongoing China Phase 1 trial expected in mid-2023"
            },
            {
              "key": "Geographical Scope",
              "value": "Trial sites planned in the United States, Europe, and other countries"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 9,
          "title": "Pipeline Candidates for Liver and Metabolic Diseases",
          "data": [
            {
              "key": "Product Name",
              "value": "TERN-501"
            },
            {
              "key": "Description",
              "value": "TERN-501 is a THR-β agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR-β compared to other THR-β agonists in development."
            },
            {
              "key": "Potential Benefits",
              "value": "THR-β stimulation may reduce hepatic steatosis, improve fibrosis and serum lipid parameters including LDL cholesterol and triglycerides."
            },
            {
              "key": "Clinical Trial Announcement Date",
              "value": "November 2021"
            },
            {
              "key": "Trial Results",
              "value": "Positive top-line data from Phase 1 clinical trial in healthy volunteers."
            },
            {
              "key": "Next Steps",
              "value": "The Phase 2a DUET trial evaluating TERN-501 as a monotherapy and in combination with TERN-101 completed enrollment in February 2023."
            },
            {
              "key": "Expected Data Release",
              "value": "Top-line data expected in the third quarter of 2023."
            },
            {
              "key": "Second Product Name",
              "value": "TERN-601"
            },
            {
              "key": "Second Product Description",
              "value": "TERN-601 is a small-molecule GLP-1R agonist intended for oral administration for metabolic diseases."
            },
            {
              "key": "Second Product Development Timeline",
              "value": "First-in-human clinical trial for obesity expected to initiate in the second half of 2023 with top-line data expected in 2024."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 11,
          "title": "Clinical Proof-of-Concept for Drug Candidates",
          "data": [
            {
              "key": "Approach",
              "value": "Using non-invasive biomarkers in clinical trials to confirm and benchmark target engagement."
            },
            {
              "key": "Clinical Trials Initiatives",
              "value": "Expedited trials for CML and NASH using markers such as polymerase chain reaction blood test, MRI-PDFF, and corrected T1."
            },
            {
              "key": "Obesity Treatment Measurement",
              "value": "Body weight change."
            },
            {
              "key": "Strategy",
              "value": "Independently develop drug candidates ensuring maximum value and potential collaboration for promising candidates."
            },
            {
              "key": "Key Statistics on CML",
              "value": "Approximately 90,000 existing CML cases projected to reach 180,000 by 2030, with about 9,000 new cases expected in 2023."
            },
            {
              "key": "CML Definition",
              "value": "A chronic leukemia that develops slowly and may result from chromosomal translocation leading to BCR-ABL1 fusion oncogene."
            },
            {
              "key": "Symptoms and Age of Diagnosis",
              "value": "Average age is 64 years, typically diagnosed in adults over 65."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 12,
          "title": "Treatment of CML and Approval of New Treatment Options",
          "data": [
            {
              "key": "Product",
              "value": "TERN-701"
            },
            {
              "key": "Type",
              "value": "Allosteric BCR-ABL TKI"
            },
            {
              "key": "First Approval Date",
              "value": "2021"
            },
            {
              "key": "Related Products",
              "value": "asciminib (approved 2021), imatinib (approved 2001), dasatinib (approved 2006), nilotinib (approved 2007), bosutinib (approved 2012)"
            },
            {
              "key": "Clinical Efficacy",
              "value": "Improved compared to active-site TKIs"
            },
            {
              "key": "Target Population",
              "value": "Adults with CML, including those with T315I mutation"
            },
            {
              "key": "Mechanism of Action",
              "value": "Targets myristoyl-binding pocket, locking BCR-ABL1 into inactive state"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 13,
          "title": "Product Development and Clinical Trials of TERN-701",
          "data": [
            {
              "key": "Product Name",
              "value": "TERN-701 (HS-10382)"
            },
            {
              "key": "Licensor",
              "value": "Hansoh"
            },
            {
              "key": "Indication",
              "value": "Chronic Myeloid Leukemia (CML)"
            },
            {
              "key": "Trial Start Date",
              "value": "Second half of 2023"
            },
            {
              "key": "Trial Type",
              "value": "Open-label, multicenter, dose-escalation and expansion, first-in-human study"
            },
            {
              "key": "Target Population",
              "value": "Patients with chronic or accelerated phase CML resistant or intolerant to prior therapy"
            },
            {
              "key": "Geographical Focus",
              "value": "Greater China region"
            },
            {
              "key": "Clinical Trials",
              "value": "Ongoing Phase 1 trial in China"
            },
            {
              "key": "Sales of Competitive TKIs in 2022",
              "value": "Approximately $5 billion"
            },
            {
              "key": "Expected Readouts",
              "value": "Potential interim top-line readouts from initial cohorts in 2024"
            },
            {
              "key": "Regulatory Status in US for ALL",
              "value": "Not pursuing approval due to price controls under IRA 2022"
            },
            {
              "key": "Clinical Response Measurements",
              "value": "Molecular, hematologic and cytogenic response"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 15,
          "title": "Launch of Allosteric TKI TERN-701 for CML treatment",
          "data": [
            {
              "key": "Product Name",
              "value": "TERN-701"
            },
            {
              "key": "Indication",
              "value": "CML (Chronic Myeloid Leukemia)"
            },
            {
              "key": "Mechanism of Action",
              "value": "Allosteric inhibitor targeting BCR-ABL"
            },
            {
              "key": "Comparison Product",
              "value": "asciminib"
            },
            {
              "key": "Unique Selling Points",
              "value": "Improved tumor suppression, broad range mutation activity, better safety profile"
            },
            {
              "key": "Clinical Status",
              "value": "Under development in the United States"
            },
            {
              "key": "Combination Therapy Potential",
              "value": "Can be combined with active-site TKIs for enhanced efficacy"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 18,
          "title": "Development of THR-β Agonists for NASH Treatment",
          "data": [
            {
              "key": "FDA-approved therapies",
              "value": "None for NASH, limited treatment options available"
            },
            {
              "key": "Treatment options",
              "value": "Control metabolic dysfunction, weight loss, lifestyle modifications"
            },
            {
              "key": "Current clinical stage program",
              "value": "TERN-501, a THR-β agonist"
            },
            {
              "key": "Phase 1 trial results",
              "value": "Positive top-line data announced in November 2021"
            },
            {
              "key": "Fast Track designation",
              "value": "Granted by FDA for TERN-501 in June 2021"
            },
            {
              "key": "Combination therapies",
              "value": "Potential to address multiple disease processes in NASH patients"
            },
            {
              "key": "Goals for ideal NASH therapy",
              "value": "Address steatosis, inflammation, fibrosis, and improve metabolic profile"
            },
            {
              "key": "Key milestone",
              "value": "Phase 2a DUET trial completed enrollment in February 2023, with top-line data expected Q3 2023"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 20,
          "title": "Metabolism and Selectivity of TERN-501",
          "data": [
            {
              "key": "Metabolized by",
              "value": "CYP P450"
            },
            {
              "key": "Adverse Events",
              "value": "Cardiovascular, gastrointestinal"
            },
            {
              "key": "Gastrointestinal Adverse Events",
              "value": "Diarrhea (33%), Nausea (14%)"
            },
            {
              "key": "Cardiovascular Events",
              "value": "Ventricular run, Chest pressure, Palpitations"
            },
            {
              "key": "Selectivity for THR-β",
              "value": "23-fold vs THR-α"
            },
            {
              "key": "Chemical Structure Changes",
              "value": "Designed to enhance metabolic stability"
            },
            {
              "key": "Development Stage",
              "value": "Late-stage"
            },
            {
              "key": "Comparison with Other Agonists",
              "value": "Higher selectivity than other THR agonists"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 21,
          "title": "Clinical development of TERN-501",
          "data": [
            {
              "key": "Product Name",
              "value": "TERN-501"
            },
            {
              "key": "Indication",
              "value": "NASH"
            },
            {
              "key": "Clinical Trial Phase",
              "value": "Phase 1"
            },
            {
              "key": "Main Findings",
              "value": "Positive top-line data, well-tolerated, significant decreases in LDL cholesterol"
            },
            {
              "key": "Dosing Regimen",
              "value": "Single doses of 3, 10, 30 or 60 mg; multiple doses of 1, 3, 6 or 10 mg once daily for 14 days"
            },
            {
              "key": "Adverse Events",
              "value": "All mild to moderate, no serious AEs"
            },
            {
              "key": "PK Profile",
              "value": "Predictable, dose-proportional, plasma half-life > 13 hours, no significant accumulation"
            },
            {
              "key": "Effect on LDL cholesterol",
              "value": "Maximum mean decreases of -13%, -22%, -28%, -27% for respective doses compared to placebo (-8%)"
            },
            {
              "key": "SHBG",
              "value": "Significant increases observed, linked to NASH histologic efficacy"
            },
            {
              "key": "Research Significance",
              "value": "Well-suited for co-formulation with other NASH agents as a fixed dose combination"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 28,
          "title": "Obesity Treatments and Drug Candidates",
          "data": [
            {
              "key": "Obesity-related diseases",
              "value": "heart disease, type 2 diabetes, stroke, gallbladder disease, gastroesophageal reflux disease, cancer, sleep apnea"
            },
            {
              "key": "Projected obesity-related healthcare costs (2030)",
              "value": "$780 billion"
            },
            {
              "key": "Global pharmaceutical market for obesity (2020)",
              "value": "$1 billion"
            },
            {
              "key": "Expected obesity market growth (2025)",
              "value": "beyond $5 billion"
            },
            {
              "key": "Forecasted worldwide obesity market (2031)",
              "value": "exceed $27 billion"
            },
            {
              "key": "New drug TERN-601 summary",
              "value": "oral GLP-1R agonist, nominated for development for obesity and NASH, clinical trial planned for late 2023"
            },
            {
              "key": "Mechanisms of GLP-1 for obesity",
              "value": "reducing glucagon, slowing gastric emptying, increasing satiety, reducing inflammation, improving cardiac function"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "product_launch",
          "page": 31,
          "title": "Pipeline Update: Novel Therapeutic Candidates for Obesity, Metabolic Diseases and Cancer",
          "data": [
            {
              "key": "AMG 133",
              "value": "A monomolecular combination of a GIPR antagonist/GLP-1R agonist developed by Amgen. In a Phase 1 clinical study, a single high dose produced ~8 kg weight loss and in the MAD portion (420 mg dose given every 4 weeks) resulted in a mean body weight reduction of 10%-15% through approximately Day 150, with a peak 14.5% decrease at Day 85."
            },
            {
              "key": "TERN-201",
              "value": "An oral, highly selective vascular adhesion protein-1 (VAP-1) inhibitor that has demonstrated sustained target engagement and near-complete (>98%) suppression of VAP-1 enzymatic activity in multiple clinical trials, and was generally well-tolerated across ~100 subjects."
            },
            {
              "key": "TERN-301",
              "value": "A potent and selective orally bioavailable ASK1 inhibitor with slow metabolic turnover, low clearance, and good oral absorption. It showed superior selectivity compared to selonsertib and improved NAFLD activity scores in the MCD model of NASH."
            },
            {
              "key": "TRN-000546",
              "value": "A novel oral, liver-directed monophosphate prodrug of fluorodeoxyuridylate (FdUMP), designed to protect FdUMP from enzymatic deactivation and enhance delivery into the liver. It is more potent than 5-FU and has demonstrated comparable or improved efficacy in various in vivo tumor models (liver, gastric, and colon cancers)."
            },
            {
              "key": "Manufacturing and Supply",
              "value": "The company does not own manufacturing facilities and relies on third-party contract manufacturers for production during preclinical research and clinical trials, with plans to establish agreements for commercial production upon regulatory approval."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 32,
          "title": "Sales and Marketing and Competition Overview",
          "data": [
            {
              "key": "Commercial Organization Status",
              "value": "Not yet established; plan to build targeted commercial infrastructure in key geographies prior to regulatory approval"
            },
            {
              "key": "Sales, Marketing and Distribution Strategy",
              "value": "Manage through internal resources and third-party relationships, with opportunistic exploration of commercialization partnerships outside the United States"
            },
            {
              "key": "Factors Influencing Commercialization Strategy",
              "value": "Clinical data, size of development programs, target market size, commercial infrastructure, and manufacturing needs"
            },
            {
              "key": "Industry Competition",
              "value": "Biotechnology industry is highly competitive with rapid technological change"
            },
            {
              "key": "Competitors in CML Treatments",
              "value": "Ascentage Pharma Group, BristolMyers Squibb Company, Enliven Therapeutics Inc., Jiangsu Hansoh Pharmaceutical Group, Novartis Pharmaceuticals Corp., Pfizer Inc., Shenzhen TargetRx Inc., Sun Pharma Industries Ltd., Takeda Pharmaceutical Co., Ltd. and Theseus Pharmaceuticals, Inc."
            },
            {
              "key": "Competitors in NASH Treatments",
              "value": "AbbVie, Inc., Amgen Inc., AstraZeneca PLC/MedImmune LLC, Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb Company, Eisai, Inc., Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis Pharmaceuticals Corp., Novo Nordisk A/S, Pfizer Inc., Roche Holding AG, Sanofi, Sumitomo Dainippon Pharma Co., Ltd. and Takeda Pharmaceutical Co., Ltd."
            },
            {
              "key": "Competitors in Obesity Treatments",
              "value": "Amgen, Inc., Boehringer Ingelheim GmbH, Bristol Myers Squibb Company, Eli Lilly and Co., Hanmi Pharmaceutical Co., Ltd., Johnson & Johnson, LG Chem, Ltd., Novartis AG, Novo Nordisk A/S, Otsuka Holdings Co., Ltd., Pfizer Inc. and Shionogi & Co. Ltd."
            },
            {
              "key": "Competitors in THR-β Targeted Clinical Trials for NASH (TERN-501)",
              "value": "Ascletis Pharma Inc., Aligos Therapeutics, Inc., Madrigal Pharmaceuticals, Inc. and Viking Therapeutics, Inc."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 42,
          "title": "U.S. Review and Approval Process",
          "data": [
            {
              "key": "Submission Requirements",
              "value": "Includes results from product development, preclinical/non-clinical studies, clinical trials, manufacturing process details, analytical tests, and proposed labeling."
            },
            {
              "key": "Regulatory Submission",
              "value": "Submitted as an NDA to the FDA for marketing approval."
            },
            {
              "key": "User Fees",
              "value": "Substantial fees are required; waivers possible under limited circumstances, especially for orphan drugs."
            },
            {
              "key": "Preliminary Review",
              "value": "FDA reviews NDAs within 60 days to check completeness before filing."
            },
            {
              "key": "Review Timeline",
              "value": "Standard review goal is ten months from filing, typically taking around twelve months from submission."
            },
            {
              "key": "Advisory Committee",
              "value": "Applications for novel drugs may be referred to an independent advisory committee for recommendation."
            },
            {
              "key": "Inspections",
              "value": "FDA inspects manufacturing facilities for cGMP compliance and clinical sites for GCP compliance prior to approval."
            },
            {
              "key": "Possible Outcomes",
              "value": "Outcome may be an approval letter for marketing or a Complete Response Letter (CRL) requiring additional data and resubmission."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 62,
          "title": "Product Candidate Development and Regulatory Factors",
          "data": [
            {
              "key": "Investigational New Drug Applications (INDs)",
              "value": "Our ability to complete INDs and related studies."
            },
            {
              "key": "Regulatory Authority Studies",
              "value": "FDA or similar authorities may require further studies beyond planned."
            },
            {
              "key": "Acceptance of Proposed Indications",
              "value": "Acceptance of indications by FDA including non-invasive endpoints."
            },
            {
              "key": "Safety and Efficacy Demonstration",
              "value": "Ability to demonstrate safety and efficacy for product candidates."
            },
            {
              "key": "Potential Side Effects",
              "value": "Prevalence and severity of potential side effects or issues."
            },
            {
              "key": "Marketing Approvals",
              "value": "Timely receipt of marketing approvals from regulatory authorities."
            },
            {
              "key": "Third-party Contractor Compliance",
              "value": "Achieving compliance with regulatory requirements for product candidates."
            },
            {
              "key": "Manufacturing Compliance",
              "value": "Ability of contractors to meet cGMPs and maintain manufacturing processes."
            },
            {
              "key": "Commercial Strategy and Market Strategy",
              "value": "Successfully developing commercial strategy in the U.S. and internationally."
            },
            {
              "key": "Market Acceptance",
              "value": "Achieving market acceptance, coverage, and revenue for approved drugs."
            },
            {
              "key": "Treatment and Compliance",
              "value": "Convenience of treatments affecting patient compliance."
            },
            {
              "key": "Acceptance by Physicians and Patients",
              "value": "Acceptance of product candidates' benefits by stakeholders."
            },
            {
              "key": "Patient Demand and Enrollment",
              "value": "Willingness of patients to participate in trials and demand for products."
            },
            {
              "key": "Competing Therapies",
              "value": "Ability to compete effectively with other therapies."
            },
            {
              "key": "Fixed-dose Combination Development",
              "value": "Ease of developing combination therapy candidates."
            },
            {
              "key": "Intellectual Property Rights",
              "value": "Ability to establish and enforce intellectual property rights."
            },
            {
              "key": "Avoiding Patent Issues",
              "value": "Avoidance of patent interference or infringement claims."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 67,
          "title": "Challenges in Clinical Trials for Product Candidates",
          "data": [
            {
              "key": "Product Candidates",
              "value": "New drug candidates for indications without approved therapies or regulatory pathways."
            },
            {
              "key": "Challenges",
              "value": "Difficulties in enrolling patients for clinical trials may delay development."
            },
            {
              "key": "Factors Affecting Enrollment",
              "value": "Includes eligibility criteria, proximity to sites, competition with other trials, etc."
            },
            {
              "key": "Competition",
              "value": "Face significant competition from pharmaceutical, biopharmaceutical, and biotechnology companies."
            },
            {
              "key": "Market Penetration",
              "value": "Approval and competition may hinder achieving significant market penetration."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 68,
          "title": "Pharmaceutical and Biotechnology Companies Developing Treatments",
          "data": [
            {
              "key": "CML Treatment Companies",
              "value": "Ascentage Pharma Group, Bristol Myer Squibb Company, Enliven Therapeutics, Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Novartis Pharmaceuticals Corp., Pfizer Inc., Shenzhen TargetRx Inc., Sun Pharma Industries Ltd., Takeda Pharmaceutical Co., Ltd. and Theseus Pharmaceuticals."
            },
            {
              "key": "NASH Treatment Companies",
              "value": "AbbVie, Inc., Amgen Inc., AstraZeneca PLC/MedImmune LLC, Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb Company, Eisai, Inc., Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novo Nordisk A/S, Pfizer Inc., Roche Holding AG, Sanofi, Sumitomo Dainippon Pharma Co., Ltd. and Takeda Pharmaceutical Co., Ltd."
            },
            {
              "key": "Obesity Treatment Companies",
              "value": "Amgen, Inc., Boehringer Ingelheim GmbH, Bristol Myers Squibb Company, Eli Lilly and Co., Hanmi Pharmaceutical Co., Ltd., Johnson & Johnson, LG Chem, Ltd., Novartis AG, Novo Nordisk A/S, Otsuka Holdings Co., Ltd., Pfizer Inc. and Shionogi & Co. Ltd."
            },
            {
              "key": "Clinical Trials for TERN-501 in NASH",
              "value": "Ascletis Pharma Inc., Aligos Therapeutics, Inc., Madrigal Pharmaceuticals, Inc. and Viking Therapeutics, Inc."
            },
            {
              "key": "Clinical Trials for TERN-601 in Obesity",
              "value": "9 Meters Biopharma, Inc., Amgen Inc., Altimmune, AstraZeneca plc, Boehringer Ingelheim GmbH, Carmot Therapeutics, Inc., CinRx Pharma, Cyrus Therapeutics, Inc., D&D Pharmatech, Eiger BioPharmaceuticals, Inc., Eli Lilly and Co., Hanmi Pharmaceutical Co., Ltd., ImmunoForge, Co. Ltd., Intarcia Therapeutics, Inc., Invex Therapeutics Inc., Longevity Biotech Inc., Novo Nordisk A/S, Opko Health, Oramed Pharmaceuticals, PegBio Co Ltd., Pfizer Inc., Pharmaxis, Regor Therapeutics Group, Sanofi, Sciwind Biosciences Co., Structure Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Viking Therapeutics, Inc., vTv Therapeutics Inc. and Zealand Pharma A/S."
            },
            {
              "key": "Clinical Trials for TERN-101 with FXR Agonists in NASH",
              "value": "AbbVie, Inc., Ascletis Pharma, Inc., Enanta Pharmaceuticals, Inc., ENYO Pharma SA, Gilead Sciences, Inc., Hepagene Therapeutics, Inc., Intercept Pharmaceuticals, Inc., Metacrine Inc. and Novartis Pharmaceuticals Corp."
            },
            {
              "key": "Clinical Trials for TERN-800 targeting GIPR in Obesity",
              "value": "9 Meters Biopharma, Inc., Amgen, Inc., Carmot Therapeutics, D&D Pharmatech, Eli Lilly and Co., Sciwind Biosciences Co., Viking Therapeutics, Inc. and Zealand Pharma A/S."
            },
            {
              "key": "Other Companies Developing Clinical-stage Drugs for Serious Diseases",
              "value": "89Bio, Inc., Aardvark Therapeutics, Inc., Akero Therapeutics, Inc., Arrowhead Pharmaceuticals, Inc., Axcella Health, Inc., Carmot Therapeutics, Inc., Cirius Therapeutics, Inc., CohBar, Inc., Coherus Biosciences Inc., Corcept Therapeutics, Inc., Currax Pharmaceuticals LLC, CymaBay Therapeutics, Inc., CytoDyne Inc., Diasome Pharmaceuticals, Esperion Therapeutics, Inc., Fusion Pharma, LLC, Galectin Therapeutics Inc., Galmed Pharmaceuticals Ltd., Gila Therapeutics, Inc., Hanmi Pharmaceutical Co., Ltd., IL-YANG Pharm. Co. Ltd., Inhibikase Therapeutics, Inc., Inventiva Pharma SA, Ionis Pharmaceuticals, Inc., MediciNova, Inc., NGM Biopharmaceuticals, Inc., Norgine B.V., NorthSea Therapeutics, Inc., Pliant Therapeutics, Inc., Poxel SA, Saniona AB, Sagimet Biosciences, Inc., T3D Therapeutics, Inc., Vivus, Inc., and Zydus Cadila Healthcare."
            },
            {
              "key": "Future Drug Development Expectations",
              "value": "The number of companies seeking to develop drugs and therapies for the treatment of serious diseases such as oncology, NASH or obesity is expected to increase."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 69,
          "title": "Product Candidates and Market Penetration Challenges",
          "data": [
            {
              "key": "Main Competitors",
              "value": "Many competitors have greater resources and capabilities."
            },
            {
              "key": "Mergers and Acquisitions Impact",
              "value": "Mergers in the pharmaceutical industry may concentrate resources."
            },
            {
              "key": "Challenges",
              "value": "Lack of non-invasive methods for diagnosis of NASH is a challenge."
            },
            {
              "key": "Market Penetration Issues",
              "value": "Current diagnostic methods hinder the progression into the market for product candidates."
            },
            {
              "key": "Regulatory Approvals",
              "value": "Competitors might obtain regulatory approvals faster, impacting market entry."
            },
            {
              "key": "Commercial Potential",
              "value": "Commercial success of product candidates may be limited by awareness and diagnosis challenges."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 124,
          "title": "Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations",
          "data": [
            {
              "key": "Section Overview",
              "value": "Management’s Discussion and Analysis of Financial Condition and Results of Operations; contains forward-looking statements and discussion of operational risks."
            },
            {
              "key": "Company Overview",
              "value": "A clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates targeting serious diseases including oncology and metabolic diseases (e.g., NASH and obesity)."
            },
            {
              "key": "Pipeline Details",
              "value": "Key product candidates include TERN-701 (an allosteric BCR-ABL TKI for CML), TERN-501 (a highly selective THR-β agonist for NASH in Phase 2a), and TERN-601 (a small-molecule GLP-1R agonist for metabolic diseases). Also mentions TERN-800 series (GIPR modulators for obesity)."
            },
            {
              "key": "Clinical Trial Plans",
              "value": "Intends to initiate a Phase 1 clinical trial for TERN-701 in the US in the second half of 2023; TERN-501 expects top-line data in Q3 2023; TERN-601 aims for a first-in-human clinical trial in the second half of 2023; updates for the ongoing China Phase 1 trial (in-licensed to Hansoh) anticipated."
            },
            {
              "key": "Strategic Partnership",
              "value": "In July 2020, Hansoh in-licensed TERN-701 (referred to as HS-10382) for development in the greater China region, bearing local development costs, while worldwide rights outside China are retained."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_capital_expenditures": {
      "value": true,
      "elements": [
        {
          "type": "capital_expenditure",
          "page": 57,
          "title": "Capital Resources and Future Funding",
          "data": [
            {
              "key": "Capital Resources",
              "value": "$283.1 million"
            },
            {
              "key": "Planned Operating Expenses",
              "value": "Into 2026"
            },
            {
              "key": "Potential Need for Additional Funds",
              "value": "Yes, may be required sooner than planned"
            },
            {
              "key": "Sources for Additional Funds",
              "value": "Public/private equity offerings, debt financing, strategic collaborations"
            },
            {
              "key": "Future Capital Requirements Factors",
              "value": "Scope and costs of R&D, success of clinical trials, regulatory approval costs, number of product candidates, milestone payments, manufacturing costs, marketing and sales costs, strategic collaborations, hiring skilled personnel, company public costs, IP portfolio management, sales timing and amount, impact of COVID-19"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 58,
          "title": "Funding and Development Allocation Risks",
          "data": [
            {
              "key": "Additional funding risks",
              "value": "Additional funds may not be available when needed, affecting operations."
            },
            {
              "key": "Impact of COVID-19",
              "value": "Global economic conditions and disruptions from COVID-19 may hinder capital raising."
            },
            {
              "key": "Financing operations",
              "value": "Operations primarily financed through equity and debt securities."
            },
            {
              "key": "Future funding sources",
              "value": "Future funding through public or private offerings, debt financings, or collaborations."
            },
            {
              "key": "Dilution risk",
              "value": "Issuing equity may dilute stockholder rights."
            },
            {
              "key": "Debt financing risks",
              "value": "Debt covenants may restrict future business flexibility."
            },
            {
              "key": "Resource allocation",
              "value": "Prioritization needed due to limited resources for product development."
            },
            {
              "key": "Current focus areas",
              "value": "Focus on CML, NASH, and obesity for product candidates."
            },
            {
              "key": "Decision on resource allocation",
              "value": "Based on strategic review, certain candidates prioritized over others."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 149,
          "title": "Notes to Consolidated Financial Statements - Property and Equipment & Deferred Offering Costs",
          "data": [
            {
              "key": "Company",
              "value": "TERNS PHARMACEUTICALS, INC."
            },
            {
              "key": "Deferred Offering Costs",
              "value": "Certain legal, professional, accounting and third-party fees directly associated with in-process equity financings are capitalized as deferred offering costs until the financing is consummated. If abandoned, these costs are expensed immediately as an operating expense."
            },
            {
              "key": "Property and Equipment Accounting",
              "value": "Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed on a straight-line basis over estimated useful lives, which typically range from 3 to 5 years. Repairs and maintenance costs are expensed as incurred."
            },
            {
              "key": "Depreciation Expense",
              "value": "$0.5 million was recorded as depreciation expense for each of the years ended December 31, 2022 and 2021."
            },
            {
              "key": "Impairment of Long-Lived Assets",
              "value": "The assets are evaluated for impairment when conditions indicate that the carrying amount may not be recoverable. No impairments of long-lived assets were recorded for the periods presented."
            },
            {
              "key": "Property and Equipment Summary",
              "value": "A table breakdown shows key categories including Leasehold improvements, Furniture and fixtures, Computer equipment, Office equipment, and Lab equipment. Total property and equipment, net decreased from $1,046K in 2021 to $757K in 2022, largely due to increased accumulated depreciation."
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_financial_performance_indicators": {
      "value": true,
      "elements": [
        {
          "type": "financial_performance",
          "page": 1,
          "title": "SEC Form 10-K - Annual Report",
          "data": [
            {
              "key": "Filing Document",
              "value": "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Form 10-K (Annual Report)"
            },
            {
              "key": "Fiscal Year End",
              "value": "December 31, 2022"
            },
            {
              "key": "Commission File Number",
              "value": "001-39926"
            },
            {
              "key": "Registrant Name",
              "value": "Terns Pharmaceuticals, Inc."
            },
            {
              "key": "State of Incorporation",
              "value": "Delaware"
            },
            {
              "key": "Principal Executive Office Address",
              "value": "1065 East Hillsdale Blvd., Suite 100, Foster City, California 94404"
            },
            {
              "key": "Employer Identification Number",
              "value": "98-1448275"
            },
            {
              "key": "Registrant Telephone",
              "value": "(650) 525-5535"
            },
            {
              "key": "Well-Known Seasoned Issuer",
              "value": "No"
            },
            {
              "key": "Filer Reporting Compliance",
              "value": "Yes (all required reports filed in the preceding period)"
            },
            {
              "key": "Electronic Submission of Interactive Data Files",
              "value": "Yes"
            },
            {
              "key": "Company Category",
              "value": "Smaller reporting company; Emerging growth company"
            },
            {
              "key": "Market Value (Non-Affiliate Common Stock as of June 30, 2022)",
              "value": "$46,808,820"
            },
            {
              "key": "Common Stock Outstanding (as of March 3, 2023)",
              "value": "56,669,596"
            },
            {
              "key": "Incorporation of External Documents",
              "value": "Portions of Part III are incorporated by reference from the definitive proxy statement for the 2023 annual meeting of stockholders."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 127,
          "title": "Results of Operations",
          "data": [
            {
              "key": "License revenue",
              "value": "2022: 0, 2021: 1000, Change: -1000 (in thousands)"
            },
            {
              "key": "Research and development",
              "value": "2022: 39617, 2021: 31311, Change: 8306 (in thousands)"
            },
            {
              "key": "General and administrative",
              "value": "2022: 22412, 2021: 19549, Change: 2863 (in thousands)"
            },
            {
              "key": "Total operating expenses",
              "value": "2022: 62029, 2021: 50860, Change: 11169 (in thousands)"
            },
            {
              "key": "Loss from operations",
              "value": "2022: -62029, 2021: -49860, Change: -12169 (in thousands)"
            },
            {
              "key": "Interest income",
              "value": "2022: 2110, 2021: 170, Change: 1940 (in thousands)"
            },
            {
              "key": "Other (expense) income, net",
              "value": "2022: -68, 2021: 40, Change: -108 (in thousands)"
            },
            {
              "key": "Total other income, net",
              "value": "2022: 2042, 2021: 210, Change: 1832 (in thousands)"
            },
            {
              "key": "Loss before income taxes",
              "value": "2022: -59987, 2021: -49650, Change: -10337 (in thousands)"
            },
            {
              "key": "Income tax expense",
              "value": "2022: -358, 2021: -508, Change: 150 (in thousands)"
            },
            {
              "key": "Net loss",
              "value": "2022: -60345, 2021: -50158, Change: -10187 (in thousands)"
            },
            {
              "key": "Revenue Commentary",
              "value": "No product sale revenue to date; decrease in revenue due to one-time $1.0 million recognized in 2021 from an exclusive option exercised by Hansoh."
            },
            {
              "key": "R&D Expenses Commentary",
              "value": "Expenses primarily related to discovery, preclinical, and clinical development of product candidates; costs are recognized as incurred with capitalization for prepayment until receipt."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 129,
          "title": "Financial Performance and Liquidity Overview",
          "data": [
            {
              "key": "Interest Income 2022",
              "value": "$2.1 million"
            },
            {
              "key": "Interest Income 2021",
              "value": "$0.2 million"
            },
            {
              "key": "Reason for Increase in Interest Income",
              "value": "Increase in interest rates"
            },
            {
              "key": "Other (Expense) Income, Net 2022",
              "value": "Less than $0.1 million expense"
            },
            {
              "key": "Other (Expense) Income, Net 2021",
              "value": "Less than $0.1 million income"
            },
            {
              "key": "Income Tax Expense 2022",
              "value": "$0.4 million"
            },
            {
              "key": "Income Tax Expense 2021",
              "value": "$0.5 million"
            },
            {
              "key": "Accumulated Deficit as of Dec 31, 2022",
              "value": "$242.4 million"
            },
            {
              "key": "Net Loss as of Dec 31, 2022",
              "value": "$60.3 million"
            },
            {
              "key": "Negative Cash Flows from Operations",
              "value": "$49.1 million"
            },
            {
              "key": "Cash, Cash Equivalents, and Marketable Securities",
              "value": "$283.1 million"
            },
            {
              "key": "Funding Sources Mentioned",
              "value": "Convertible promissory notes, convertible preferred stock issuance, IPO proceeds"
            },
            {
              "key": "Primary Use of Cash",
              "value": "Fund operating expenses including research & development and general & administrative expenditures"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 132,
          "title": "Cash Flow Analysis: Investing and Financing Activities",
          "data": [
            {
              "key": "Net cash used in investing activities (2022)",
              "value": "$22.3 million"
            },
            {
              "key": "Purchases of investments (2022)",
              "value": "$139.7 million"
            },
            {
              "key": "Purchases of property and equipment (2022)",
              "value": "$0.3 million"
            },
            {
              "key": "Proceeds from sale and maturity of investments (2022)",
              "value": "$117.7 million"
            },
            {
              "key": "Net cash used in investing activities (2021)",
              "value": "$119.7 million"
            },
            {
              "key": "Purchases of investments (2021)",
              "value": "$166.3 million"
            },
            {
              "key": "Purchases of property and equipment (2021)",
              "value": "$0.3 million"
            },
            {
              "key": "Proceeds from sale and maturity of investments (2021)",
              "value": "$46.9 million"
            },
            {
              "key": "Net cash provided by financing activities (2022)",
              "value": "$167.1 million"
            },
            {
              "key": "Proceeds from issuance of common stock in connection with the December 2022 Financing",
              "value": "$81.1 million"
            },
            {
              "key": "Proceeds from issuance of common stock and pre-funded warrants in connection with the August 2022 Financing",
              "value": "$61.1 million"
            },
            {
              "key": "Proceeds from issuance of common stock in an at-the-market offering",
              "value": "$25.0 million"
            },
            {
              "key": "Proceeds from issuance of common stock under the employee stock purchase plan",
              "value": "$0.2 million"
            },
            {
              "key": "Payments of deferred offering costs (2022)",
              "value": "$0.4 million"
            },
            {
              "key": "Net cash provided by financing activities (2021)",
              "value": "$134.4 million"
            },
            {
              "key": "Proceeds from issuance of common stock upon closing of the IPO in February 2021",
              "value": "$136.4 million"
            },
            {
              "key": "Proceeds from stock option exercises (2021)",
              "value": "$0.9 million"
            },
            {
              "key": "Payments of deferred offering costs (2021)",
              "value": "$2.7 million"
            },
            {
              "key": "Net payment on loans payable (2021)",
              "value": "$0.2 million"
            },
            {
              "key": "Off-balance sheet arrangements",
              "value": "None"
            },
            {
              "key": "Critical accounting policies discussion",
              "value": "Based on U.S. GAAP with significant estimates and judgments as described in Note 1 and related sections."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 135,
          "title": "INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Report of Independent Registered Public Accounting Firm (PCAOB ID: 42)",
          "data": [
            {
              "key": "Table Title",
              "value": "Financial Statements Index"
            },
            {
              "key": "Statements",
              "value": "Consolidated Balance Sheets (page 137), Consolidated Statements of Operations and Comprehensive Loss (page 138), Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (page 139), Consolidated Statements of Cash Flows (page 140), Notes to Consolidated Financial Statements (page 141)"
            },
            {
              "key": "Summary",
              "value": "This table appears to be an index or table of contents for a financial report, listing the main financial statements and their corresponding page numbers in a typical sequence found in annual reports or financial filings."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 136,
          "title": "Report of Independent Registered Public Accounting Firm To the Stockholders and the Board of Directors of Terns Pharmaceuticals, Inc.",
          "data": [
            {
              "key": "Report Type",
              "value": "Independent Auditor's Report"
            },
            {
              "key": "Opinion Title",
              "value": "Opinion on the Financial Statements"
            },
            {
              "key": "Company",
              "value": "Terns Pharmaceuticals, Inc."
            },
            {
              "key": "Financial Statements Reviewed",
              "value": "Consolidated balance sheets, consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders’ equity, and cash flows"
            },
            {
              "key": "Financial Statement Dates",
              "value": "As of December 31, 2022 and 2021; period ended December 31, 2022"
            },
            {
              "key": "Audit Standards",
              "value": "Audited in accordance with PCAOB standards"
            },
            {
              "key": "Auditor Independence",
              "value": "The auditor is independent as required by U.S. federal securities laws and PCAOB rules"
            },
            {
              "key": "Audit Procedures",
              "value": "Procedures included examining evidence, assessing risks of material misstatement, and evaluating significant estimates and overall presentation"
            },
            {
              "key": "Auditor",
              "value": "Ernst & Young LLP"
            },
            {
              "key": "Audit Report Date",
              "value": "March 27, 2023"
            },
            {
              "key": "Location",
              "value": "San Jose, California"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 138,
          "title": "Financial Statement Summary",
          "data": [
            {
              "key": "License revenue 2021",
              "value": "1,000"
            },
            {
              "key": "License revenue 2022",
              "value": "0"
            },
            {
              "key": "Research and development 2021",
              "value": "31,311"
            },
            {
              "key": "Research and development 2022",
              "value": "39,617"
            },
            {
              "key": "General and administrative 2021",
              "value": "19,549"
            },
            {
              "key": "General and administrative 2022",
              "value": "22,412"
            },
            {
              "key": "Total operating expenses 2021",
              "value": "50,860"
            },
            {
              "key": "Total operating expenses 2022",
              "value": "62,029"
            },
            {
              "key": "Loss from operations 2021",
              "value": "(49,860)"
            },
            {
              "key": "Loss from operations 2022",
              "value": "(62,029)"
            },
            {
              "key": "Interest income 2021",
              "value": "170"
            },
            {
              "key": "Interest income 2022",
              "value": "2,110"
            },
            {
              "key": "Other (expense) income, net 2021",
              "value": "40"
            },
            {
              "key": "Other (expense) income, net 2022",
              "value": "(68)"
            },
            {
              "key": "Total other income, net 2021",
              "value": "210"
            },
            {
              "key": "Total other income, net 2022",
              "value": "2,042"
            },
            {
              "key": "Net loss 2021",
              "value": "(50,158)"
            },
            {
              "key": "Net loss 2022",
              "value": "(60,345)"
            },
            {
              "key": "Net loss per share, basic and diluted 2021",
              "value": "(2.21)"
            },
            {
              "key": "Net loss per share, basic and diluted 2022",
              "value": "(1.67)"
            },
            {
              "key": "Weighted average common stock outstanding (as noted)",
              "value": "22,705,948"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 140,
          "title": "Cash Flow Statement",
          "data": [
            {
              "key": "Operating Activities - Net Loss (2022)",
              "value": "-60345"
            },
            {
              "key": "Operating Activities - Net Loss (2021)",
              "value": "-50158"
            },
            {
              "key": "Stock-based Compensation Expense (2022)",
              "value": "10768"
            },
            {
              "key": "Stock-based Compensation Expense (2021)",
              "value": "8146"
            },
            {
              "key": "Depreciation and Amortization Expense (2022)",
              "value": "484"
            },
            {
              "key": "Depreciation and Amortization Expense (2021)",
              "value": "512"
            },
            {
              "key": "Amortization on Marketable Securities (2022)",
              "value": "81"
            },
            {
              "key": "Amortization on Marketable Securities (2021)",
              "value": "879"
            },
            {
              "key": "Change in Deferred Taxes (2022)",
              "value": "392"
            },
            {
              "key": "Change in Deferred Taxes (2021)",
              "value": "219"
            },
            {
              "key": "Net Cash used in Operating Activities (2022)",
              "value": "-49109"
            },
            {
              "key": "Net Cash used in Operating Activities (2021)",
              "value": "-41827"
            },
            {
              "key": "Purchase of Investments (2022)",
              "value": "-139731"
            },
            {
              "key": "Purchase of Investments (2021)",
              "value": "-166297"
            },
            {
              "key": "Proceeds from Sales and Maturities (2022)",
              "value": "117734"
            },
            {
              "key": "Proceeds from Sales and Maturities (2021)",
              "value": "46941"
            },
            {
              "key": "Net Cash used in Investing (2022)",
              "value": "-22272"
            },
            {
              "key": "Net Cash used in Investing (2021)",
              "value": "-119696"
            },
            {
              "key": "Net Proceeds from Common Stock Issuance (2022)",
              "value": "81115"
            },
            {
              "key": "Net Proceeds from Common Stock Issuance (2021)",
              "value": "0"
            },
            {
              "key": "Net Proceeds from At-the-Market Offering (2022)",
              "value": "24993"
            },
            {
              "key": "Net Proceeds from At-the-Market Offering (2021)",
              "value": "0"
            },
            {
              "key": "Net Proceeds from IPO (2022)",
              "value": "0"
            },
            {
              "key": "Net Proceeds from IPO (2021)",
              "value": "136362"
            },
            {
              "key": "Net Cash provided by Financing (2022)",
              "value": "167095"
            },
            {
              "key": "Net Cash provided by Financing (2021)",
              "value": "134393"
            },
            {
              "key": "Cash and Cash Equivalents at Beginning (2022)",
              "value": "47699"
            },
            {
              "key": "Cash and Cash Equivalents at Beginning (2021)",
              "value": "74854"
            },
            {
              "key": "Cash and Cash Equivalents at End (2022)",
              "value": "143235"
            },
            {
              "key": "Cash and Cash Equivalents at End (2021)",
              "value": "47699"
            },
            {
              "key": "Summary",
              "value": "This is a cash flow statement comparing fiscal years 2022 and 2021. The company experienced net losses in both years (-$60.3M in 2022 vs -$50.2M in 2021). While operating and investing activities consumed cash, financing activities provided significant positive cash flow through various stock issuances. The company's cash position improved from $47.7M to $143.2M by the end of 2022, despite operating losses. Notable financing activities include stock issuances and an at‐the‐market offering in 2022, while 2021 saw significant proceeds from an IPO."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 144,
          "title": "TERNS PHARMACEUTICALS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS",
          "data": [
            {
              "key": "Milestone payments",
              "value": "At the inception of arrangements with development, regulatory or commercial milestone payments, the Company evaluates the probability of reaching those milestones and estimates the variable consideration using either the expected value method or the most likely amount method. The most likely amount method is expected to be used for development and regulatory milestones."
            },
            {
              "key": "Revenue recognition",
              "value": "Revenue from milestone payments is included in the transaction price if it is probable that a significant revenue reversal will not occur. The transaction price is allocated to performance obligations on a relative stand-alone selling price basis and recognized as those obligations are satisfied. Adjustments are recorded on a cumulative catch-up basis."
            },
            {
              "key": "Royalty and Upfront Payments",
              "value": "Arrangements including sales-based royalties lead to revenue recognition when related sales occur. Upfront payments and fees are recorded as deferred revenue until obligations are performed."
            },
            {
              "key": "Use of Estimates",
              "value": "The preparation of the financial statements requires management to make estimates and assumptions affecting reported amounts of assets and liabilities, including accruals for R&D expenses, research contract costs, unrecognized tax benefits, fair value of common stock, and stock option valuations."
            },
            {
              "key": "Cash, Cash Equivalents and Marketable Securities",
              "value": "Cash and cash equivalents include standard checking accounts and money market funds, with cash equivalents defined as investments with an original maturity of 90 days or less. Marketable securities, classified as available-for-sale if maturity exceeds three months, are carried at fair value with unrealized gains/losses recorded in other comprehensive loss."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 145,
          "title": "TERNS PHARMACEUTICALS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS",
          "data": [
            {
              "key": "description",
              "value": "The note discusses how discounts are recorded in interest income/expense and explains the treatment of realized and unrealized gains/losses on debt securities and marketable securities. It details the method used for marking investments to market, including assessing whether a decline in fair value is “other-than-temporary.”"
            },
            {
              "key": "investment_breakdown",
              "value": "Multiple tables provide a breakdown of financial instruments showing amortized cost, unrealized gains/losses, and fair value for categories such as Money market funds, U.S. government securities, Non-U.S. government securities, Corporate debt securities, and Commercial paper. Additional tables classify these as liquid assets including cash equivalents and marketable securities, with summaries for different reporting dates (one table dated December 31, 2021)."
            },
            {
              "key": "operating_leases",
              "value": "The document also explains the accounting treatment for operating leases and rent expense, including the recognition of lease liabilities and corresponding right-of-use assets."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 147,
          "title": "Accrued Expenses and Other Current Liabilities & Income Taxes Notes",
          "data": [
            {
              "key": "Research and development costs (2022)",
              "value": "1209 (in thousands)"
            },
            {
              "key": "Research and development costs (2021)",
              "value": "1570 (in thousands)"
            },
            {
              "key": "Accrued professional fees (2022)",
              "value": "925 (in thousands)"
            },
            {
              "key": "Accrued professional fees (2021)",
              "value": "363 (in thousands)"
            },
            {
              "key": "Compensation and benefit costs (2022)",
              "value": "3843 (in thousands)"
            },
            {
              "key": "Compensation and benefit costs (2021)",
              "value": "2403 (in thousands)"
            },
            {
              "key": "Other (2022)",
              "value": "185 (in thousands)"
            },
            {
              "key": "Other (2021)",
              "value": "358 (in thousands)"
            },
            {
              "key": "Total accrued expenses and other current liabilities (2022)",
              "value": "6162 (in thousands)"
            },
            {
              "key": "Total accrued expenses and other current liabilities (2021)",
              "value": "4694 (in thousands)"
            },
            {
              "key": "Income Taxes",
              "value": "Provision for income taxes is computed using an estimated annual effective tax rate and includes deferred tax assets and liabilities with a valuation allowance as necessary."
            },
            {
              "key": "Comprehensive Loss",
              "value": "Represents the change in equity from non-owner sources due to various transactions and events."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 150,
          "title": "TERNS PHARMACEUTICALS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS",
          "data": [
            {
              "key": "Functional Currencies",
              "value": "The Company’s reporting currency is U.S. dollars. Terns U.S. Opco and Terns H.K. use U.S. dollars, while Terns Suzhou and Terns China use the Chinese Yuan (CNY)."
            },
            {
              "key": "Foreign Currency Translation",
              "value": "Transactions in non‐functional currencies are remeasured at prevailing exchange rates; balance sheet items are remeasured at the balance sheet date rate. Translation adjustments are recorded in the consolidated statements of operations and comprehensive loss as foreign exchange related gains or losses and reported as accumulated other comprehensive loss."
            },
            {
              "key": "Concentration of Credit Risk",
              "value": "Financial instruments (cash, cash equivalents, and marketable securities) expose the Company to concentration of credit risk; investments are held at large financial institutions believed to be of high credit quality."
            },
            {
              "key": "Patent Costs",
              "value": "All costs related to filing and prosecuting patent applications are expensed as incurred due to the uncertainty of expenditure recovery and are classified as general and administrative expenses."
            },
            {
              "key": "Commitments and Contingencies",
              "value": "The Company may incur contingent liabilities in the ordinary course of business. Liabilities are accrued when future expenditures are probable and estimable. For all periods presented, there have been no pending material litigation or legal proceedings."
            },
            {
              "key": "Recent Accounting Pronouncements",
              "value": "In February 2016, FASB issued ASU 2016-02, Leases (Topic 842), requiring lessees to classify leases as either finance or operating leases, record a right-of-use asset and lease liability for leases with terms greater than 12 months, and adopt a dual expense recognition approach. Effective dates vary for public and non-public entities, with early adoption permitted."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 151,
          "title": "TERNS PHARMACEUTICALS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS",
          "data": [
            {
              "key": "Adoption Date (New Lease Standard)",
              "value": "January 1, 2022"
            },
            {
              "key": "Historical Lease Standard",
              "value": "ASC 840: Leases"
            },
            {
              "key": "Practical Expedients Election",
              "value": "Not reassessing prior conclusions on lease identification, classification, and initial direct costs"
            },
            {
              "key": "Short-term Lease Election",
              "value": "Does not recognize ROU assets and lease liabilities for leases 12 months or less"
            },
            {
              "key": "Component Treatment",
              "value": "Lease and non-lease components treated as a single component"
            },
            {
              "key": "Operating Lease Liability Recognized",
              "value": "$1.7 million"
            },
            {
              "key": "Right-of-Use (ROU) Asset Recognized",
              "value": "$1.5 million"
            },
            {
              "key": "Operating Lease Portfolio Composition",
              "value": "Primarily comprised of property leases"
            },
            {
              "key": "FASB ASU 2016-13",
              "value": "Issued in June 2016; effective for non-public entities after December 15, 2022 with adoption on January 1, 2023"
            },
            {
              "key": "Fair Value Definition",
              "value": "Price that would be received to sell an asset or paid to transfer a liability in an orderly transaction"
            },
            {
              "key": "Fair Value Measurement - Level 1",
              "value": "Quoted prices in active markets for identical assets or liabilities"
            },
            {
              "key": "Fair Value Measurement - Level 2",
              "value": "Observable inputs other than quoted prices, e.g., quoted prices for similar assets or liabilities"
            },
            {
              "key": "Fair Value Measurement - Level 3",
              "value": "Unobservable inputs, including pricing models and discounted cash flow methodologies"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 152,
          "title": "Cash, Cash Equivalents and Marketable Securities Fair Value Hierarchy",
          "data": [
            {
              "key": "Total cash and equivalents",
              "value": "143,235"
            },
            {
              "key": "Total marketable securities",
              "value": "139,879"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 152,
          "title": "Cash and Marketable Securities by Level",
          "data": [
            {
              "key": "Total cash and equivalents",
              "value": "47,699"
            },
            {
              "key": "Total marketable securities",
              "value": "118,283"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 153,
          "title": "Marketable Securities Maturity Schedule",
          "data": [
            {
              "key": "Due in one year or less",
              "value": "136,008"
            },
            {
              "key": "Due after one year through two years",
              "value": "3,871"
            },
            {
              "key": "Total marketable securities",
              "value": "139,879"
            },
            {
              "key": "Note",
              "value": "Figures are in thousands for the years ended December 31, 2022 and 2021 with no transfers among fair value levels."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 153,
          "title": "Lease Costs and Terms as of December 31, 2022",
          "data": [
            {
              "key": "Operating lease cost",
              "value": "610"
            },
            {
              "key": "Short-term cost",
              "value": "43"
            },
            {
              "key": "Total lease cost",
              "value": "653"
            },
            {
              "key": "Weighted-average remaining lease term",
              "value": "1.79"
            },
            {
              "key": "Weighted-average discount rate",
              "value": "6.00%"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 153,
          "title": "Operating Lease Obligations Schedule",
          "data": [
            {
              "key": "2023 Operating Leases",
              "value": "850"
            },
            {
              "key": "2024 Operating Leases",
              "value": "559"
            },
            {
              "key": "Total lease payments",
              "value": "1,409"
            },
            {
              "key": "Less: Imputed interest",
              "value": "(204)"
            },
            {
              "key": "Present value of lease liabilities",
              "value": "1,205"
            },
            {
              "key": "Less: Current portion of lease liabilities",
              "value": "(661)"
            },
            {
              "key": "Total lease liabilities, non-current",
              "value": "544"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 153,
          "title": "Future Minimum Annual Lease Payments (pre-ASC 842)",
          "data": [
            {
              "key": "2022",
              "value": "669"
            },
            {
              "key": "2023",
              "value": "652"
            },
            {
              "key": "2024",
              "value": "559"
            },
            {
              "key": "2025 and thereafter",
              "value": "Not specified"
            },
            {
              "key": "Total",
              "value": "1,880"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 160,
          "title": "TERNS PHARMACEUTICALS, INC. - Notes to Consolidated Financial Statements",
          "data": [
            {
              "key": "Stock-Based Compensation - R&D Expense 2022",
              "value": "3,025"
            },
            {
              "key": "Stock-Based Compensation - R&D Expense 2021",
              "value": "2,055"
            },
            {
              "key": "Stock-Based Compensation - General & Administrative Expense 2022",
              "value": "7,743"
            },
            {
              "key": "Stock-Based Compensation - General & Administrative Expense 2021",
              "value": "6,091"
            },
            {
              "key": "Total Stock-Based Compensation Expense 2022",
              "value": "10,768"
            },
            {
              "key": "Total Stock-Based Compensation Expense 2021",
              "value": "8,146"
            },
            {
              "key": "Total Loss Before Income Tax 2022",
              "value": "-59,987"
            },
            {
              "key": "Total Loss Before Income Tax 2021",
              "value": "-49,650"
            },
            {
              "key": "Income Tax Expense - Total 2022",
              "value": "358"
            },
            {
              "key": "Income Tax Expense - Total 2021",
              "value": "508"
            },
            {
              "key": "Effective Tax Rate 2022",
              "value": "-0.60%"
            },
            {
              "key": "Effective Tax Rate 2021",
              "value": "-1.02%"
            },
            {
              "key": "U.S. Federal Statutory Rate",
              "value": "21.00%"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 161,
          "title": "TERNS PHARMACEUTICALS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS",
          "data": [
            {
              "key": "Company",
              "value": "TERNS PHARMACEUTICALS, INC."
            },
            {
              "key": "Document Section",
              "value": "Notes to Consolidated Financial Statements"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 162,
          "title": "TERNS PHARMACEUTICALS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Deferred Tax Assets and Liabilities",
          "data": [
            {
              "key": "Table Title",
              "value": "Deferred Tax Assets and Liabilities"
            },
            {
              "key": "Accruals and reserves",
              "value": "2022: 820, 2021: 575"
            },
            {
              "key": "Intangibles",
              "value": "2022: 12929, 2021: 14574"
            },
            {
              "key": "Stock-based compensation",
              "value": "2022: 3549, 2021: 1582"
            },
            {
              "key": "Net operating loss",
              "value": "2022: 13841, 2021: 10271"
            },
            {
              "key": "Research and development credits",
              "value": "2022: 3650, 2021: 1930"
            },
            {
              "key": "Lease liability",
              "value": "2022: 241, 2021: 0"
            },
            {
              "key": "Capitalized research and development",
              "value": "2022: 7410, 2021: 0"
            },
            {
              "key": "Other",
              "value": "2022: 61, 2021: 87"
            },
            {
              "key": "Valuation allowance",
              "value": "2022: -42207, 2021: -28849"
            },
            {
              "key": "Total deferred tax assets",
              "value": "2022: 294, 2021: 170"
            },
            {
              "key": "Fixed assets",
              "value": "2022: -50, 2021: -78"
            },
            {
              "key": "Operating lease assets",
              "value": "2022: -207, 2021: 0"
            },
            {
              "key": "Total deferred tax liabilities",
              "value": "2022: -257, 2021: -78"
            },
            {
              "key": "Net deferred tax assets",
              "value": "$37"
            },
            {
              "key": "Summary",
              "value": "The table presents deferred tax assets and liabilities for 2021 and 2022. Although significant deferred tax assets from intangibles and net operating losses are recorded, a full valuation allowance (increasing from -28,849 in 2021 to -42,207 in 2022) reduces the net deferred tax assets. Additional narrative discusses federal and state NOL carryforwards, R&D credit carryforwards, and recent tax legislation affecting the capitalization and amortization of R&D expenditures."
            },
            {
              "key": "Additional Observation",
              "value": "The Company recorded a full valuation allowance against its U.S. net deferred tax assets as of December 31, 2022, based on historical operating performance, changes due to Domestication, and expectations of future net losses."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 163,
          "title": "TERNS PHARMACEUTICALS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS",
          "data": [
            {
              "key": "Unrecognized Tax Benefits as of Dec 31, 2022",
              "value": "$6.3 million"
            },
            {
              "key": "Unrecognized Tax Benefits as of Dec 31, 2021",
              "value": "$5.8 million"
            },
            {
              "key": "Income Tax Expense Impact if Recognized (2022)",
              "value": "$4.2 million"
            },
            {
              "key": "Income Tax Expense Impact if Recognized (2021)",
              "value": "$4.5 million"
            },
            {
              "key": "Unrecognized Tax Benefits Reconciliation Table",
              "value": "Beginning: 2022 $5,849K, 2021 $5,406K; Increases from Prior Year: 2022 $150K, 2021 $365K; Current Year Increases: 2022 $706K, 2021 $451K; Decreases from Prior Year: 2022 -$389K, 2021 -$373K; End: 2022 $6,316K, 2021 $5,849K."
            },
            {
              "key": "Gross Interest and Penalties Accrued",
              "value": "2022: $0.3 million; 2021: $0.1 million"
            },
            {
              "key": "License Agreement Overview",
              "value": "TERN-101 License Agreement with Eli Lilly entered in February 2018. Grants an exclusive, royalty-bearing license covering development, manufacture and commercialization rights, including sublicensing in specified territories. Milestone payments up to $6.0M for the first covered product in mainland China and up to $50.0M for ex-mainland China; tiered royalties in mid-single digits to low teens. As of Dec 31, 2022, no payments or milestone achievements have been recorded and no related R&D expense recognized."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 165,
          "title": "Hansoh Option and License Agreement",
          "data": [
            {
              "key": "Company",
              "value": "TERNS PHARMACEUTICALS, INC."
            },
            {
              "key": "Agreement Name",
              "value": "Hansoh 2020 Option and License Agreement"
            },
            {
              "key": "Agreement Parties",
              "value": "Hansoh (Shanghai) Healthtech Co., Ltd. and Jiangsu Hansoh Pharmaceutical Group Company Ltd."
            },
            {
              "key": "Licensed Compound",
              "value": "TERN-701 (formerly TRN-000632)"
            },
            {
              "key": "Scope",
              "value": "Preliminary studies and exclusive license for development and commercialization in oncology (all prophylactic, palliative, therapeutic and/or diagnostic uses) in mainland China, Taiwan, Hong Kong and Macau"
            },
            {
              "key": "Upfront Payment",
              "value": "$0.8 million received in 2020, recorded as a refund liability"
            },
            {
              "key": "License Fee Revenue",
              "value": "$1.0 million recognized in 2021 upon exercise of the option"
            },
            {
              "key": "Milestone Payments",
              "value": "Up to $67.0 million in pre-specified clinical, regulatory and sales milestones, none achieved as of December 31, 2022"
            },
            {
              "key": "Royalty Terms",
              "value": "Royalties in the mid-single digits on net sales of all licensed products"
            },
            {
              "key": "Agreement Duration",
              "value": "Until the end of the last-to-expire royalty term"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 173,
          "title": "Анализ страницы 173",
          "data": [
            {
              "key": "raw_text",
              "value": "173"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 196,
          "title": "Certification Pursuant to Rules 13a-14(a) and 15d-14(a) – Annual Report on Form 10-K Certification",
          "data": [
            {
              "key": "Issuer",
              "value": "Terns Pharmaceuticals, Inc."
            },
            {
              "key": "Certification Summary",
              "value": "The document certifies that the Annual Report on Form 10-K has been reviewed and that its financial statements fairly present the financial condition, results of operations, and cash flows. It further confirms the design and evaluation of disclosure and internal controls over financial reporting."
            },
            {
              "key": "Certifying Officer",
              "value": "Senthil Sundaram"
            },
            {
              "key": "Officer Title",
              "value": "Chief Executive Officer (Principal Executive Officer)"
            },
            {
              "key": "Certification Date",
              "value": "March 27, 2023"
            },
            {
              "key": "Related Exhibit",
              "value": "Exhibit 31.1"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 197,
          "title": "CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a)",
          "data": [
            {
              "key": "Report Type",
              "value": "Annual Report on Form 10-K"
            },
            {
              "key": "Company",
              "value": "Terns Pharmaceuticals, Inc."
            },
            {
              "key": "Certifier",
              "value": "Mark Vignola, Chief Financial Officer (Principal Financial and Accounting Officer)"
            },
            {
              "key": "Certification Details",
              "value": "The certifier attests that the report does not contain any untrue statement or omission of material facts, and that the financial statements fairly present the financial condition, results of operations, and cash flows of the registrant."
            },
            {
              "key": "Internal Control Disclosure",
              "value": "Disclosure and evaluation of the effectiveness of disclosure controls and internal control over financial reporting are provided, including any changes affecting the registrant’s controls."
            },
            {
              "key": "Date",
              "value": "March 27, 2023"
            },
            {
              "key": "Exhibit",
              "value": "Exhibit 31.2"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 198,
          "title": "CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350",
          "data": [
            {
              "key": "Report",
              "value": "Annual Report on Form 10-K for the period ending December 31, 2022"
            },
            {
              "key": "Company",
              "value": "Terns Pharmaceuticals, Inc."
            },
            {
              "key": "Certification Reference",
              "value": "18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002"
            },
            {
              "key": "Compliance Statement",
              "value": "The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and fairly presents, in all material respects, the financial condition and result of operations of the Company."
            },
            {
              "key": "Certification Date",
              "value": "March 27, 2023"
            },
            {
              "key": "Signed By",
              "value": "Senthil Sundaram"
            },
            {
              "key": "Title",
              "value": "Chief Executive Officer (Principal Executive Officer)"
            },
            {
              "key": "Exhibit",
              "value": "Exhibit 32.1"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 199,
          "title": "CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350",
          "data": [
            {
              "key": "Report Title",
              "value": "Annual Report of Terns Pharmaceuticals, Inc. on Form 10-K for the period ending December 31, 2022"
            },
            {
              "key": "Certification Statement",
              "value": "The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and fairly presents, in all material respects, the financial condition and result of operations of the Company."
            },
            {
              "key": "Legal Reference",
              "value": "18 U.S.C. § 1350 as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002"
            },
            {
              "key": "Certification Date",
              "value": "March 27, 2023"
            },
            {
              "key": "Signer",
              "value": "Mark Vignola"
            },
            {
              "key": "Title",
              "value": "Chief Financial Officer (Principal Financial and Accounting Officer)"
            },
            {
              "key": "Exhibit",
              "value": "Exhibit 32.2"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_dividend_policy_changes": {
      "value": true,
      "elements": [
        {
          "type": "dividend_policy",
          "page": 117,
          "title": "Dividend Policy and Associated Risk Factors",
          "data": [
            {
              "key": "Dividend Policy Statement",
              "value": "No cash dividends are intended to be paid on common stock for the foreseeable future. Returns for investors will depend on stock price appreciation."
            },
            {
              "key": "Growth Investment Strategy",
              "value": "Future earnings, if any, will be reinvested to fund growth instead of being distributed as dividends."
            },
            {
              "key": "Risk Factors",
              "value": "The common stock price may be volatile with risks including clinical trial delays, regulatory approvals or disapprovals, and market factors, which may affect the resale value of the stock."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "dividend_policy",
          "page": 123,
          "title": "Item 5. Market for Registrant’s Common Equity and Dividend Policy",
          "data": [
            {
              "key": "Dividend Policy",
              "value": "The company has never declared or paid cash dividends on its capital stock and does not intend to do so in the foreseeable future, opting to retain all available funds and future earnings for business development and expansion."
            },
            {
              "key": "Equity Market Information",
              "value": "Common stock listed on the Nasdaq Global Select Market since February 5, 2021 under the symbol 'TERN'. Prior to that, there was no public market for the stock."
            },
            {
              "key": "Stockholder Information",
              "value": "As of March 3, 2023, there were approximately 9 stockholders of record, not including beneficial owners of shares held in 'street' name."
            },
            {
              "key": "IPO and Use of Proceeds",
              "value": "In February 2021, an IPO was completed issuing 8,625,000 shares at $17.00 per share, resulting in net proceeds of $133.0 million. Approximately $19.7 million of those proceeds have been used as of December 31, 2022 to advance the product pipeline, support working capital, and for other general corporate purposes."
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_share_buyback_plans": {
      "value": false,
      "elements": []
    },
    "has_capital_structure_changes": {
      "value": true,
      "elements": [
        {
          "type": "capital_structure",
          "page": 130,
          "title": "Equity Financing and Capital Structure Changes",
          "data": [
            {
              "key": "Sales Agreement Date",
              "value": "March 2022"
            },
            {
              "key": "Sales Agent",
              "value": "Cowen and Company, LLC"
            },
            {
              "key": "At-the-market Offering Limit",
              "value": "$75.0 million"
            },
            {
              "key": "Shares Sold Through Dec 2022",
              "value": "4,122,628 shares"
            },
            {
              "key": "Net Proceeds Through Dec 2022",
              "value": "$24.9 million"
            },
            {
              "key": "Additional Shares Sold in Feb 2023",
              "value": "2,929,922 shares"
            },
            {
              "key": "Net Proceeds Feb 2023",
              "value": "$27.9 million"
            },
            {
              "key": "August 2022 Issuance Details",
              "value": "Issued 12,250,000 shares at $2.42 per share and pre-funded warrants for 14,630,000 shares at $2.4199"
            },
            {
              "key": "Net Proceeds August 2022",
              "value": "$60.7 million"
            },
            {
              "key": "December 2022 Public Offering",
              "value": "Underwriting Agreement for 10,350,000 shares at $7.25 per share with an option for an additional 1,552,500 shares"
            },
            {
              "key": "Net Proceeds December 2022",
              "value": "$80.8 million"
            },
            {
              "key": "Future Funding Strategy",
              "value": "Existing cash expected to fund operations and capital expenditures into 2026; additional capital needed for R&D, clinical trials, and commercialization"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 137,
          "title": "TERNS PHARMACEUTICALS, INC. CONSOLIDATED BALANCE SHEETS",
          "data": [
            {
              "key": "Balance Sheet Title",
              "value": "Balance Sheet"
            },
            {
              "key": "Total Assets 2022",
              "value": "287026"
            },
            {
              "key": "Total Assets 2021",
              "value": "168070"
            },
            {
              "key": "Total Current Assets 2022",
              "value": "285185"
            },
            {
              "key": "Total Current Assets 2021",
              "value": "166930"
            },
            {
              "key": "Additional Paid-in Capital 2022",
              "value": "520178"
            },
            {
              "key": "Additional Paid-in Capital 2021",
              "value": "342711"
            },
            {
              "key": "Accumulated Other Comprehensive Loss 2022",
              "value": "-822"
            },
            {
              "key": "Accumulated Other Comprehensive Loss 2021",
              "value": "-338"
            },
            {
              "key": "Accumulated Deficit 2022",
              "value": "-242418"
            },
            {
              "key": "Accumulated Deficit 2021",
              "value": "-182073"
            },
            {
              "key": "Summary",
              "value": "This balance sheet shows the company's financial position for 2021 and 2022. Notable observations include a significant increase in total assets and current assets, as well as substantial growth in stockholders' equity mainly driven by additional paid-in capital. The company’s strong liquidity position is supported by significant cash and marketable securities, indicating robust capital raising activity."
            },
            {
              "key": "Notes",
              "value": "The accompanying notes are an integral part of these financial statements."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 139,
          "title": "Stockholders' Equity Statement",
          "data": [
            {
              "key": "Balances at December 31, 2020",
              "value": "Preferred Stock Conversion: 12,958,452 shares ($186,033); Common Stock: 337,508 shares ($0); Total Equity: -117,441"
            },
            {
              "key": "Conversion of preferred stock to common stock upon IPO",
              "value": "16,079,230 shares converted, amount: $186,033"
            },
            {
              "key": "Sale of common stock in IPO",
              "value": "8,625,000 shares issued, net proceeds: $133,023"
            },
            {
              "key": "Exercise of stock options",
              "value": "156,104 shares, amount: $914"
            },
            {
              "key": "Stock-based compensation expense",
              "value": "Amount: $8,146"
            },
            {
              "key": "Net loss 2021",
              "value": "Amount: -$50,158"
            },
            {
              "key": "Balances at December 31, 2021",
              "value": "Common Stock: 25,269,271 shares ($342,711); Total Equity: $160,303"
            },
            {
              "key": "Various 2022 stock issuances",
              "value": "Total shares issued: 28,275,128, net proceeds: $166,458"
            },
            {
              "key": "Stock-based compensation expense 2022",
              "value": "Amount: $10,768"
            },
            {
              "key": "Net loss 2022",
              "value": "Amount: -$60,345"
            },
            {
              "key": "Balances at December 31, 2022",
              "value": "Common Stock: 53,723,171 shares ($520,178); Total Equity: $276,943"
            },
            {
              "key": "Summary",
              "value": "This statement illustrates significant changes in the company's capital structure from 2020 to 2022. Key events include the conversion of preferred stock to common stock following the IPO, subsequent stock issuances, stock-based compensation, and reported net losses, ultimately showing an improvement from a deficit to a positive equity position along with substantial dilution in the number of outstanding shares."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 142,
          "title": "TERNS PHARMACEUTICALS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS",
          "data": [
            {
              "key": "August 2022 Financing",
              "value": "Issued 12,250,000 shares of common stock at $2.42 per share and pre-funded warrants for 14,630,000 shares at $2.4199 per warrant (exercise price $0.0001 per share). Net proceeds were $60.7 million after underwriting discounts, with $33.0 million allocated to pre-funded warrants recorded as additional paid-in capital."
            },
            {
              "key": "December 2022 Financing",
              "value": "Underwritten public offering of 10,350,000 shares at $7.25 per share with an option granted to underwriters for an additional 1,552,500 shares (option fully exercised). Net proceeds were $80.8 million after fees."
            },
            {
              "key": "Certificate of Incorporation Changes",
              "value": "The December 2020 Charter authorized substantial numbers of common and convertible preferred shares. In February 2021, the amended and restated certificate of incorporation effective with the IPO revised the authorized shares to 150,000,000 common shares and 10,000,000 preferred shares."
            },
            {
              "key": "Reverse Stock Split",
              "value": "In January 2021, a 1-for-14 reverse stock split was implemented, with retroactive adjustment of all issued and outstanding shares, options, and per share financial amounts."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 146,
          "title": "Operating Lease, Convertible Preferred Stock Classification and Research and Development Expenses",
          "data": [
            {
              "key": "Operating Lease",
              "value": "Right-of-use assets and liabilities are recognized on the balance sheet at lease commencement date based on the present value of the future minimum lease payments. Rent expense is recognized on a straight-line basis, and lease incentives reduce the ROU asset."
            },
            {
              "key": "Convertible Preferred Stock",
              "value": "Holders of Series A, B, and C convertible preferred stock had certain liquidation rights and were classified outside of stockholders’ equity. Upon completion of the IPO in February 2021, all convertible preferred stock converted into common stock."
            },
            {
              "key": "Research and Development Expenses",
              "value": "R&D costs are expensed as incurred, including personnel costs, stock-based compensation, third-party fees, and costs related to clinical trials. Prepayments for future R&D activities are recorded as prepaid expenses and expensed as goods or services are received."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_structure",
          "page": 154,
          "title": "TERNS PHARMACEUTICALS, INC. - Loans Payable and Convertible Debt Transactions",
          "data": [
            {
              "key": "2020 Notes Issuance",
              "value": "In May 2020, issued convertible promissory notes with an aggregate amount of $15.0 million at an interest rate of 10.0% per annum, unsecured and due May 2021."
            },
            {
              "key": "2020 Notes Conversion",
              "value": "Unpaid principal and accrued interest of $15.9 million converted into 1,366,820 shares of Series C convertible preferred stock in connection with the Series C Convertible Preferred Stock Financing."
            },
            {
              "key": "Bridge Loan Details",
              "value": "In May 2020, entered into a bridge loan with Terns China for $1.8 million in proceeds payable in renminbi, with a 10% annual interest rate accruing from drawdown. The holders had conversion rights identical to the 2020 Notes."
            },
            {
              "key": "Bridge Loan Conversion and Repayment",
              "value": "Converted into Series C preferred stock on terms similar to the 2020 Notes based on an outstanding balance of $1.9 million (principal of $1.8 million plus $0.1 million accrued interest). Fair value determined at $2.1 million as of December 31, 2020; repaid in full in March 2021."
            },
            {
              "key": "LAV Series A and B Promissory Notes",
              "value": "In November-December 2020, related to approvals from the Chinese government and repurchase arrangements via Terns Hong Kong; issuance of Series A and B convertible preferred stock in exchange for promissory notes was settled with proceeds of $10.8 million in January 2021."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 155,
          "title": "TERNS PHARMACEUTICALS, INC. Convertible Preferred Stock Transactions and Repurchase",
          "data": [
            {
              "key": "Document Section",
              "value": "Notes to Consolidated Financial Statements 2021"
            },
            {
              "key": "Convertible Preferred Stock",
              "value": "All convertible preferred stock was converted into common shares at the time of the IPO in February 2021."
            },
            {
              "key": "Series A Preferred Stock",
              "value": "In April 2017, 2,089,285 shares were issued at $10.50 per share for an aggregate of $21.9 million. Terns China received $8.0 million from LAV PRC Entities, presented as noncontrolling interest, along with an option (LAV Option) to convert their interest into an interest in Terns Cayman."
            },
            {
              "key": "Series B Preferred Stock",
              "value": "In October 2018, 2,384,195 shares were issued at $30.80 per share for an aggregate of $73.4 million. Terns China received $6.7 million from LAV PRC Entities as a noncontrolling interest, with a similar LAV Option associated."
            },
            {
              "key": "LAV Series A and B Stock Options and Repurchase",
              "value": "In November 2020, approval was received for LAV Option exercise. Terns Hong Kong repurchased all equity interests held by the LAV PRC Entities, and in December 2020, additional Series A and B shares were issued to an affiliate of LAV in exchange for a promissory note. The note was repaid in January 2021 using the proceeds from the Repurchase."
            },
            {
              "key": "Other Transaction",
              "value": "A promissory note for $1.9 million was substantially paid with proceeds received from the LAV Affiliate Promissory Note."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 156,
          "title": "Convertible Preferred Stock Financing and Stock-Based Compensation Overview",
          "data": [
            {
              "key": "Transaction",
              "value": "Series C Convertible Preferred Stock Financing"
            },
            {
              "key": "Shares Issued (Series C)",
              "value": "7,500,665 shares at $11.65 per share for gross proceeds of $87.4 million"
            },
            {
              "key": "2020 Notes Conversion",
              "value": "Unpaid principal and accrued interest totaling $15.9 million converted into 1,366,820 shares"
            },
            {
              "key": "Bridge Loan Conversion",
              "value": "167,159 shares issued upon effective conversion"
            },
            {
              "key": "Post-IPO Conversion",
              "value": "All outstanding convertible preferred stock converted into common stock as of December 31, 2022"
            },
            {
              "key": "Stock-Based Compensation Plans",
              "value": "Details include the 2017 Incentive Award Plan (terminated at IPO), the 2021 Incentive Award Plan, and the 2022 Employment Inducement Award Plan"
            },
            {
              "key": "Share Distribution Table",
              "value": "The table shows options outstanding, unvested restricted stock units, pre-funded warrants, and total shares reserved with notable increase from 4.96M in 2021 to 22.32M in 2022 (driven largely by 14.63M pre-funded warrants)"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 174,
          "title": "DESCRIPTION OF CAPITAL STOCK",
          "data": [
            {
              "key": "Company",
              "value": "Terns Pharmaceuticals, Inc."
            },
            {
              "key": "Authorized Common Stock",
              "value": "150,000,000 shares of common stock, par value $0.0001 per share"
            },
            {
              "key": "Authorized Preferred Stock",
              "value": "10,000,000 shares of preferred stock, par value $0.0001 per share"
            },
            {
              "key": "Common Stock Voting Rights",
              "value": "Each common stock holder is entitled to one vote per share; non-cumulative voting; majority voting can elect all directors"
            },
            {
              "key": "Amendment Vote Requirement",
              "value": "66 2/3% of the voting power of all outstanding voting stock is required for certain actions, including amending the certificate of incorporation and bylaws"
            },
            {
              "key": "Dividends",
              "value": "Common stockholders are entitled to dividends declared by the board, subject to any preferences of outstanding preferred stock"
            },
            {
              "key": "Liquidation Rights",
              "value": "In a liquidation, common stockholders share ratably in the net assets after payment of debts and liabilities, subject to any preferred stock liquidation preferences"
            },
            {
              "key": "Rights and Preferences",
              "value": "Common stockholders do not have preemptive, conversion, or subscription rights and are affected by rights of any future preferred stock issuances"
            },
            {
              "key": "Fully Paid and Nonassessable",
              "value": "All outstanding common shares are fully paid and nonassessable"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 175,
          "title": "Preferred Stock and Registration Rights",
          "data": [
            {
              "key": "Preferred Stock Issuance",
              "value": "Our board of directors is authorized to issue up to 10,000,000 shares of preferred stock in one or more series. These shares may have dividend rights, conversion rights, voting rights, redemption terms, liquidation preferences, and other rights that, if greater than those of common stock, could adversely affect common stockholders' voting power and dividend or liquidation recoveries. The issuance might also impact corporate control changes."
            },
            {
              "key": "Registration Rights",
              "value": "Certain holders of common stock have registration rights under the Securities Act of 1933 via an amended and restated investors’ rights agreement. These include demand registration rights (allowing investors holding at least 20% of registrable securities to request registration on up to two occasions starting August 3, 2021), piggyback registration rights to include shares in issuer-led registrations, and Form S-3 registration rights for investors holding at least 10% of registrable securities subject to conditions and limitations."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "mentions_new_risk_factors": {
      "value": true,
      "elements": [
        {
          "type": "risk_factor",
          "page": 2,
          "title": "Form 10-K Table of Contents",
          "data": [
            {
              "key": "Overview",
              "value": "This table of contents from a Form 10-K report lists major sections divided into PART I, PART II, PART III, and PART IV with items such as Risk Factors, Legal Proceedings, Executive Compensation, and more."
            },
            {
              "key": "Notable Items",
              "value": "Item 1A: Risk Factors (page 56); Item 7: Management's Discussion and Analysis (page 124); Item 11: Executive Compensation (page 168)"
            },
            {
              "key": "Summary",
              "value": "The TOC encompasses 16 main items with detailed references to business risks, legal issues, financial performance, and corporate governance. This indicates that risk factors are a key disclosure area."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 3,
          "title": "SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS",
          "data": [
            {
              "key": "description",
              "value": "This section of the Annual Report on Form 10-K contains forward-looking statements regarding business operations, clinical studies, regulatory and commercialization plans, and financial performance. It emphasizes that statements based on future expectations are subject to various risks and uncertainties."
            },
            {
              "key": "forward_looking_terms",
              "value": "aim, anticipate, assume, believe, contemplate, continue, could, due, estimate, expect, goal, intend, may, objective, plan, predict, potential, positioned, seek, should, target, will, would"
            },
            {
              "key": "risk_warning",
              "value": "The document highlights that these forward-looking statements involve both known and unknown risks, uncertainties, and other critical factors that could cause actual outcomes to differ materially from those expressed or implied."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 4,
          "title": "Summary of Principal Risks Associated with Our Business",
          "data": [
            {
              "key": "Business Stage",
              "value": "Clinical-stage biopharmaceutical company with a limited operating history and no approved products for commercial sale."
            },
            {
              "key": "Financial Losses",
              "value": "The company has incurred significant losses since inception and anticipates continuing losses, making future viability difficult to assess."
            },
            {
              "key": "Financing Requirements",
              "value": "Requires substantial additional financing to achieve goals; failure to secure capital may force delays, limitations, or termination of key programs."
            },
            {
              "key": "Clinical Development Risks",
              "value": "Dependent on successful development, regulatory approval, and commercialization of product candidates; clinical trials are lengthy, expensive, and outcomes uncertain."
            },
            {
              "key": "Competition",
              "value": "Faces significant competition in drug discovery and development with competitors having greater resources, which may hamper market penetration."
            },
            {
              "key": "Regulatory and Approval Uncertainty",
              "value": "Uncertainty regarding regulatory approval and acceptable development plans for product candidates, with potential delays in clinical and commercial timelines."
            },
            {
              "key": "Pandemic and External Risks",
              "value": "Operations can be adversely affected by ongoing COVID-19 impacts or future epidemics, affecting manufacturing and clinical trials."
            },
            {
              "key": "Third-Party Dependencies",
              "value": "Reliance on third parties for manufacturing and conducting clinical trials introduces risks if they fail to meet regulatory standards or deadlines."
            },
            {
              "key": "Key Personnel",
              "value": "Adverse effects are possible if the company fails to attract or retain senior management and key scientific personnel."
            },
            {
              "key": "Operating Results Variability",
              "value": "Significant fluctuations in operating results may make future outcomes unpredictable."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 17,
          "title": "Risk Factors Associated with NAFLD and NASH",
          "data": [
            {
              "key": "Prevalence of NAFLD in the United States",
              "value": "80 to 100 million individuals"
            },
            {
              "key": "Progression from NAFLD to NASH",
              "value": "20% of NAFLD patients progress to NASH"
            },
            {
              "key": "Estimated NASH patients in the US",
              "value": "20 million adults"
            },
            {
              "key": "Risk of liver fibrosis leading to cirrhosis",
              "value": "20% of patients with NASH"
            },
            {
              "key": "Healthcare cost for managing NASH (2017)",
              "value": "Over $220 billion"
            },
            {
              "key": "Main causes of NAFLD and NASH",
              "value": "Chronic excess caloric intake, obesity, metabolic syndrome"
            },
            {
              "key": "Consequence of cirrhosis",
              "value": "Key risk factor for hepatocellular carcinoma"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 33,
          "title": "Competitive Clinical Trials and Associated Risks",
          "data": [
            {
              "key": "TERN-601 Companies",
              "value": "9 Meters Biopharma, Inc., Amgen Inc., Altimmune, AstraZeneca plc, Boehringer Ingelheim GmbH, Carmot Therapeutics, Inc., CinRx Pharma, Cyrus Therapeutics, Inc., D&D Pharmatech, Eiger BioPharmaceuticals, Inc., Eli Lilly and Co., Hanmi Pharmaceutical Co., Ltd., ImmunoForge, Co. Ltd., Intarcia Therapeutics, Inc., Invex Therapeutics Inc., Longevity Biotech Inc., Novo Nordisk A/S, Opko Health, Oramed Pharmaceuticals, PegBio Co Ltd., Pfizer Inc., Pharmaxis, Regor Therapeutics Group, Sanofi, Sciwind Biosciences Co., Structure Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Viking Therapeutics, Inc., vTv Therapeutics Inc. and Zealand Pharma A/S"
            },
            {
              "key": "TERN-101 Companies",
              "value": "AbbVie, Inc., Ascletis Pharma, Inc., Enanta Pharmaceuticals, Inc., ENYO Pharma SA, Gilead Sciences, Inc., Hepagene Therapeutics, Inc., Intercept Pharmaceuticals, Inc., Metacrine Inc. and Novartis Pharmaceuticals Corp."
            },
            {
              "key": "TERN-800 Companies",
              "value": "9 Meters Biopharma, Inc., Amgen, Inc., Carmot Therapeutics, D&D Pharmatech, Eli Lilly and Co., Sciwind Biosciences Co., Viking Therapeutics, Inc. and Zealand Pharma A/S"
            },
            {
              "key": "Other Clinical Development Competitors",
              "value": "89Bio, Inc., Aardvark Therapeutics, Inc., Akero Therapeutics, Inc., Arrowhead Pharmaceuticals, Inc., Axcella Health, Inc., Carmot Therapeutics, Inc., Cirius Therapeutics, Inc., CohBar, Inc., Coherus Biosciences Inc., Corcept Therapeutics, Inc., Currax Pharmaceuticals LLC, CymaBay Therapeutics, Inc., CytoDyne Inc., Diasome Pharmaceuticals, Esperion Therapeutics, Inc., Galectin Therapeutics Inc., Galmed Pharmaceuticals Ltd., Gila Therapeutics, Inc., Hanmi Pharmaceutical Co., Ltd., Inventiva Pharma SA, Ionis Pharmaceuticals, Inc., MediciNova, Inc., NGM Biopharmaceuticals, Inc., Norgine B.V., NorthSea Therapeutics, Inc., Pliant Therapeutics, Inc., Poxel SA, Saniona AB, Sagimet Biosciences, Inc., T3D Therapeutics, Inc., Vivus, Inc. and Zydus Cadila Healthcare"
            },
            {
              "key": "Competitive Risks",
              "value": "Competitors possess substantially greater financial, technical, and human resources, with enhanced experience in preclinical and clinical studies, stronger regulatory track records, established distribution channels, and greater market name recognition. Additionally, the availability of generic products and evolving pricing pressures introduce further risks to the competitive positioning and market success of the product candidates."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 34,
          "title": "Intellectual Property",
          "data": [
            {
              "key": "Overview",
              "value": "Discussion on the importance of protecting drug candidates, discovery programs, processes, and know-how through patents, trade secrets, confidential information and licensing agreements. Emphasis is placed on both the strategic protection and the associated risks related to patent grant and enforcement."
            },
            {
              "key": "TERN-701",
              "value": "One patent family for TERN-701 (a small-molecule allosteric inhibitor of the BCR-ABL fusion gene) covering composition-of-matter and methods of use in treating leukemia and other diseases. Includes one issued US patent and 20 pending applications in jurisdictions such as Australia, Brazil, Canada, China, the EPO, India, Japan, and Korea. Projected expiration is generally 2039, subject to adjustments. Subject to an exclusive option and license agreement for Greater China with Hansoh."
            },
            {
              "key": "TERN-501",
              "value": "Five patent families for the THR-β agonist TERN-501 covering composition-of-matter and methods of use, including combination therapy, in the treatment of liver, metabolic, and other diseases. Projected expiration is generally 2039."
            },
            {
              "key": "TERN-601",
              "value": "Four patent families covering GLP-1R agonists including TERN-601, with projected expirations between 2041 and 2043."
            },
            {
              "key": "TERN-101",
              "value": "For the FXR agonist TERN-101, ten owned patent families and two exclusively licensed from Eli Lilly are directed to composition-of-matter coverage, formulations, and methods of use. The US issued patent is projected to expire in 2029 (with adjustments) and corresponding foreign patents are generally projected to expire in 2028."
            },
            {
              "key": "Risk Disclosure",
              "value": "The commercial success of the business depends on effectively obtaining, maintaining, defending, and enforcing patent rights. There is inherent uncertainty regarding whether patents will be granted, remain enforceable, or successfully protect commercial interests, which poses a significant risk."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 35,
          "title": "Patent Term Extensions and Intellectual Property Risks",
          "data": [
            {
              "key": "Patent Term Duration",
              "value": "Generally 20 years from the earliest filing date for non-provisional applications in most countries, including the United States."
            },
            {
              "key": "Patent Term Extension",
              "value": "For FDA-approved drugs, an extension of up to 5 years may be granted, but the total patent life cannot exceed 14 years from the date of product approval in the U.S."
            },
            {
              "key": "Legislative Reference",
              "value": "Drug Price Competition and Patent Term Restoration Act of 1984"
            },
            {
              "key": "Jurisdictional Considerations",
              "value": "Extensions are available in the U.S., Europe, and select other foreign jurisdictions subject to regulatory review."
            },
            {
              "key": "Additional IP Protections",
              "value": "Reliance on trademarks, trade secrets, know-how, and confidentiality agreements to protect proprietary information."
            },
            {
              "key": "Risks Identified",
              "value": "Uncertainty in obtaining extensions, dependency on regulatory approvals, potential breaches of confidentiality, and challenges from third parties regarding proprietary rights."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 38,
          "title": "License Agreement Terms and Regulatory Environment for TERN-101 Products",
          "data": [
            {
              "key": "Milestone Payment",
              "value": "Up to $56 million payable upon achieving pre-specified clinical, regulatory, and commercial milestones for TERN-101 Products"
            },
            {
              "key": "Royalty Terms",
              "value": "Tiered royalties on annual net sales ranging from mid-single digit to mid-teen percentages with customary reductions, including adjustments for generic competition and third party license payments"
            },
            {
              "key": "Royalty Termination",
              "value": "Royalty term ends per TERN-101 Product on a country-by-country basis upon the later of: expiration of the last valid patent claim, loss of regulatory exclusivity, or the tenth anniversary of first commercial sale"
            },
            {
              "key": "IP Ownership and Responsibilities",
              "value": "Each party retains sole ownership of intellectual property developed independently, while jointly-developed IP is co-owned; the company is solely responsible to prosecute, maintain, and has first right to defend certain patents"
            },
            {
              "key": "Termination Conditions",
              "value": "Agreement may be terminated for material breach (with 90 days' cure period), insolvency, or if patent challenges are initiated as outlined"
            },
            {
              "key": "Regulatory Environment",
              "value": "Detailed regulatory requirements from the FDA, European Commission, CMS and other authorities governing clinical development, manufacturing, approval, and marketing of drug products"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "risk_factor",
          "page": 47,
          "title": "Regulatory Exclusivity and Approval Processes",
          "data": [
            {
              "key": "Pediatric Exclusivity",
              "value": "Provides an additional six-month regulatory exclusivity extension when an NDA sponsor submits pediatric data that fairly responds to an FDA written request. This extension applies to any existing unexpired patent or regulatory exclusivity, including orphan drug exclusivity."
            },
            {
              "key": "FDA Regulatory Impact",
              "value": "The additional exclusivity is not a patent term extension, but extends the period during which the FDA cannot approve another application if the submitted pediatric studies are accepted within statutory time limits."
            },
            {
              "key": "Foreign Government Regulation",
              "value": "Product candidates are subject to similar laws and regulations in foreign jurisdictions, including the EU, which impose requirements related to clinical trials, marketing authorization, post-marketing safety surveillance, anti-fraud laws, and corporate compliance programs."
            },
            {
              "key": "EU Clinical Trials and Regulations",
              "value": "In the EU, non-clinical and clinical studies must adhere to strict regulatory controls, including GLP and GCP standards. The EU Clinical Trials Regulation (CTR), effective January 31, 2022, harmonizes trial assessments through a centralized portal, and requires additional measures such as clinical trial insurance and no-fault compensation."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 56,
          "title": "Item 1A. Risk Factors",
          "data": [
            {
              "key": "high_degree_of_risk",
              "value": "Investing in our common stock involves a high degree of risk."
            },
            {
              "key": "financial_losses",
              "value": "We have incurred significant losses since our inception, with a net loss attributable to common stockholders for the years ended December 31, 2022 and 2021 of approximately $60.3 million and $50.2 million, respectively."
            },
            {
              "key": "accumulated_deficit",
              "value": "As of December 31, 2022, we had an accumulated deficit of $242.4 million."
            },
            {
              "key": "operating_history",
              "value": "We are a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale."
            },
            {
              "key": "dependency_on_funding",
              "value": "We will require substantial additional funding to finance our operations and achieve our goals."
            },
            {
              "key": "uncertainty_of_development",
              "value": "The outcome of any preclinical study or clinical trial is highly uncertain."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 59,
          "title": "Impact of COVID-19 on Business and Clinical Trials",
          "data": [
            {
              "key": "Main Risks",
              "value": "Allocation of resources toward product candidates may not lead to viable drugs."
            },
            {
              "key": "COVID-19 Pandemic Effects",
              "value": "Ongoing disruptions affecting business operations and clinical trials."
            },
            {
              "key": "Consequences of Incorrect Decisions",
              "value": "Potential for missing valuable opportunities and relinquishing rights to product candidates."
            },
            {
              "key": "Clinical Trial Disruptions",
              "value": "Delays in patient enrollment, site initiation, and materials supply."
            },
            {
              "key": "Regulatory Impact",
              "value": "Potential interruptions in operations of FDA and other regulatory authorities."
            },
            {
              "key": "Healthcare Resource Diversions",
              "value": "Healthcare system diversions may impact clinical trial conduct."
            },
            {
              "key": "Adverse Events",
              "value": "Risk of trial participants or staff acquiring COVID-19 affecting data integrity."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 60,
          "title": "COVID-19 Impact on Clinical Trials",
          "data": [
            {
              "key": "Impact on enrollment",
              "value": "COVID-19 may impact patient enrollment, visits, or continued participation in ongoing trials."
            },
            {
              "key": "Site adjustments",
              "value": "Some sites may pause enrollment to focus resources on COVID-19."
            },
            {
              "key": "Patient concerns",
              "value": "Potential patients may opt not to enroll or continue participation due to COVID-19 risks."
            },
            {
              "key": "Regulatory impact",
              "value": "Operations of the FDA and foreign regulatory authorities may be delayed."
            },
            {
              "key": "Remote trial adjustments",
              "value": "Clinical trial protocols adjusted for remote visits."
            },
            {
              "key": "Public health emergency",
              "value": "Biden Administration announced end of public health emergency on May 11, 2023."
            },
            {
              "key": "Supply chain risks",
              "value": "Potential shortages or delays in supplies due to COVID-19."
            },
            {
              "key": "Economic impact",
              "value": "COVID-19 may significantly disrupt global financial markets, affecting liquidity."
            },
            {
              "key": "Stock volatility",
              "value": "Trading prices for biopharmaceutical companies may be highly volatile due to COVID-19."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 61,
          "title": "Risks Related to COVID-19 Impact on Product Development",
          "data": [
            {
              "key": "Impact of COVID-19 on product candidates development",
              "value": "COVID-19 may impede development, reduce productivity, disrupt supply chains, delay clinical trials."
            },
            {
              "key": "Regulatory approval and commercialization issues",
              "value": "Uncertainty regarding obtaining regulatory approvals for product candidates."
            },
            {
              "key": "Clinical trials success",
              "value": "Success depends on the development speed and external factors affecting clinical trials."
            },
            {
              "key": "Global regulatory compliance",
              "value": "Need to comply with varying regulatory requirements in different countries."
            },
            {
              "key": "Financial resource sufficiency",
              "value": "Dependence on sufficient financial resources to complete studies and trials."
            },
            {
              "key": "Additional capital raising",
              "value": "Ability to raise capital under potentially adverse conditions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 63,
          "title": "Risk Factors in Clinical Drug Development",
          "data": [
            {
              "key": "Factors Influencing Development",
              "value": "Delays or inability to obtain regulatory approvals."
            },
            {
              "key": "Challenges in Commercialization",
              "value": "Difficulty in commercializing product candidates."
            },
            {
              "key": "Costs of Clinical Trials",
              "value": "Clinical testing is expensive and time-consuming."
            },
            {
              "key": "Uncertain Outcomes",
              "value": "Success in early trials does not guarantee later success."
            },
            {
              "key": "Regulatory Authority Disagreements",
              "value": "Potential disagreements with regulatory authorities may delay trials."
            },
            {
              "key": "Recruitment Challenges",
              "value": "Challenges in recruiting patients for trials."
            },
            {
              "key": "Manufacturing Issues",
              "value": "Challenges in manufacturing sufficient product candidates."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 72,
          "title": "Regulatory Approval Risks and Impact",
          "data": [
            {
              "key": "Regulatory Authorities",
              "value": "FDA and applicable foreign regulatory authorities"
            },
            {
              "key": "Potential Delays and Limitations",
              "value": "Approval delays, limited indications, or denial of marketing authorization due to disagreements on trial design, data interpretation, labeling, and manufacturing processes"
            },
            {
              "key": "Additional Requirements",
              "value": "May require additional nonclinical or clinical testing, extra costly Phase 4 trials, or implementation of a REMS"
            },
            {
              "key": "Risks to Business",
              "value": "Failure to obtain timely regulatory approval could delay, prevent, or limit commercialization, adversely impacting business, financial condition, and prospects"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 73,
          "title": "Clinical Trial Regulatory Risks",
          "data": [
            {
              "key": "Trial Locations",
              "value": "Conducting additional clinical trials outside the United States, with risks that FDA may not accept data from these trials."
            },
            {
              "key": "FDA Conditions",
              "value": "Data acceptance depends on trial design, conduct by qualified investigators, adherence to ethical principles, and representation of the U.S. population."
            },
            {
              "key": "Regulatory Compliance",
              "value": "Trials must comply with both local laws and applicable U.S. laws and regulations, with FDA determining clinical meaningfulness."
            },
            {
              "key": "Risk Implications",
              "value": "If data is not accepted, additional costly and time-consuming trials may be required, potentially delaying or halting product development. Other risks include regulatory burdens, foreign exchange fluctuations, and logistical challenges."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 74,
          "title": "Regulatory Designations and Associated Risks",
          "data": [
            {
              "key": "Fast Track Designation",
              "value": "Received for TERN-501 and TERN-101 for the treatment of NASH. The designation is intended to expedite development and review but does not guarantee faster approval."
            },
            {
              "key": "Breakthrough Therapy Designation",
              "value": "Potential designation may be sought for additional product candidates. Even if granted, it may not accelerate development or regulatory review and is subject to FDA discretion."
            },
            {
              "key": "Regulatory Uncertainty",
              "value": "There is inherent risk that these designations might not be granted, or if granted, may be withdrawn or may not result in the anticipated benefits in the drug development and approval process."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 75,
          "title": "Regulatory Approval Risks and PRIME Designation",
          "data": [
            {
              "key": "Context",
              "value": "Discussion on seeking PRIME designation in the EU and its implications on regulatory review processes."
            },
            {
              "key": "PRIME Designation",
              "value": "A voluntary program by the EMA to enhance scientific and regulatory support, potentially accelerating the approval of innovative medicines."
            },
            {
              "key": "Benefits",
              "value": "Includes appointment of a rapporteur, early dialogue, scientific advice at key milestones, and potential for accelerated review."
            },
            {
              "key": "Uncertainties",
              "value": "Even if designated, it may not lead to a materially faster development, review, or approval process compared to traditional procedures."
            },
            {
              "key": "Regulatory Challenges",
              "value": "Obtaining and maintaining regulatory approvals in various jurisdictions may involve different requirements, potential delays, and additional costs."
            },
            {
              "key": "Brexit Impact",
              "value": "Regulatory approval in the UK is affected by its withdrawal from the EU, leading to differing procedures between Great Britain and Northern Ireland."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 76,
          "title": "Regulatory Risks Related to Brexit and Product Approval Delays",
          "data": [
            {
              "key": "Regulatory Framework",
              "value": "UK pharmaceutical regulation significantly derives from EU directives and regulations."
            },
            {
              "key": "Brexit Impact",
              "value": "Brexit may materially impact the regulatory regime affecting development, manufacture, importation, approval, and commercialization of product candidates in the UK."
            },
            {
              "key": "Marketing Authorization Risk",
              "value": "Delays or inability to obtain marketing approvals could prevent commercialization in the UK/EU, restricting revenue generation and profitability."
            },
            {
              "key": "Ongoing Compliance",
              "value": "Even with approval, product candidates are subject to continuous regulatory obligations, including labeling restrictions, post-market testing and surveillance, and adherence to cGMP and GCP requirements."
            },
            {
              "key": "Enforcement and Penalties",
              "value": "Potential penalties include warning letters, fines, consent decrees, clinical trial suspensions, or even product recalls if regulatory requirements are not met."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 77,
          "title": "Regulatory Risks Impacting Business Operations",
          "data": [
            {
              "key": "Investigation Risk",
              "value": "Any government investigation of alleged violations of law could require significant time and resources and may generate negative publicity."
            },
            {
              "key": "Compliance Risk",
              "value": "Failure to comply with ongoing regulatory requirements may adversely impact the ability to commercialize and generate revenue."
            },
            {
              "key": "Regulatory Sanctions",
              "value": "If regulatory sanctions are applied or approvals withdrawn, the company’s value and operating results could be adversely affected."
            },
            {
              "key": "Advertising and Promotion Scrutiny",
              "value": "Advertising and promotion efforts for approved products are heavily scrutinized by multiple authorities (e.g., FDA, FTC, DOJ, and foreign regulatory bodies), with possible enforcement actions including fines and other penalties."
            },
            {
              "key": "Impact of Government Shutdowns",
              "value": "Prolonged government shutdowns can delay reviews and inspections by agencies like the FDA, adversely affecting business operations."
            },
            {
              "key": "COVID-19 Related Disruptions",
              "value": "Pandemic-related restrictions have already led to delays in regulatory inspections and reviews, potentially extending timelines for product approvals."
            },
            {
              "key": "Potential Policy Changes",
              "value": "Changes in regulatory policies, such as those promoted by current government administrations, might further impact business operations and profitability."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 78,
          "title": "Regulatory and Manufacturing Risk Factors",
          "data": [
            {
              "key": "Off-Label Promotion Risks",
              "value": "The FDA and other regulatory agencies enforce laws prohibiting off-label promotion. Improper promotion can lead to significant liabilities including large civil and criminal fines, consent decrees, and injunctions."
            },
            {
              "key": "Regulatory Compliance",
              "value": "Strict regulations govern promotional claims made about prescription drugs. Only approved uses as per FDA labeling are permitted, although limited non-promotional communications are allowed under narrow conditions and the PIE Act."
            },
            {
              "key": "Pre-Approval Information Exchange Act (PIE Act)",
              "value": "Passed in December 2022, the PIE Act allows sponsors to communicate certain information regarding products in development to payors, providing explicit protection for such communications about unapproved uses."
            },
            {
              "key": "Manufacturing Risk",
              "value": "The company relies on third parties for manufacturing clinical and commercial supplies. Any failure by these manufacturers to obtain or maintain FDA or comparable regulatory approvals, ensure quality control, or meet cGMP standards could delay or halt product development and commercialization."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 80,
          "title": "Risks in Third Party Collaborations and Clinical Trial Disruptions",
          "data": [
            {
              "key": "Risk Factor",
              "value": "Dependence on third parties for GLP preclinical, nonclinical studies, and clinical trials poses risks if they fail to meet contractual obligations, experience work stoppages, or provide compromised data."
            },
            {
              "key": "Potential Consequences",
              "value": "Delays, extensions, termination, or repetition of studies may occur, which could affect regulatory approval, harm financial results, and delay revenue generation."
            },
            {
              "key": "Collaboration Challenges",
              "value": "Challenges include negotiating complex collaboration agreements, facing competition for appropriate partners, and risks associated with partners altering their strategic focus or failing to commit sufficient resources."
            },
            {
              "key": "Examples",
              "value": "The company is currently collaborating with Hansoh (Shanghai) Healthtech Co., Ltd. and Jiangsu Hansoh Pharmaceutical Group Company Ltd. on aspects of TERN-701, a small-molecule allosteric inhibitor of the BCR-ABL fusion gene."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 81,
          "title": "Risks Related to Collaborations and Commercialization",
          "data": [
            {
              "key": "intellectual_property_risk",
              "value": "Collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in a way that results in actual or threatened litigation."
            },
            {
              "key": "collaboration_disputes",
              "value": "Disputes with collaborators could delay or terminate research, development, or commercialization, diverting management attention and resources."
            },
            {
              "key": "collaboration_termination",
              "value": "Terminated collaborations may require additional capital for further development or commercialization of current or future product candidates."
            },
            {
              "key": "shared_intellectual_property",
              "value": "Collaborators may co-own intellectual property, limiting our exclusive rights to develop or commercialize resulting innovations."
            },
            {
              "key": "compliance_risks",
              "value": "Collaborators’ sales, marketing, or other operations may not comply with applicable laws, potentially exposing us to civil or criminal proceedings."
            },
            {
              "key": "milestone_and_royalty_payments",
              "value": "If collaborations fail or are terminated, we may not receive expected future milestone or royalty payments."
            },
            {
              "key": "competitive_development",
              "value": "Collaborators or strategic partners might develop competing products that could limit our own product development efforts."
            },
            {
              "key": "commercialization_risk",
              "value": "Successful commercialization depends on obtaining adequate coverage, reimbursement, and pricing from governmental authorities and insurers; failure could harm revenue generation."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 82,
          "title": "Reimbursement and Pricing Challenges for Product Candidates",
          "data": [
            {
              "key": "Third-party payor challenges",
              "value": "Third-party payors are questioning the prices for pharmaceutical products and may refuse coverage if cheaper alternatives exist, impacting reimbursement."
            },
            {
              "key": "Pricing pressure",
              "value": "Existing lower-cost therapies and generics may limit the amount charged for new product candidates, reducing potential revenue."
            },
            {
              "key": "Coverage determination process",
              "value": "Obtaining coverage and adequate reimbursement is time-consuming and costly, requiring extensive clinical and scientific support for each payor."
            },
            {
              "key": "International market considerations",
              "value": "Governmental price controls and cost-containment initiatives abroad further pressure reimbursement levels and commercial viability."
            },
            {
              "key": "Commercial success risk",
              "value": "Limited reimbursement and pricing challenges could hinder physician and patient adoption, jeopardizing the commercial success of product candidates."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 83,
          "title": "Risks Affecting Market Acceptance of Product Candidates",
          "data": [
            {
              "key": "Comparative Safety and Efficacy",
              "value": "The safety and efficacy of our product candidates as compared to other available therapies."
            },
            {
              "key": "Coverage and Reimbursement",
              "value": "The availability of coverage and adequate reimbursement from managed care plans, insurers and other healthcare payors for our product candidates."
            },
            {
              "key": "Acceptance by Healthcare Providers and Patients",
              "value": "Acceptance by physicians, operators of clinics, and patients of the product candidate as a safe and effective treatment."
            },
            {
              "key": "Adoption of New Therapy",
              "value": "Physician and patient willingness to adopt a new therapy over other available therapies to treat approved indications."
            },
            {
              "key": "Overcoming Biases",
              "value": "Overcoming any biases physicians or patients may have toward particular therapies for the treatment of approved indications."
            },
            {
              "key": "Training and Administration",
              "value": "Proper training and administration of our product candidates by physicians and medical staff."
            },
            {
              "key": "Public Perception",
              "value": "Public misperception regarding the use of our therapies if approved for commercial sale."
            },
            {
              "key": "Patient Satisfaction and Convenience",
              "value": "Patient satisfaction with the results and administration of our product candidates, including the convenience of any dosing regimen."
            },
            {
              "key": "Treatment Cost and Willingness to Pay",
              "value": "The cost of treatment with our product candidates relative to alternative treatments and reimbursement levels, and the willingness of insurance companies, physicians, and patients to pay."
            },
            {
              "key": "Revenue and Profitability for Physicians",
              "value": "The revenue and profitability that our product candidates may offer a physician as compared to alternative therapies."
            },
            {
              "key": "Side Effects",
              "value": "The prevalence and severity of side effects."
            },
            {
              "key": "Labeling Limitations",
              "value": "Limitations or warnings contained in the approved labeling for our drugs."
            },
            {
              "key": "Utilization and Adoption",
              "value": "The willingness of physicians, clinic operators, and patients to utilize or adopt our products as a solution."
            },
            {
              "key": "Regulatory Requirements",
              "value": "Any FDA requirement to undertake a REMS or similar foreign regulatory requirement."
            },
            {
              "key": "Sales, Marketing and Distribution Effectiveness",
              "value": "The effectiveness of our sales, marketing, and distribution efforts."
            },
            {
              "key": "Publicity",
              "value": "Adverse publicity about our product candidates or favorable publicity about competitive drugs."
            },
            {
              "key": "Product Liability",
              "value": "Potential product liability claims."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 84,
          "title": "Risk Factor - Limitations in Sales and Commercialization Capabilities",
          "data": [
            {
              "key": "Lack of Sales Organization",
              "value": "The company currently has no internal marketing, sales, or distribution capabilities, which poses a risk in effectively commercializing product candidates."
            },
            {
              "key": "Reliance on Third Parties",
              "value": "There is uncertainty in establishing sales capabilities either independently or via partnerships, which could negatively impact the ability to generate drug revenue."
            },
            {
              "key": "Operational and Regulatory Risks",
              "value": "Building a sales organization involves challenges such as hiring qualified personnel, training, managing geographically dispersed teams, and complying with extensive healthcare laws and regulations."
            },
            {
              "key": "Risk of Misconduct",
              "value": "Employees, contractors, and partners may engage in misconduct (including non-compliance and insider trading), potentially leading to regulatory sanctions, reputational harm, and financial penalties."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 85,
          "title": "Healthcare Regulatory Compliance Risks",
          "data": [
            {
              "key": "Description",
              "value": "Operations and business relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers are subject to extensive healthcare regulatory laws."
            },
            {
              "key": "Key Regulations",
              "value": "U.S. federal Anti-Kickback Statute, False Claims Act, HIPAA, Physician Payments Sunshine Act; analogous state laws and regulations; and similar laws in the EEA and other jurisdictions."
            },
            {
              "key": "Potential Impact",
              "value": "Exposure to penalties for non-compliance, fraud and abuse violations, and restrictions affecting research, marketing, sales, and distribution of product candidates."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 86,
          "title": "Regulatory and Compliance Risks Related to Healthcare Laws",
          "data": [
            {
              "key": "Description",
              "value": "The document outlines potential risks and substantial costs related to ensuring compliance with applicable healthcare laws and regulations. It highlights that non-compliance may result in severe penalties including civil, criminal, and administrative sanctions, as well as reputational harm and operational restructuring. The text also emphasizes the complexities and risks involved in participating in government pricing programs such as the Medicaid Drug Rebate Program, which could lead to significant liabilities for reporting errors."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 87,
          "title": "Risk Factor: Impact of Healthcare Legislation on Operations",
          "data": [
            {
              "key": "Legislation Impact",
              "value": "Enacted and future healthcare legislation, including the ACA and subsequent regulatory changes, could increase the difficulty and cost of obtaining marketing approval and commercializing product candidates."
            },
            {
              "key": "Key Laws and Amendments",
              "value": "Key elements include the Patient Protection and Affordable Care Act (ACA) with its amendments, Budget Control Act of 2011, and the American Taxpayer Relief Act of 2012, among others."
            },
            {
              "key": "Healthcare Reimbursement Changes",
              "value": "Provisions such as non-deductible fees for manufacturers, changes in Medicare Part D discount programs, and increased Medicaid Drug Rebate liabilities may negatively affect financial operations."
            },
            {
              "key": "Regulatory and Judicial Actions",
              "value": "Judicial challenges and Congressional actions, including the U.S. Supreme Court dismissal of challenges to the ACA, and executive orders affecting enrollment periods, are highlighted."
            },
            {
              "key": "Financial Impact",
              "value": "Future legislative changes could result in reduced Medicare payments and other healthcare funding, potentially impacting customer base and overall financial performance."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 89,
          "title": "Legislative Impact and Regulatory Risks in Pharmaceutical Operations",
          "data": [
            {
              "key": "Civil Monetary Penalties",
              "value": "Legislation imposes civil monetary penalties on drug manufacturers for offering prices not equal to or less than the negotiated 'maximum fair price'."
            },
            {
              "key": "Excise Tax",
              "value": "Manufacturers may be subject to a potential excise tax if they fail to comply with the pricing legislation."
            },
            {
              "key": "Rebates Requirement",
              "value": "Manufacturers need to pay rebates for Medicare Part D drugs when price increases exceed inflation."
            },
            {
              "key": "Medicare Out-of-Pocket Cap",
              "value": "The law caps Medicare out-of-pocket drug costs at an estimated $4,000 in 2024, dropping to $2,000 per year from 2025 onward."
            },
            {
              "key": "Coverage Gap Risk",
              "value": "Risks include potential gaps in coverage for individuals requiring services beyond the initial annual coverage limit before reaching the catastrophic period."
            },
            {
              "key": "Regulatory Compliance and Market Risks",
              "value": "The legislation could lead to new or more stringent regulatory requirements, reduced reimbursement, and increased legal risks, thereby adversely affecting business operations and financial performance."
            },
            {
              "key": "Competitive and Market Limitations",
              "value": "Additional state regulations and competitive pressures, including bidding procedures and price controls, may diminish market opportunities and product demand."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 90,
          "title": "Risks Related to Intellectual Property",
          "data": [
            {
              "key": "Description",
              "value": "The document outlines the risks related to intellectual property, including potential allegations of patent infringement and other IP rights issues that could lead to costly litigation, substantial damages, and restricted commercialization of product candidates."
            },
            {
              "key": "Implications",
              "value": "Defending against IP claims could divert financial and managerial resources, possibly requiring licensing agreements, modifications to product candidates, or ceasing development of potentially infringing products."
            },
            {
              "key": "Industry Context",
              "value": "The pharmaceutical, biopharmaceutical, and biotechnology industries are noted for extensive IP litigation, increasing the risk of encountering unforeseen patents that might block operations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 91,
          "title": "Patent Litigation and Intellectual Property Risk Disclosures",
          "data": [
            {
              "key": "Summary",
              "value": "The passage discusses the risks associated with patent applications, publication delays, potential priority contests, litigation costs, and uncertainties around patent infringement and validity. It highlights that if a competitor files a similar patent, there may be costly and uncertain legal proceedings, which could have material adverse effects on the company’s financial condition and operations."
            },
            {
              "key": "Jurisdiction",
              "value": "United States and international jurisdictions"
            },
            {
              "key": "Potential Impacts",
              "value": "Substantial litigation costs, diversion of management focus, possible negative effects on stock price, and increased operating losses."
            },
            {
              "key": "Legal Risks",
              "value": "Possible priority contests, interference proceedings, difficulties in proving invalidity or unenforceability of patents, and the unpredictability of litigation outcomes."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 92,
          "title": "Intellectual Property Risk Factors",
          "data": [
            {
              "key": "risk_description",
              "value": "The document outlines risks related to intellectual property, including potential claims from employees, consultants, and contractors over ownership of IP. It discusses challenges in executing IP assignment agreements, risks of litigation, substantial legal costs, and the uncertainty surrounding the scope, validity, and enforceability of patents. These issues could materially adversely affect the company's competitive position, business operations, and financial condition."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 93,
          "title": "Intellectual Property Risk Factors",
          "data": [
            {
              "key": "patent_claims",
              "value": "The USPTO, international patent offices or judicial bodies may deny or narrow claims under our patent applications, and issued patents may be challenged, designed around, or of insufficient scope."
            },
            {
              "key": "trademark_protection",
              "value": "Trademark applications may be denied or, even if registered, may not effectively protect our brand and goodwill; trademarks may also be opposed or challenged."
            },
            {
              "key": "reverse_engineering",
              "value": "There is uncertainty about preventing unauthorized use or reverse engineering of our technology."
            },
            {
              "key": "competitive_technologies",
              "value": "Third parties may independently develop competitive technologies that do not infringe our intellectual property."
            },
            {
              "key": "legal_enforcement",
              "value": "The enforcement of intellectual property rights depends on the success of legal actions which may not always be successful."
            },
            {
              "key": "scope_and_interpretation",
              "value": "Even valid and enforceable patents may be interpreted narrowly, allowing competitors to create similar products or design around our patents."
            },
            {
              "key": "intellectual_property_coverage",
              "value": "Patent claims may not cover all product candidates or future products, and there may be competing patents that block commercialization."
            },
            {
              "key": "operating_expenses",
              "value": "Costs related to obtaining, filing, prosecuting, defending, and enforcing intellectual property could lead to significant fluctuations in operating expenses."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 95,
          "title": "Intellectual Property Licensing and Risk Factors",
          "data": [
            {
              "key": "LicensingArrangements",
              "value": "The company licenses or has access to patent rights from third-party owners through various agreements, including those with companies like Eli Lilly and Vintagence Biotechnology."
            },
            {
              "key": "ObligationsAndFees",
              "value": "Under these agreements, the company is required to pay fees such as annual license fees, milestone payments, royalties, and a percentage of revenues associated with the technology."
            },
            {
              "key": "TerminationRisk",
              "value": "Failure to comply with contractual obligations may lead to early termination of agreements, resulting in the loss of valuable rights or technology critical to the business."
            },
            {
              "key": "IPProtectionControl",
              "value": "The company has limited control over the patent prosecution, enforcement, and defense activities conducted by licensors, which may impact the validity and enforceability of the intellectual property."
            },
            {
              "key": "JointOwnershipIssues",
              "value": "Joint ownership of patent rights with third parties may restrict the company’s ability to out-license these patents without consent from the joint owner, particularly in certain jurisdictions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 96,
          "title": "Risk Factors: Intellectual Property Licensing and Litigation",
          "data": [
            {
              "key": "Government Agency Involvement",
              "value": "Dependence on intellectual property licensed or developed with government funding, with potential mandatory sublicensing requirements."
            },
            {
              "key": "Licensing Obligations",
              "value": "Failure to meet obligations to licensors or upstream licensors may result in loss of crucial intellectual property rights."
            },
            {
              "key": "Inventorship Disputes",
              "value": "Risk of disputes over inventorship and ownership, which could render patents unenforceable."
            },
            {
              "key": "Litigation Risks",
              "value": "Potential claims challenging patent ownership or inventorship may lead to costly litigation and adverse business impact."
            },
            {
              "key": "Competitive Impact",
              "value": "If third parties gain rights to in-licensed patents, competitors might license these patents, adversely affecting market position."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 97,
          "title": "Intellectual Property Risks and Litigation Concerns",
          "data": [
            {
              "key": "Overview",
              "value": "The document discusses potential claims related to the wrongful hiring of competitors' employees and the misuse or disclosure of proprietary trade secrets from former employers."
            },
            {
              "key": "Consultant and Employee Conflicts",
              "value": "It highlights the risks that consultants and employees, with prior affiliations to competitors or universities, may inadvertently use or disclose proprietary information covered by non-disclosure and non-competition agreements."
            },
            {
              "key": "Litigation Risk",
              "value": "The text outlines that litigation may be necessary to defend against claims, which could result in monetary damages, loss of intellectual property rights, or being forced to license technology from third parties."
            },
            {
              "key": "Intellectual Property Protection Challenges",
              "value": "It explains the difficulties in obtaining and enforcing patent protection, especially outside the United States, and the risk that competitors could exploit gaps in international protection."
            },
            {
              "key": "Potential Impact",
              "value": "Any adverse outcomes from these disputes could materially affect business operations, financial condition, and prospects."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 98,
          "title": "Risk: Intellectual Property Challenges",
          "data": [
            {
              "key": "Overview",
              "value": "Risks associated with protecting and enforcing intellectual property and proprietary rights in foreign jurisdictions."
            },
            {
              "key": "Jurisdictional Variability",
              "value": "Foreign countries, especially outside the US and Europe (e.g., India, PRC, developing countries), may offer less robust IP protection."
            },
            {
              "key": "Compulsory Licensing",
              "value": "Many foreign countries have compulsory licensing laws that may force the company to grant licenses to third parties."
            },
            {
              "key": "Enforcement Challenges",
              "value": "Legal systems in various countries may not favor enforcement of patents, potentially leading to high legal costs, diversion of resources, and risk of invalidation."
            },
            {
              "key": "Patent Scope and Uncertainty",
              "value": "Challenges in determining the scope, expiration, and relevance of patents and pending patent applications, which may impair marketability of product candidates."
            },
            {
              "key": "Impact on Business",
              "value": "The uncertainty in IP protection can adversely affect competitive position, financial condition, operational results, and commercial opportunities."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 99,
          "title": "Patent Term and Regulatory Risks Affecting Competitive Position",
          "data": [
            {
              "key": "Patent Term Limitations",
              "value": "Patent terms, typically 20 years from the earliest U.S. non-provisional filing date, may be insufficient to secure a competitive edge due to limited lifespan and various adjustments."
            },
            {
              "key": "Risk of Patent Rights Loss",
              "value": "Risks include shortened patent terms due to non-payment, delays in filings, or failure to meet extension deadlines, potentially resulting in loss of valuable patent rights."
            },
            {
              "key": "Regulatory and Extension Challenges",
              "value": "Patent term extensions under laws such as the Hatch-Waxman Act may be limited or denied, impacting the time available to exclusively market product candidates and exposing the company to earlier generic competition."
            },
            {
              "key": "Competitive Impact",
              "value": "If patent protection is inadequate, competitors may enter the market sooner, potentially reducing revenue and harming the company's competitive position."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 100,
          "title": "Risks Related to Patent Protection and Intellectual Property",
          "data": [
            {
              "key": "Compliance Requirements",
              "value": "Obtaining and maintaining patent protection depends on strict compliance with procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies."
            },
            {
              "key": "Maintenance Fees",
              "value": "Periodic maintenance, renewal, and annuity fees must be paid to avoid infringement or loss of patent rights."
            },
            {
              "key": "Legislative Changes",
              "value": "Changes such as the America Invents Act and the shift to a 'first-to-file' system introduce uncertainties that may reduce the value and enforceability of patents."
            },
            {
              "key": "Enforcement and Litigation Risks",
              "value": "Post-grant proceedings and litigation challenges can diminish the scope of patent rights, adversely affecting competitive positioning."
            },
            {
              "key": "Competitive Impact",
              "value": "Failure to maintain patent protection or uncertainties in intellectual property law could allow competitors to enter the market earlier."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 101,
          "title": "Risks Related to Intellectual Property and Key Personnel",
          "data": [
            {
              "key": "Patent Invention Priority",
              "value": "We or our licensors might not have been the first to invent or file patents, and others may independently develop similar or alternative technologies."
            },
            {
              "key": "Patent Application Risks",
              "value": "There is uncertainty whether our owned or licensed pending patent applications will result in issued patents or provide effective protection."
            },
            {
              "key": "Patent Validity and Litigation Risk",
              "value": "Issued patents may be invalidated or challenged by competitors, potentially leading to costly litigation or administrative proceedings."
            },
            {
              "key": "Competitor Development Risk",
              "value": "Competitors may conduct R&D in countries where we lack patent rights, using the information to develop competitive products."
            },
            {
              "key": "Trade Secrets and Trademark Risk",
              "value": "We may fail to protect our trade secrets or trademarks, and third parties may secure patents on related technologies."
            },
            {
              "key": "Key Personnel Risk",
              "value": "Failure to attract or retain senior management and scientific personnel could delay our pipeline development and affect clinical trials and commercialization."
            },
            {
              "key": "Overall Business Impact",
              "value": "Any of these events could significantly harm our business, operations, and prospects."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 103,
          "title": "Risks associated with product liability and commercialization challenges",
          "data": [
            {
              "key": "description",
              "value": "The potential for collaboration partners to alter development plans and abandon products, leading to increased risk in product development efforts and operational challenges."
            },
            {
              "key": "impact",
              "value": "Potential material adverse effects on business, operational results and prospects."
            },
            {
              "key": "risks",
              "value": "Product candidates may fail to meet safety and effectiveness standards required for regulatory approval, leading to potential product liability lawsuits."
            },
            {
              "key": "outcomes",
              "value": "Liability claims may result in decreased demand, reputational damage, delays in clinical trials, increased costs, and regulatory challenges."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 104,
          "title": "Potential Risks Related to Product Liability and International Operations",
          "data": [
            {
              "key": "Product Liability Insurance",
              "value": "The company may not obtain sufficient product liability insurance to cover claims."
            },
            {
              "key": "Coverage Limitations",
              "value": "Any claims may result in expenses exceeding the limits of insurance coverage."
            },
            {
              "key": "International Operations Risks",
              "value": "The company faces risks including inflation and political instability in non-U.S. economies."
            },
            {
              "key": "Economic Weakness",
              "value": "Factors such as economic weakness in countries where operations are conducted."
            },
            {
              "key": "Intellectual Property",
              "value": "Potentially reduced protection of intellectual property rights in different jurisdictions."
            },
            {
              "key": "Regulatory Compliance",
              "value": "Challenges associated with compliance with complex laws in multiple jurisdictions."
            },
            {
              "key": "Currency Exchange Risks",
              "value": "Risks from fluctuations in currency exchange rates and controls."
            },
            {
              "key": "Political Environment",
              "value": "Changes in the political or economic environment in regions where operations are located."
            },
            {
              "key": "Trade and Tariff Risks",
              "value": "Impacts from trade protection measures and licensing requirements."
            },
            {
              "key": "Tax Law Changes",
              "value": "Potential negative consequences from changes in tax laws."
            },
            {
              "key": "Labor Law Compliance",
              "value": "Challenges in complying with labor laws in various jurisdictions."
            },
            {
              "key": "Workforce Uncertainty",
              "value": "Potential labor unrest affecting operations abroad."
            },
            {
              "key": "Litigation Risks",
              "value": "Risk of litigation from employees or consultants."
            },
            {
              "key": "Staffing Challenges",
              "value": "Difficulties in staffing and managing international operations."
            },
            {
              "key": "Production Shortages",
              "value": "Risks of production shortages due to raw material supply issues."
            },
            {
              "key": "Business Interruptions",
              "value": "Potential business disruptions from geo-political actions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 109,
          "title": "Increased Security Breach Risks",
          "data": [
            {
              "key": "Risk Source",
              "value": "cyber-attacks or cyber intrusion by various actors"
            },
            {
              "key": "Business Impact",
              "value": "Potential loss of confidential information and operational disruptions"
            },
            {
              "key": "Current Situation",
              "value": "No material system failure or security breach experienced to date"
            },
            {
              "key": "Potential Consequences",
              "value": "Regulatory approval delays, increased costs, liability for data breaches"
            },
            {
              "key": "Reliance on",
              "value": "Third-party research collaborators and CROs for product development"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 110,
          "title": "Risk Factors Related to Technology and Compliance",
          "data": [
            {
              "key": "Risk of technology failure",
              "value": "Any failure of our technology or systems to perform satisfactorily could result in an adverse impact on our business."
            },
            {
              "key": "Reliance on third-party technology",
              "value": "We rely on software, hardware, network systems and similar technology, including cloud-based technology, developed by us or licensed from or maintained by third parties."
            },
            {
              "key": "Cyber-attack vulnerabilities",
              "value": "The integrity of our technology may be compromised due to third-party cyber-attacks."
            },
            {
              "key": "Impact of disruptions",
              "value": "Disruptions in our technology could significantly impact our data storage and clinical research data."
            },
            {
              "key": "Compliance with anti-corruption laws",
              "value": "We are subject to anti-corruption and anti-money laundering laws, with non-compliance leading to criminal and civil liability."
            },
            {
              "key": "Consequences of non-compliance",
              "value": "Noncompliance could result in penalties, investigations, and significant diversion of management resources."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 112,
          "title": "Risks Related to Economic, Political, Legal and Social Conditions in China",
          "data": [
            {
              "key": "Economic Influence",
              "value": "China’s economic, political and social conditions could significantly impact business operations."
            },
            {
              "key": "Regulatory Changes",
              "value": "The pharmaceutical industry is highly regulated, affecting drug approval and commercialization."
            },
            {
              "key": "Compliance Risks",
              "value": "Failure to comply with environmental, health and safety regulations may lead to fines."
            },
            {
              "key": "Contamination Liability",
              "value": "Potential liabilities from contamination or injury due to hazardous materials."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 114,
          "title": "Risk Factors Related to Clinical Trials and Market Fluctuations",
          "data": [
            {
              "key": "Factors Influencing Success of Product Candidates",
              "value": "The timing and success or failure of preclinical studies and clinical trials."
            },
            {
              "key": "Regulatory Approvals",
              "value": "Time of receipt of approvals for marketing authorizations."
            },
            {
              "key": "Reimbursement Policies",
              "value": "Coverage and reimbursement policies related to product candidates."
            },
            {
              "key": "Demand Variability",
              "value": "Level of demand for product candidates may vary significantly."
            },
            {
              "key": "Impact of COVID-19",
              "value": "Effect magnifying many factors concerning operating results."
            },
            {
              "key": "Influence of Major Stockholders",
              "value": "Principal stockholders and management own significant percentage of stock."
            },
            {
              "key": "Stockholder Influence on Corporate Matters",
              "value": "Ability to exert significant influence over corporate matters."
            },
            {
              "key": "Ownership Change and Tax Attributes",
              "value": "Limits on use of net operating loss carryforwards due to ownership change."
            },
            {
              "key": "Provisions Against Takeovers",
              "value": "Charter provisions discouraging favorable takeovers and management entrenchment."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 118,
          "title": "Risk Factors: Economic Conditions, Compliance and Reporting Challenges",
          "data": [
            {
              "key": "summary",
              "value": "The document discusses general economic conditions in the United States and abroad, noting the effects of recessions, depressions, and COVID-19 related market volatility on various sectors including pharmaceuticals and biotechnology. It highlights the high costs and administrative burdens of operating as a public company, including compliance with Sarbanes-Oxley Section 404, SEC reporting requirements, and Nasdaq governance rules. The text further addresses the risks associated with potential deficiencies in internal controls, possible material misstatements in financial statements, increased litigation exposure, and the challenges of attracting qualified personnel, all of which may materially and adversely affect the business, financial condition, and stock trading liquidity."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 119,
          "title": "Emerging Growth Company Risk Factors and Reporting Exemptions",
          "data": [
            {
              "key": "EmergingGrowthStatus",
              "value": "Company is classified as an 'emerging growth company' under the JOBS Act, benefiting from reduced disclosure and governance requirements."
            },
            {
              "key": "ReducedReportingRequirements",
              "value": "The company takes advantage of exemptions such as not complying with the auditor attestation requirements of Section 404 and reduced disclosure obligations regarding executive compensation and golden parachute payments."
            },
            {
              "key": "DelayedAdoptionOfStandards",
              "value": "The company may delay adopting new or revised accounting pronouncements applicable to public companies, leading to potential non-comparability of financial statements."
            },
            {
              "key": "MarketVolatilityRisk",
              "value": "These exemptions may make the common stock less attractive to investors, possibly resulting in a less active trading market and increased volatility."
            },
            {
              "key": "GlobalEconomicAndPoliticalRisks",
              "value": "The business is exposed to risks from global financial crises, economic downturns, and political disruptions that could adversely affect operations and demand."
            },
            {
              "key": "AnalystCoverageRisk",
              "value": "Reliance on external analyst coverage introduces the risk that adverse or misleading reports may negatively impact the stock price and trading volume."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 120,
          "title": "Trade Secrets Confidentiality Risks",
          "data": [
            {
              "key": "Risk Description",
              "value": "The document highlights the risks associated with failing to protect trade secrets and proprietary information. It discusses the potential harm to the business and competitive position if confidential data, including unpatented know-how and technology, is improperly disclosed. It further outlines challenges with enforcing confidentiality agreements, limitations of physical and technological security measures, and the risks posed by independent development or reverse engineering by competitors."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 121,
          "title": "Risk Factors - Trademark and Dilution Risks",
          "data": [
            {
              "key": "Trademark Protection Issues",
              "value": "The document outlines risks related to inadequate protection of trademarks and trade names, including challenges, infringement, circumvention, and the potential for marks to be declared generic or descriptive, which could impair brand recognition."
            },
            {
              "key": "Regulatory and Opposition Risks",
              "value": "It discusses potential rejections by the USPTO or foreign jurisdictions, oppositions from third parties during trademark registration, and challenges posed by compliance with FDA and similar regulatory bodies regarding product names."
            },
            {
              "key": "Dilution and Securities Litigation Risks",
              "value": "It also highlights risks related to additional issuances of common stock, leading to dilution of shareholders' ownership and potential securities litigation that may distract management and incur significant costs."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 126,
          "title": "Risk Factor Discussion: Product Candidates and COVID-19 Impact",
          "data": [
            {
              "key": "Product Approval Status",
              "value": "No product candidates have been approved for commercial sale."
            },
            {
              "key": "Revenue Generation",
              "value": "No revenue has been generated from product sales; future revenue is contingent on successful development, clinical trials, and regulatory approval."
            },
            {
              "key": "Commercialization Requirements",
              "value": "Successful regulatory approval would necessitate significant investments in building internal commercialization capabilities, including sales, marketing, and distribution."
            },
            {
              "key": "Manufacturing Strategy",
              "value": "The company relies on third parties for manufacturing during preclinical, clinical testing, and potential commercial manufacturing, avoiding direct investments in its own facilities."
            },
            {
              "key": "COVID-19 Impact",
              "value": "Ongoing uncertainties regarding the COVID-19 pandemic impact operations, clinical trial timelines, third-party collaborations, and regulatory processes."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 131,
          "title": "Risk Factors and Cash Flow Discussion",
          "data": [
            {
              "key": "collaborations_and_agreements",
              "value": "Discusses the ability to establish and maintain collaborations on favorable terms, including achieving milestones and managing obligations such as reimbursing clinical trial costs under collaboration agreements."
            },
            {
              "key": "intellectual_property_and_costs",
              "value": "Highlights costs related to preparing, filing, and prosecuting patent applications, maintaining and enforcing intellectual property rights, and defending related claims."
            },
            {
              "key": "product_development_risks",
              "value": "Describes the long, expensive, and uncertain process of identifying product candidates, conducting preclinical studies and clinical trials, and the risk that approved product candidates may not achieve commercial success."
            },
            {
              "key": "financing_risks",
              "value": "Emphasizes the need for additional financing through equity offerings, debt financings, collaborations, strategic alliances, and licensing arrangements, along with risks of dilution and restrictive covenants affecting business operations."
            },
            {
              "key": "operating_cash_flow_2022",
              "value": "Net cash used in operating activities for 2022 was $49.1 million, driven by a net loss of $60.3 million, partially offset by non-cash adjustments including stock-based compensation, depreciation, amortization, and other items."
            },
            {
              "key": "operating_cash_flow_2021",
              "value": "Net cash used in operating activities for 2021 was $41.8 million, with a net loss of $50.2 million, partially offset by non-cash adjustments such as stock-based compensation, depreciation, and amortization."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "risk_factor",
          "page": 134,
          "title": "Quantitative and Qualitative Disclosures About Market Risk",
          "data": [
            {
              "key": "smaller_reporting_company_exemption",
              "value": "The company may still qualify as a smaller reporting company, allowing it to use disclosure exceptions including reduced disclosure obligations regarding executive compensation."
            },
            {
              "key": "investor_attractiveness",
              "value": "Potential reduced investor attractiveness could lead to a less active trading market and increased share price volatility."
            },
            {
              "key": "recent_accounting_pronouncements",
              "value": "References to recently issued accounting pronouncements, as noted in Note 1 of the financial statements."
            },
            {
              "key": "interest_rate_risk",
              "value": "Cash, cash equivalents, and marketable securities held in bank and time deposits are not significantly affected by changes in interest rates due to their short-term nature."
            },
            {
              "key": "foreign_currency_risk",
              "value": "Risk arises from transactions denominated in Chinese Yuan, the functional currency of Terns Suzhou and Terns China."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 143,
          "title": "Impact of COVID-19 Pandemic and Revenue Recognition Policies",
          "data": [
            {
              "key": "Company",
              "value": "TERNS PHARMACEUTICALS, INC."
            },
            {
              "key": "COVID-19 Impact",
              "value": "The document discusses the evolving impact of the COVID-19 pandemic on global operations, including uncertainties related to business operations, development timelines, clinical trial enrollment, and third-party collaborations."
            },
            {
              "key": "Risk Considerations",
              "value": "Uncertainty in regulatory responses, potential modifications to employee travel and on-site activities, and the overall impact on expenditures and capital needs."
            },
            {
              "key": "Revenue Recognition Overview",
              "value": "Outlines the company's five-step model for revenue recognition, including considerations for upfront license fees, research funding, milestone and royalty payments in corporate collaborations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 166,
          "title": "Item 9 & 9A: Disclosure Controls, Procedures and Internal Control over Financial Reporting",
          "data": [
            {
              "key": "Changes in and Disagreements With Accountants",
              "value": "None"
            },
            {
              "key": "Evaluation of Disclosure Controls and Procedures",
              "value": "Management, with participation from the CEO and CFO, evaluated the design and operation of disclosure controls and procedures as of December 31, 2022 under Rules 13a-15(e) and 15d-15(e) of the Exchange Act and concluded they were effective at a reasonable assurance level."
            },
            {
              "key": "Internal Control over Financial Reporting",
              "value": "Management assessed internal control over financial reporting as of December 31, 2022 using the Internal Control-Integrated Framework (2013) and concluded it was effective, while noting inherent limitations that may not prevent or detect misstatements."
            },
            {
              "key": "Risk Consideration",
              "value": "The evaluation acknowledges that internal controls, no matter how well designed, provide only reasonable assurance and that future controls may become inadequate due to changing conditions or deterioration in compliance."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 167,
          "title": "Attestation Report and Internal Control Over Financial Reporting",
          "data": [
            {
              "key": "Attestation Report",
              "value": "This report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting."
            },
            {
              "key": "Review of Internal Controls",
              "value": "We regularly review our system of internal control over financial reporting and make changes to improve controls, increase efficiency, and maintain an effective control environment."
            },
            {
              "key": "Changes to Internal Control",
              "value": "There were no changes during the quarter ended December 31, 2022 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting."
            },
            {
              "key": "Other Information (Item 9B)",
              "value": "None"
            },
            {
              "key": "Foreign Jurisdictions Disclosure (Item 9C)",
              "value": "None"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_guidance_updates": {
      "value": true,
      "elements": [
        {
          "type": "guidance_update",
          "page": 24,
          "title": "Percent Change from Baseline in LDL and HDL",
          "data": [
            {
              "key": "LDL Change 5mg",
              "value": "No significant changes compared to placebo"
            },
            {
              "key": "LDL Change 10mg",
              "value": "No significant changes compared to placebo"
            },
            {
              "key": "LDL Change 15mg",
              "value": "Significant reduction at all observed time points"
            },
            {
              "key": "HDL Change 5mg",
              "value": "Significant decrease from baseline at Week 4 and Week 8, but returned to baseline at Week 12"
            },
            {
              "key": "HDL Change 10mg",
              "value": "Significant decrease from baseline at Week 4 and Week 8, but returned to baseline at Week 12"
            },
            {
              "key": "HDL Change 15mg",
              "value": "Significant decrease at all observed time points"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 64,
          "title": "Guidance Update on Clinical Trials and Regulatory Approvals",
          "data": [
            {
              "key": "Disruptions",
              "value": "COVID-19 and future pandemics may increase complexities in clinical trial management."
            },
            {
              "key": "Regulatory Delays",
              "value": "Delays may arise from various factors including interruptions by regulatory authorities."
            },
            {
              "key": "Financial Relationships",
              "value": "Conflicts of interest may arise from financial ties between investigators and the company."
            },
            {
              "key": "Impact on Approval",
              "value": "Delays in clinical trials may lead to rejection of marketing applications."
            },
            {
              "key": "Policy Changes",
              "value": "FDA's policies regarding clinical trials may change, impacting trial processes."
            },
            {
              "key": "Diversity Action Plans",
              "value": "New requirements for diversity plans in Phase 3 clinical trials are mandated."
            },
            {
              "key": "Initiatives",
              "value": "FDA OCE's Project Optimus aims to enhance dosing strategies in oncology."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 66,
          "title": "FDA Approval Requirements and Associated Risks",
          "data": [
            {
              "key": "Summary",
              "value": "The FDA requires two pivotal clinical trials for NDA approval and may grant accelerated approval based on surrogate endpoints. However, there is no guarantee of approval."
            },
            {
              "key": "Risks",
              "value": "Possibility of delayed reviews and complete response letters requiring additional trials before reconsideration for approval."
            },
            {
              "key": "Case Example",
              "value": "Intercept Pharmaceuticals’ NDA for obeticholic acid received a complete response letter."
            },
            {
              "key": "Legislative Changes",
              "value": "FDORA modified accelerated approval provisions, requiring ongoing confirmatory trials before approval."
            },
            {
              "key": "Financial Implications",
              "value": "Delays in approval could increase development costs and impact revenue generation."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 71,
          "title": "Regulatory Approval Process and Risks in Clinical Trials",
          "data": [
            {
              "key": "summary",
              "value": "The company discusses the uncertainty and risks associated with interim, top-line, and preliminary data from clinical trials. They emphasize that these data are subject to change and may differ from final results, potentially impacting the business's success."
            },
            {
              "key": "regulatory_hurdles",
              "value": "The regulatory approval process is lengthy, expensive, and uncertain, with strict adherence required to FDA regulations before marketing product candidates."
            },
            {
              "key": "clinical_studies",
              "value": "Successful marketing of product candidates requires substantial evidence from well-controlled clinical trials to demonstrate safety and effectiveness."
            },
            {
              "key": "potential_risks",
              "value": "The risk that interim results may differ significantly from final results, leading to adverse consequences for the company's business and financial condition."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_regulatory_or_litigation_issues": {
      "value": true,
      "elements": [
        {
          "type": "regulatory_litigation",
          "page": 14,
          "title": "Hematologic and Cytogenic Response in CML Treatment",
          "data": [
            {
              "key": "Hematologic Response",
              "value": "Categorized as either partial or complete based on CBC test results."
            },
            {
              "key": "Partial Hematologic Response",
              "value": "Achieved when blood cell types start returning to normal levels."
            },
            {
              "key": "Complete Hematologic Response",
              "value": "Achieved when blood cell counts return to normal. Observable within one month of treatment."
            },
            {
              "key": "Cytogenic Response Measurement",
              "value": "Assessed by measuring the percentage of Ph+ cells in bone marrow."
            },
            {
              "key": "Minor Cytogenic Response",
              "value": "Present in more than 35% of bone marrow cells."
            },
            {
              "key": "Major Cytogenic Response",
              "value": "35% or fewer cells have the Philadelphia chromosome."
            },
            {
              "key": "Complete Cytogenic Response",
              "value": "No cells with Philadelphia chromosome detected."
            },
            {
              "key": "Asciminib MMR Rate",
              "value": "25% at 6 months in pre-treated third-line patients."
            },
            {
              "key": "Bosutinib MMR Rate",
              "value": "13%, compared to asciminib's superior rate."
            },
            {
              "key": "Discontinuation Rate after 96 weeks",
              "value": "31.2% for asciminib vs 60.5% for bosutinib."
            },
            {
              "key": "Novel BCR-ABL inhibitors",
              "value": "Potential clinical benefit in initial CML treatment."
            },
            {
              "key": "Ongoing Phase 3 Study",
              "value": "Compares asciminib against TKIs in newly diagnosed CML patients."
            },
            {
              "key": "Active-site TKIs MMR Rates",
              "value": "Nilotinib 44%, bosutinib 47%, dasatinib 52%, imatinib 22%-37%."
            },
            {
              "key": "Medical Needs in CML",
              "value": "Ineffective responses to TKIs, safety warnings, and mutations."
            },
            {
              "key": "Patient Treatment Modifications",
              "value": "Based on individual disease progression and patient needs."
            },
            {
              "key": "Impact of TKI Intolerance",
              "value": "Can lead to non-compliance and poorer outcomes."
            },
            {
              "key": "Compliance Rate and MMR Achievement",
              "value": "94% of compliant patients achieved MMR vs 14% non-compliant."
            },
            {
              "key": "BCR-ABL Resistance Mutations",
              "value": "15%-20% of patients, with T315I being significant."
            },
            {
              "key": "Ponatinib Use",
              "value": "Approved for T315I mutation but carries safety warnings."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 41,
          "title": "Regulatory Compliance and Noncompliance Issues in Clinical Trials and Pediatric Studies",
          "data": [
            {
              "key": "Clinical Trials and Nonclinical Studies",
              "value": "Concurrent execution of clinical trials and additional animal studies, along with development of chemistry, manufacturing, and testing methods to comply with cGMP requirements."
            },
            {
              "key": "Manufacturing Process",
              "value": "Development of a consistent manufacturing process capable of producing quality batches; includes testing for identity, strength, quality, and purity, as well as packaging and stability studies."
            },
            {
              "key": "IND Reporting Requirements",
              "value": "Mandatory submission of annual progress reports summarizing clinical and nonclinical study results, along with IND safety reports for serious and unexpected adverse events."
            },
            {
              "key": "Clinical Trial Registration",
              "value": "Obligation to register and disclose clinical trial information on clinicaltrials.gov, including details about the product, study design, sites, and investigators."
            },
            {
              "key": "Noncompliance and Penalties",
              "value": "FDA has issued Notices of Noncompliance for failures, with potential civil monetary penalties up to $10,000 per day under FDCA."
            },
            {
              "key": "Pediatric Study Requirements",
              "value": "Under PREA, NDAs must include adequate pediatric data, and sponsors must submit pediatric study plans with possible deferrals or waivers as mandated by FDASIA."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 43,
          "title": "Regulatory Approval Conditions and Expedited Development Programs",
          "data": [
            {
              "key": "Regulatory Approval Conditions",
              "value": "Approval may be granted for specific indications with limitations; may include requirements such as REMS, changes to labeling, or development of adequate controls and specifications."
            },
            {
              "key": "Risk Evaluation and Mitigation Strategy (REMS)",
              "value": "REMS may be required to ensure that the benefits of the product outweigh its risks through safety strategies like restricted distribution and patient registries."
            },
            {
              "key": "Post-Marketing Requirements",
              "value": "The FDA may require Phase 4 studies or surveillance, and can withdraw approval if pre- and post-marketing requirements are not met."
            },
            {
              "key": "Expedited Development Programs",
              "value": "Programs such as Fast Track, Breakthrough Therapy, Priority Review, and Accelerated Approval are available for products treating serious conditions or addressing unmet medical needs."
            },
            {
              "key": "Fast Track and Breakthrough Therapy Designations",
              "value": "These designations provide for more frequent FDA interactions and potential rolling reviews, expediting the development process."
            },
            {
              "key": "Priority Review and Accelerated Approval",
              "value": "Products with these designations may receive an expedited review timeline, provided they offer significant improvements in treatment or meet surrogate endpoint criteria."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 44,
          "title": "FDA Regulatory Changes under FDORA and PREVENT Pandemics Act",
          "data": [
            {
              "key": "Legislation",
              "value": "FDORA and PREVENT Pandemics Act, enacted December 2022, modify FDA accelerated approval and manufacturing compliance requirements."
            },
            {
              "key": "Accelerated Approval Requirements",
              "value": "Sponsors must have confirmatory clinical trials underway prior to accelerated approval, submit progress reports every six months, and face expedited withdrawal if the confirmatory trial fails to verify clinical benefit."
            },
            {
              "key": "Post-Approval Regulatory Obligations",
              "value": "Products remain subject to comprehensive FDA regulations, including record-keeping, adverse event reporting, periodic reporting, product sampling, and oversight of advertising and promotion. Most post-approval product changes require prior FDA review."
            },
            {
              "key": "Manufacturing and cGMP Compliance",
              "value": "Drug manufacturers and subcontractors must register with FDA (and state agencies), adhere to cGMP, and are subject to unannounced inspections; foreign manufacturing establishments must also comply with registration and listing requirements."
            },
            {
              "key": "Additional FDA Programs",
              "value": "Designations such as Fast Track, breakthrough therapy, and priority review expedite the process but do not change approval standards. FDA may later revise program eligibility."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 45,
          "title": "FDA Regulatory Enforcement and Compliance Risks",
          "data": [
            {
              "key": "Withdrawal of Approval",
              "value": "The FDA may withdraw approval if regulatory compliance and standards are not maintained."
            },
            {
              "key": "Post-Market Requirements",
              "value": "Discovery of new safety problems may require revised labeling, post-market or clinical studies, and additional risk management measures."
            },
            {
              "key": "Enforcement Actions",
              "value": "Consequences may include product recalls, fines, warning letters, consent decrees, corporate integrity agreements, seizures, and import/export restrictions."
            },
            {
              "key": "Communication Restrictions",
              "value": "FDA restrictions on promotional practices and off-label use communications can lead to penalties or corrective actions."
            },
            {
              "key": "Legislative Changes",
              "value": "New legislation like the PIE Act provides protections for sponsors in communicating information on products in development."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 46,
          "title": "Regulatory Exclusivity and Orphan Drug Provisions",
          "data": [
            {
              "key": "PDMA",
              "value": "Regulates distribution of prescription pharmaceutical products and samples; imposes accountability requirements at the state and federal levels."
            },
            {
              "key": "FDCA - 5 Year Exclusivity",
              "value": "Provides a five-year period of non-patent marketing exclusivity in the US for first NDA approvals for new chemical entities, blocking competing ANDAs or 505(b)(2) NDAs."
            },
            {
              "key": "FDCA - 3 Year Exclusivity",
              "value": "Provides three-year regulatory exclusivity for NDAs or supplement NDAs based on new clinical investigations essential for approval of modifications such as new indications, dosages or strengths."
            },
            {
              "key": "Submission Requirements",
              "value": "Full NDAs require conducting or obtaining rights to preclinical studies and adequate, well-controlled clinical trials for demonstration of safety and effectiveness."
            },
            {
              "key": "Orphan Drug Act",
              "value": "Provides incentives including tax credits, waiver of the Prescription Drug User Fee, and up to seven years of market exclusivity for drugs treating rare diseases, subject to conditions regarding approval history and clinical superiority."
            },
            {
              "key": "Eleventh Circuit Decision",
              "value": "Catalyst Pharmaceuticals, Inc. vs. FDA decision may affect the interpretation of orphan drug exclusivity provisions for label expansions; legislative proposals to overrule this decision have been discussed but not enacted."
            },
            {
              "key": "FDA Announcement",
              "value": "On January 23, 2023, FDA announced continuation of existing regulations tying orphan-drug exclusivity to approved indications beyond the scope of the court order."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 48,
          "title": "EU Clinical Trials Regulation (CTR) and Marketing Authorization Process",
          "data": [
            {
              "key": "Clinical Trials Directive vs CTR",
              "value": "The text compares the older Clinical Trials Directive with the new Clinical Trials Regulation, detailing the centralized submission process for CTAs and the transitional arrangements."
            },
            {
              "key": "CTA Submission Process",
              "value": "Under the CTR, a single submission is made to all concerned member states, including both competent authorities and ethics committees, leading to a single decision per member state."
            },
            {
              "key": "Trial Protocol and Dossier",
              "value": "The CTA must include a copy of the trial protocol and an investigational medicinal product dossier with manufacturing and quality details."
            },
            {
              "key": "Transitional Arrangements",
              "value": "Clinical trials with CTAs submitted under the directive before January 31, 2022 follow a transitional period, with options extended until January 31, 2023 and up to January 31, 2025 for some trials."
            },
            {
              "key": "Marketing Authorization (MA)",
              "value": "Before marketing a product in the EU, a separate marketing authorization application (MAA) is required. Describes centralized MAs via the European Commission and national MAs with mutual recognition or decentralized procedures."
            },
            {
              "key": "Regulatory Assessments",
              "value": "Both the EMA and national competent authorities assess the overall risk-benefit balance based on scientific criteria concerning quality, safety, and efficacy."
            },
            {
              "key": "Additional Regulatory Requirements",
              "value": "Manufacturing must comply with Good Manufacturing Practice (GMP) as specified under EU Commission Delegated Regulation (EU) 2017/1569, along with other national and EU-wide regulatory requirements."
            },
            {
              "key": "Clinical Trials Information Disclosure",
              "value": "Certain clinical trial information must be posted on the EU's EudraCT website."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 49,
          "title": "Regulatory Update: Adaptive Pathways, PRIME Scheme, and Exclusivity Periods",
          "data": [
            {
              "key": "MA Duration",
              "value": "Initial five-year period with possibility for unlimited renewals based on risk-benefit re-evaluation"
            },
            {
              "key": "Proposed Legislation",
              "value": "Expected new proposed legislation in March 2023 to introduce significant changes to regulatory procedures, including data and market exclusivity rules"
            },
            {
              "key": "Adaptive Pathways",
              "value": "EMA program aimed at early and progressive patient access by leveraging real-world data and early health technology assessments for treatments addressing unmet medical needs"
            },
            {
              "key": "PRIME Scheme",
              "value": "Voluntary EMA program launched in July 2016 to enhance support for developing medicines that target unmet medical needs, potentially speeding up evaluation and access"
            },
            {
              "key": "Data and Market Exclusivity",
              "value": "Upon authorization, reference medicinal products receive eight years of data exclusivity and ten years of market exclusivity, extendable to up to eleven years under certain conditions"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 50,
          "title": "Post-approval requirements and regulatory framework",
          "data": [
            {
              "key": "Regulatory oversight",
              "value": "MA holders and manufacturers are subject to oversight by EMA, the European Commission, and competent authorities."
            },
            {
              "key": "Key obligations",
              "value": "Establish and maintain a pharmacovigilance system, expedited reporting of serious adverse reactions."
            },
            {
              "key": "Risk management plan (RMP)",
              "value": "All new MAA must include a risk management plan."
            },
            {
              "key": "Advertising restrictions",
              "value": "Advertising must align with approved summaries; off-label promotion is prohibited."
            },
            {
              "key": "Advertising proposal",
              "value": "New legislative proposal expected in March 2023 regarding comparative advertising."
            },
            {
              "key": "Penalties for non-compliance",
              "value": "May include administrative, civil, or criminal penalties, including delays in trials or product withdrawals."
            },
            {
              "key": "Brexit impact",
              "value": "UK's withdrawal from EU led to separate markets and regulatory regimes for medicinal products."
            },
            {
              "key": "MHRA role post-Brexit",
              "value": "MHRA responsible for supervising medicines in Great Britain, while Northern Ireland follows EU rules."
            },
            {
              "key": "Date of UK withdrawal",
              "value": "January 31, 2020."
            },
            {
              "key": "Regulation reference",
              "value": "Human Medicines Regulations 2012 (SI 2012/1916) under which MHRA operates."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 51,
          "title": "Regulatory Oversight of Pharmaceutical Companies",
          "data": [
            {
              "key": "Oversight Entities",
              "value": "Federal government, state authorities, foreign jurisdictions"
            },
            {
              "key": "Laws and Regulations",
              "value": "Anti-kickback, fraud and abuse, false claims, transparency laws"
            },
            {
              "key": "Penalties for Violations",
              "value": "Administrative, civil, criminal penalties, damages, fines, integrity oversight, exclusion from healthcare programs, imprisonment"
            },
            {
              "key": "Third-party Payors",
              "value": "Federal, state, foreign government healthcare programs, commercial insurance"
            },
            {
              "key": "Reimbursement Issues",
              "value": "Decisions on coverage and reimbursement are plan-based, with increasing reductions"
            },
            {
              "key": "Cost-control Measures",
              "value": "Governmental price controls, restrictions on coverage, limitations on reimbursement"
            },
            {
              "key": "EU Pricing and Reimbursement",
              "value": "Varies widely, some countries require agreement on prices before marketing"
            },
            {
              "key": "Government Programs",
              "value": "Medicaid Drug Rebate Program, 340B drug pricing program, drug pricing data reporting, liability for misreporting"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 52,
          "title": "Healthcare Reform Legislative and Regulatory Changes",
          "data": [
            {
              "key": "Legislative Change",
              "value": "Patient Protection and Affordable Care Act (ACA) signed into law in March 2010."
            },
            {
              "key": "Key Provisions of ACA",
              "value": "Increases Medicaid rebates from 15.1% to 23.1%."
            },
            {
              "key": "Patient-Centered Outcomes Research Institute",
              "value": "Established to conduct clinical effectiveness research."
            },
            {
              "key": "Challenges to ACA",
              "value": "Multiple judicial challenges, including U.S. Supreme Court cases."
            },
            {
              "key": "Medicare Payment Reductions",
              "value": "2% reduction in Medicare payments to providers effective through 2032."
            },
            {
              "key": "Statutory PAYGO Sequestration",
              "value": "Sequestration order required if PAYGO scorecard shows net cost."
            },
            {
              "key": "Legislation Impacting Drug Pricing",
              "value": "Inflation Reduction Act enacted on August 16, 2022."
            },
            {
              "key": "Price Negotiation Requirement",
              "value": "CMS authorized to negotiate prices for certain high-cost drugs."
            },
            {
              "key": "Penalties for Non-compliance",
              "value": "Civil monetary penalties for not adhering to negotiated prices."
            },
            {
              "key": "Out-of-pocket Drug Costs Cap",
              "value": "Capped at $4,000 in 2024 and $2,000 starting in 2025."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 53,
          "title": "Regulatory Overview of Pharmaceutical Pricing and Data Privacy Laws",
          "data": [
            {
              "key": "Pharmaceutical Regulations",
              "value": "States in the US implementing controls on pharmaceutical product pricing, including price constraints, reimbursement rules, discounts, and transparency measures."
            },
            {
              "key": "Data Privacy Laws",
              "value": "Federal and state laws governing health-related information, including data breach, privacy, and consumer protection laws."
            },
            {
              "key": "State Privacy Laws",
              "value": "California, Colorado, Connecticut, Utah, Virginia have enacted omnibus consumer privacy laws affecting health-related information."
            },
            {
              "key": "FTC Focus",
              "value": "Increased FTC enforcement actions concerning the use and disclosure of health-related information."
            },
            {
              "key": "Pending Legislation",
              "value": "Draft federal privacy law (American Data Privacy and Protection Act) pending in Congress."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 65,
          "title": "Regulatory changes in clinical trial landscape in the EU",
          "data": [
            {
              "key": "Regulatory Change",
              "value": "Introduction of CTR replacing Clinical Trials Directive"
            },
            {
              "key": "Applicable Date",
              "value": "January 31, 2022"
            },
            {
              "key": "Transition Period",
              "value": "Three years"
            },
            {
              "key": "Impact on Ongoing Trials",
              "value": "Trials approved under Clinical Trials Directive will continue until January 31, 2025 if submitted before January 31, 2023."
            },
            {
              "key": "Risk Factors",
              "value": "Difficulty in gaining regulatory agreement for development plans and the unpredictability of trial outcomes."
            },
            {
              "key": "Specific Indication",
              "value": "Development for NASH and challenges due to the absence of approved therapy."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 88,
          "title": "Regulatory Developments Affecting Pharmaceutical Pricing",
          "data": [
            {
              "key": "Overview",
              "value": "Discussion on various US regulatory actions and legislative measures aimed at increasing pricing transparency and reducing prescription drug costs under Medicare and Medicaid."
            },
            {
              "key": "Key Regulations and Actions",
              "value": "Interim final rule using a most favored nation model for Medicare Part B pricing; subsequent nationwide preliminary injunction and final rule rescission by CMS; executive orders from Trump and Biden addressing drug pricing; final rules enabling importation of drugs from Canada; new regulations modifying safe harbor provisions for drug rebates."
            },
            {
              "key": "Legislation Referenced",
              "value": "Inflation Reduction Act of 2022, Section 804 Importation Program (SIP) rules, and additional state-level laws in Vermont, Colorado, Florida, Maine, New Mexico, and New Hampshire."
            },
            {
              "key": "Impact and Risk",
              "value": "Potential government intervention in Medicare price negotiations; risk to return on products and patent value if products become subject to price caps after a certain market period; scheduled negotiations for high-cost drugs beginning in 2026 under Medicare Part D and later years under Medicare Part B."
            },
            {
              "key": "Litigation Elements",
              "value": "The most favored nation rule faced a nationwide preliminary injunction and several ongoing litigations concerning drug importation and new safe harbor regulations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 94,
          "title": "Risks Related to Patent Litigation and Intellectual Property Enforcement",
          "data": [
            {
              "key": "litigation_risk",
              "value": "Potential involvement in lawsuits to protect or enforce patents, which may be expensive and time-consuming"
            },
            {
              "key": "patent_validity",
              "value": "Risk that issued patents may be challenged and found invalid or unenforceable, affecting protection of products"
            },
            {
              "key": "counterclaims",
              "value": "Possibility of defendant counterclaims alleging invalidity or unenforceability common in U.S. patent litigation"
            },
            {
              "key": "financial_impact",
              "value": "Adverse outcomes in litigation could affect business prospects, competitive position, and financial condition"
            },
            {
              "key": "confidentiality_risk",
              "value": "Substantial discovery processes may compromise confidential information"
            },
            {
              "key": "global_implications",
              "value": "Loss of patent protection in foreign markets may prevent marketing and reduce competitive advantage"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 105,
          "title": "Environmental Laws and Regulations Compliance",
          "data": [
            {
              "key": "Compliance Risks",
              "value": "Involves hazardous materials, environmental laws, and regulations."
            },
            {
              "key": "Third-Party Risks",
              "value": "Dependence on suppliers and contractors for compliance."
            },
            {
              "key": "Liability Risks",
              "value": "Potential liability for contamination at facilities."
            },
            {
              "key": "Insurance Coverage",
              "value": "Limitations in coverage for hazardous materials."
            },
            {
              "key": "Impact of Regulations",
              "value": "Changing regulations may impair business operations."
            },
            {
              "key": "Accidental Contamination Risk",
              "value": "Cannot eliminate risk of accidental contamination."
            },
            {
              "key": "Environmental Damage Costs",
              "value": "Potential high costs for clean-up and liabilities."
            },
            {
              "key": "Insurance Policies",
              "value": "Exclusions for biological or hazardous waste exposure."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 106,
          "title": "Data Protection Compliance Risks",
          "data": [
            {
              "key": "Summary",
              "value": "Potential non-compliance with data protection laws may adversely impact the business."
            },
            {
              "key": "Impact Areas",
              "value": "Business operations, financial condition, results of operations, and prospects."
            },
            {
              "key": "Key Legislation",
              "value": "HIPAA, CCPA, CPRA, Federal Trade Commission Act."
            },
            {
              "key": "Compliance Costs",
              "value": "High and likely to increase in the future."
            },
            {
              "key": "Risks",
              "value": "Negative publicity, investigations, enforcement actions, claims from third parties, reputational damage."
            },
            {
              "key": "State Privacy Laws",
              "value": "Virginia, Colorado, Utah, Connecticut having new privacy laws; potential future federal privacy law."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 107,
          "title": "Data Protection Laws and Compliance",
          "data": [
            {
              "key": "Regulation",
              "value": "GDPR"
            },
            {
              "key": "Effective Date",
              "value": "2018"
            },
            {
              "key": "Fines for Noncompliance",
              "value": "Up to €20 million or 4% of annual global revenue"
            },
            {
              "key": "UK GDPR Introduction",
              "value": "January 1, 2021"
            },
            {
              "key": "UK GDPR Fines",
              "value": "Up to £17.5 million or 4% of global turnover"
            },
            {
              "key": "Adequacy Decision Expiration",
              "value": "June 2025"
            },
            {
              "key": "CJEU Ruling Date",
              "value": "July 2020"
            },
            {
              "key": "Revised SCCs Issued",
              "value": "June 4, 2021"
            },
            {
              "key": "SCCs Application Start Date",
              "value": "September 27, 2021"
            },
            {
              "key": "US Data Transfers Regulation",
              "value": "Revised SCCs apply only to EEA"
            }
          ],
          "currency": "EUR"
        },
        {
          "type": "regulatory_litigation",
          "page": 108,
          "title": "Regulatory Compliance and Data Security Risks",
          "data": [
            {
              "key": "Description",
              "value": "The section discusses the evolving nature of legal obligations related to privacy and data security, outlining potential compliance challenges and associated costs."
            },
            {
              "key": "Risks",
              "value": "It highlights risks of regulatory actions, privacy breaches, natural disasters, and significant repercussions related to non-compliance."
            },
            {
              "key": "Impacts",
              "value": "Potential negative impacts on business operations, financial condition, and reputation."
            },
            {
              "key": "Insurance Issues",
              "value": "Notes the lack of earthquake insurance and the vulnerability of business operations to natural disasters."
            },
            {
              "key": "IT Vulnerabilities",
              "value": "Discusses vulnerabilities in IT systems that could lead to data breaches and impacts on business."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 111,
          "title": "Regulatory and Legal Risks",
          "data": [
            {
              "key": "Description",
              "value": "Various laws, regulations and executive orders restrict the dissemination of classified information and products related to national security. Prohibition on providing benefits to induce medical product prescriptions governed by EU laws and UK Bribery Act."
            },
            {
              "key": "Potential Consequences",
              "value": "Infringement could lead to substantial fines, imprisonment, and reputational risk."
            },
            {
              "key": "Geopolitical Risks",
              "value": "Adverse changes in US-China relations affecting business operations in China and potential trade restrictions."
            },
            {
              "key": "Impact on Operations",
              "value": "Need to comply with PRC laws or face harm to business and financial condition."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 113,
          "title": "Regulatory Challenges and Compliance Risks",
          "data": [
            {
              "key": "Insurance Coverage",
              "value": "Maintain workers’ compensation insurance; coverage may not be adequate."
            },
            {
              "key": "Environmental Regulations",
              "value": "Potential stringent regulations in China leading to unanticipated environmental expenditures."
            },
            {
              "key": "Capital Expenditures",
              "value": "Required for operational changes to comply with environmental laws."
            },
            {
              "key": "Compliance Risks",
              "value": "Failure to comply may lead to fines or sanctions."
            },
            {
              "key": "Stock Option Regulations",
              "value": "PRC citizens must register with SAFE for overseas stock ownership plans."
            },
            {
              "key": "Risks Related to Operating Results",
              "value": "Fluctuations in results due to various uncontrollable factors."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 115,
          "title": "Anti-Takeover Provisions and Board Control Issues",
          "data": [
            {
              "key": "Cumulative Voting",
              "value": "No cumulative voting in the election of directors."
            },
            {
              "key": "Board Director Elections",
              "value": "Exclusive right of the board to fill vacancies."
            },
            {
              "key": "Share Issuance Authorization",
              "value": "Board can issue preferred stock without stockholder approval."
            },
            {
              "key": "Bylaw Amendments",
              "value": "Board can alter bylaws without stockholder approval."
            },
            {
              "key": "Voting Approval Requirement",
              "value": "66 2/3% approval necessary for bylaw changes."
            },
            {
              "key": "Written Consent Prohibition",
              "value": "Prohibition on stockholder action by written consent."
            },
            {
              "key": "Special Meeting Calls",
              "value": "Special meetings can only be called by the board."
            },
            {
              "key": "Advance Notice Procedures",
              "value": "Procedures required for stockholder nominations."
            },
            {
              "key": "Delaware Section 203",
              "value": "Anti-takeover provisions regarding stockholder ownership."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 116,
          "title": "Board Composition Compliance and Forum Selection Risk Factors",
          "data": [
            {
              "key": "Board Composition Requirements",
              "value": "As a California-domiciled public company, there is a potential requirement to have at least two or three women and a minimum number of directors from an underrepresented community on the board, based on California Code Sections 301.3 and 301.4."
            },
            {
              "key": "Compliance and Recruitment Risk",
              "value": "Failure to recruit additional directors to meet these requirements, should the codes be reinstated, may result in financial penalties."
            },
            {
              "key": "Exclusive Forum Provisions",
              "value": "The company's amended and restated certificate of incorporation and bylaws designate the Court of Chancery of Delaware (and, where applicable, federal district courts) as the exclusive forum for specific disputes, including derivative actions and claims under the Securities Act."
            },
            {
              "key": "Legal and Regulatory Uncertainty",
              "value": "There is uncertainty regarding the enforceability of the board composition mandates and forum selection clauses, with potential outcomes including additional litigation costs if these provisions are challenged or deemed unenforceable."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 122,
          "title": "Indemnification, Legal Proceedings and Property Leasing Disclosures",
          "data": [
            {
              "key": "Indemnification Provisions",
              "value": "Our amended and restated certificate of incorporation, bylaws, and indemnification agreements provide that we will indemnify our directors and officers to the fullest extent permitted by Delaware law, including advancing expenses for defense and without reducing indemnification obligations even if retroactive changes occur."
            },
            {
              "key": "Impact on Available Funds",
              "value": "Claims for indemnification by directors and officers and potential litigation costs may reduce available funds to satisfy third-party claims and adversely impact cash positions, even though a directors’ and officers’ insurance policy is maintained."
            },
            {
              "key": "Legal Proceedings",
              "value": "The Company may occasionally be involved in legal proceedings or claims. As of December 31, 2022, no litigation was deemed probable to have a material adverse effect, although any proceedings could impact resources through defense and settlement costs."
            },
            {
              "key": "Properties",
              "value": "The Company leases approximately 9,750 square feet at its headquarters in Foster City, California with an expiring agreement in October 2024 and an option for a five-year extension, and also leases office space in Shanghai and Suzhou, China."
            },
            {
              "key": "Mine Safety Disclosures",
              "value": "None."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 171,
          "title": "XBRL Documentation and Filing Components",
          "data": [
            {
              "key": "101.INS",
              "value": "In ine XBRL Instance Document"
            },
            {
              "key": "101.SCH",
              "value": "In ine XBRL Taxonomy Extension Schema Document; Value: KUDU"
            },
            {
              "key": "101.CAL",
              "value": "In ine XBRL Taxonomy Extension Calculation Linkbase Document"
            },
            {
              "key": "101.DEF",
              "value": "In ine XBRL Taxonomy Extension Definition Linkbase Document; Value: ex"
            },
            {
              "key": "101.LAB",
              "value": "In ine XBRL Taxonomy Extension Label Linkbase Document; Value: «eM"
            },
            {
              "key": "101.PRE",
              "value": "In ine XBRL Taxonomy Extension Presentation Linkbase Document; Value: -«"
            },
            {
              "key": "104",
              "value": "Cover Page Interactive Data File (embedded within the Inline XBRL document); Value: <~"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 186,
          "title": "Contract Agreement Provisions",
          "data": [
            {
              "key": "Governing Law",
              "value": "This Agreement shall be governed by and construed in accordance with the laws of the State of California."
            },
            {
              "key": "Severability",
              "value": "If any term or provision is deemed invalid or unenforceable, the remaining provisions remain in full force and effect."
            },
            {
              "key": "Counterparts",
              "value": "The Agreement may be executed in any number of counterparts, with facsimile or electronic signatures treated as originals."
            },
            {
              "key": "Attorney’s Fees",
              "value": "The prevailing party in any litigation to enforce the Agreement is entitled to reasonable attorneys' fees and litigation expenses."
            },
            {
              "key": "Assignment",
              "value": "The Company’s rights and obligations extend to successors; however, the recipient's rights are non-assignable."
            },
            {
              "key": "Notice",
              "value": "Any notice must be in writing and delivered by certified mail, in person, or via a reliable electronic system as specified."
            },
            {
              "key": "Headings",
              "value": "Headings are for reference only and do not affect the interpretation of the Agreement."
            },
            {
              "key": "No Presumption Against Interest",
              "value": "No provision shall be construed against any party as having been drafted by that party."
            },
            {
              "key": "Defend Trade Secrets Act Notice",
              "value": "Provides conditions under which disclosure of trade secrets for reporting suspected legal violations is protected."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 189,
          "title": "Execution Signature Block",
          "data": [
            {
              "key": "Agreement Statement",
              "value": "IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written."
            },
            {
              "key": "Party 1",
              "value": "TERNS, INC. signed by Bryan Yoon (COO & GC)"
            },
            {
              "key": "Party 2",
              "value": "TERNS PHARMACEUTICALS, INC. (solely in respect of its explicit obligations under the Agreement) signed by Bryan Yoon (COO & GC)"
            },
            {
              "key": "Employee",
              "value": "Senthil Sundaram, with Attachment Exhibit A: Release"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 193,
          "title": "Release Agreement Terms and Clauses",
          "data": [
            {
              "key": "Clause 12",
              "value": "Acknowledges that the signatory has not relied on any statements made by the Company unless explicitly stated in the Release. Establishes that the Release represents the entire understanding regarding eligibility for benefits and supersedes prior representations and agreements, except for existing written agreements like employment, invention assignment, confidentiality, and various stock-related agreements."
            },
            {
              "key": "Modification",
              "value": "Specifies that once effective and enforceable, the Release can only be modified by a subsequent written agreement signed by both the signatory and an authorized Company representative."
            },
            {
              "key": "Clause 13",
              "value": "Provides that if any provision is found wholly or partially invalid or unenforceable by an arbitrator, court, or government agency, the remaining provisions remain in full force. It emphasizes the intent to release all claims, except for any that cannot be legally released."
            },
            {
              "key": "Signature",
              "value": "Indicates that the signature page for the General Release Agreement follows."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_strategic_restructuring": {
      "value": false,
      "elements": []
    },
    "has_supply_chain_disruptions": {
      "value": true,
      "elements": [
        {
          "type": "supply_chain_disruption",
          "page": 79,
          "title": "Supply Chain and Manufacturing Risks",
          "data": [
            {
              "key": "Dependence on Suppliers",
              "value": "Reliance on third-party suppliers and manufacturers for raw materials and finished drug products necessary for clinical trials and eventual commercial production."
            },
            {
              "key": "Limited Supplier Base",
              "value": "A limited number of suppliers for raw materials could force the need to assess alternate suppliers to avoid manufacturing disruptions."
            },
            {
              "key": "Manufacturing Capacity Risks",
              "value": "Potential delays or cost challenges in scaling up manufacturing capacity may delay clinical trials, product testing, and regulatory approvals."
            },
            {
              "key": "Third-Party Dependencies",
              "value": "Reliance on external contract manufacturers, CROs, and other third parties for GLP-compliant preclinical studies and GCP-compliant clinical trials, with limited control over their performance."
            },
            {
              "key": "Regulatory Approval Impact",
              "value": "Delays in acquiring raw materials or managing third-party performance could postpone clinical trials and regulatory approvals, impacting commercial launch."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_esg_initiatives": {
      "value": true,
      "elements": [
        {
          "type": "esg_initiative",
          "page": 16,
          "title": "Clinical development of TERN-701",
          "data": [
            {
              "key": "Study Design",
              "value": "Two-part clinical trial"
            },
            {
              "key": "Drug",
              "value": "TERN-701"
            },
            {
              "key": "Dosing",
              "value": "Once-daily"
            },
            {
              "key": "Part 1 Endpoint",
              "value": "Primary endpoint of maximum tolerated dose assessed at 28 days"
            },
            {
              "key": "Part 2 Endpoint",
              "value": "Primary endpoint of cytogenetic response assessed at 6 months"
            },
            {
              "key": "Additional Notes",
              "value": "Patients may continue therapy beyond primary endpoint measures, through the end of study"
            },
            {
              "key": "Format",
              "value": "Flow diagram showing progression from dose escalation cohorts to expansion phase"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 70,
          "title": "Risks Associated with Product Candidates",
          "data": [
            {
              "key": "Regulatory Approval Risks",
              "value": "Product candidates may cause undesirable side effects or have properties that could delay or prevent regulatory approval."
            },
            {
              "key": "Clinical Trials Interruption",
              "value": "Undesirable side effects may cause suspension or discontinuation of clinical trials."
            },
            {
              "key": "Adverse Events",
              "value": "Adverse events and laboratory abnormalities have been observed in clinical trials."
            },
            {
              "key": "Specific Example",
              "value": "Mild-to-moderate pruritus and increased LDL cholesterol observed in the Phase 2a LIFT Trial of TERN-101."
            },
            {
              "key": "Possible Tolerability Issues",
              "value": "Drug candidates may display similar or previously unobserved safety and tolerability issues."
            },
            {
              "key": "Impact of Side Effects on Trials",
              "value": "Treatment-related side effects could affect patient recruitment and trial completion."
            },
            {
              "key": "Training for Medical Staff",
              "value": "Inadequate training in recognizing side effects could lead to patient injury or death."
            },
            {
              "key": "Consequences of Side Effects Post-Approval",
              "value": "Withdrawal of product from the market, changes in regulatory approvals, or additional warnings may be required."
            },
            {
              "key": "Financial Impact",
              "value": "Negative consequences could materially affect business and financial condition."
            }
          ],
          "currency": "N/A"
        }
      ]
    }
  },
  "currency": {
    "USD": 20,
    "EUR": 23,
    "AUD": 3,
    "CAD": 6,
    "CNY": 2,
    "INR": 1
  },
  "sha1": "79ffb9b8682aa565172233c070a47d944464644c"
}